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ABSTRACT
SYSTEMS BIOLOGY OF BLOOD COAGULATION AND PLATELET
ACTIVATION
Manash Shankar Chatterjee
Supervisor: Scott L. Diamond

Blood clotting is a highly conserved physiological response that prevents
excessive blood loss following vessel injury. It involves a sequence of plasma reactions
leading to the formation of thromin (the coagulation cascade) as well as tightly controlled
intracellular reactions mediating platelet activation. These two events are inextricably
coupled, with the active platelet surface serving as a cofactor for coagulation factor
assembly and thrombin serving as a potent platelet agonist. Using the technologies of
automated liquid handling, high throughput experimental systems were developed that
allowed individual exploration of these two components of the thrombotic response under
diverse initial conditions. Based on this high dimensional experimental exploration, a
“bottom-up” mechanism based Ordinary Differential Equation (ODE) description of
thrombin generation kinetics and a “top-down” data driven Neural Network model of
platelet activation were developed. In the first study, “contact activation” (and not
“blood-borne TF” alone) despite the best available inhibitor to prevent it, was found build
up enough autocatalytic strength to trigger coagulation in the absence of exogenous tissue
factor, particularly upon activated platelets. Further, the “Platelet-Plasma model”
successfully predicted the stability of blood under multiple perturbations with active
enzymes at various physiologically realizable conditions. In the second study, “Pairwise
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Agonist Scanning” (PAS), a strategy that trains a Neural Network model based on
measurements of cellular responses to individual and all pairwise combinations of input
signals is described. PAS was used to predict calcium signaling responses of human
platelets in EDTA-treated plasma to six different agonists (ADP, Convulxin, U46619,
SFLLRN, AYPGKF and PGE2). The model predicted responses to sequentially added
agonists, to ternary combinations of agonists and to 45 different combinations of four to
six agonists (R=0.88). Furthermore, PAS was used to distinguish between the phenotypic
responses of platelets from healthy human donors. Taken together, these two studies lay
the groundwork for integration of coagulation reaction kinetics and donor specific
descriptions of platelet function with models of convection and diffusion to simulate
thrombosis under flow.
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Chapter 1
Introduction
1.1 Thrombus formation
Thrombus formation is an efficient mechanism to prevent excessive blood loss
following vascular damage. Upon vessel wall damage the continuous lining of the
endothelium is broken and flowing blood is exposed to the connective tissue matrix of the
subendothelium. Tissue Factor (TF) at the site of vascular damage binds to minute
quantities of the circulating form of activated factor VII. This triggers the coagulation
cascade, involving a series of reactions happening either in solution or upon the catalytic
surface provided by nearby activated platelets. This cascade culminates in the formation
of the master enzyme thrombin, which once formed can activate platelets, as well as
participate in its own production and destruction. Platelets are the primary cells involved
in mediating the thrombotic response. In addition to thrombin formed downstream of the
coagulation cascade, platelets are efficiently activated by collagen exposed at the site of
injury.

Moreover, platelets can self activate via released ADP or thromboxane.

Mediators like prostacyclin (PGI2) or Nitric Oxide (NO) from the intact endothelium can
down- regulate platelet activation and keep them quiescent. But once the platelets
encounter a net activating stimulus as a function of the concentration of all of these
simultaneous signals they proceed via a sequence of signaling steps (one amongst which
is the elevation of cytosolic calcium concentration) to become fully activated platelets.
These platelets make up the body of the clot and are held in place by a meshwork of
1

polymerized fibrinogen formed downstream of thrombin in the coagulation cascade. This
process is schematically represented in Figure 1.1-1 and the two individual mechanisms
that are critical for the formation of the stable platelet plug (platelet activation and the
cascade of reactions leading to thrombin production) are introduced below.

Figure 1.1-1 Coagulation and platelet activation pathways during thrombosis.
Haemostasis system involves a delicate balance of mechanisms that maintain fluidity of
blood under physiological conditions, yet allowing the body to mount a robust response
to limit blood loss following vascular injury. The coagulation stimulus at the site of
injury leads to two interlinked responses. First: the exposure of Tissue Factor (TF) at the
sub-endothelium triggers the coagulation cascade leading to the formation of thrombin.
Second: platelets are activated according to the prevailing local concentrations of
thrombin, collagen, ADP, TXA2 and adhere to the growing clot. NO and prostacyclin
(PGI2) from the intact endothelium downregulate activation and keep platelets quiescent.
Once the platelet encounters a net activating stimulus there it activates via an elevation of
cytosolic calcium concentrations. The active platelet surface in turn serves as cofactor for
several of the enzymatic reactions of the coagulation cascade.
2

1.2 Platelet activation
The signaling machinery of circulating platelets makes it possible for them to be
rapidly captured at the site of vascular damage and be transformed into a tight layer that
stems uncontrolled blood loss. The sequence of events underlying platelet activation can
broadly be divided into three stages: initial adhesion to a collagen surface, growth of
thrombus via autocatalytic signaling, and stabilization of the platelet aggregate [1] .

1.2.1 Initiation of platelet activation on collagen surfaces
Under static conditions, collagen alone at the exposed injury is able to capture and
activate platelets. However, under conditions of high shear that exist in the arterial
circulation, platelet capture also requires the presence of VWF [2]. Two of the collagen
receptors (α2β1 and GPVI) bind to collagen directly. Of these GPVI is the most potent in
terms of generating an activating signal. Collagen binding causes GPVI clustering,
leading to phosphorylation of the Fc receptor γ chain (associated with this receptor) by
tyrosine kinases of the Src family. Such phospho-tyrosine residues are recognized by Syk
[3], and the association and activation of Syk activates PLCγ2. PLCγ2 (like other forms of
PLC) converts phosphatidylinositol (PI)-4, 5 P2 to 1,4,5- IP3and diacyclglycerol (DAG).
IP3 opens Ca2+ channels in the platelet dense tubular system, and causes rapid store
operated calcium entry (SOCE), thus quickly raising cytosolic Ca2+ concentrations [4].
DAG activates Protein Kinase C (PKC) in platelets, which in turn governs several of the
serine/ threonine phosphorylation events occurring downstream. PKC activation can
cause integrin activation, aggregation and secretion independently of Ca2+ [5]. GP1B,
α2β1 and αIIbβ3, present in abundance on the platelet surface, bind to collagen via
multimeric VWF (complexed with collagen) under high shear, thus increasing the
3

probability of collagen mediated signaling via GPVI by bringing the ligand and receptor
in close proximity [6].

1.2.2 Growth of the platelet aggregate via autocatalytic signaling
Beyond the first monolayer of platelets adherent to collagen/ VWF, the addition
of subsequent layers of platelets to the growing thrombus is strongly potentiated by the
activity of locally released agonist like thromboxane (TxA2) and ADP, as well as by the
activity of locally formed thrombin. All 3 of these agonists act signal through specific GProtein Coupled Receptors on the platelet surface (GPCRs).
GPCRs are composed of α, β and γ subunits. The binding of an agonist to its
receptor causes an exchange of GTP for GDP on the α subunit, and dissociation of the α
and βγ subunits. Both these units in turn interact with secondary effectors including
PLCβ and Adenyl Cyclase. Human platelets express at least 10 forms of Gα (including
members of the Gq , Gi , G12 , and Gs families) [7].
Thrombin, ADP, and TXA2 activate PLCβ via Gq. PLCβ generates IP3 from
membrane PIP2. IP3 triggers Ca2+ release from the intracellular stores and SOCE, thus
increasing intracellular Ca2+ concentrations from ~100 nM to ~ 1 µM. Rising Ca2+ levels
activate the Ras family member, Rap1B via Cal-DAG GEF. Rap1B activation is a
precursor to αIIbβ3 activation, and allows the platelets to form aggregates with other
platelets through fibrinogen bridges [8].
In addition to integrin activation, shape change is another event that occurs
downstream of agonist induced platelet activation. There is a Ca2+ dependent activation
of myosin light chain kinase (Gq driven), and activation of GTP binding proteins of the
Rho family (GI2 driven) [9]. Rho activation in turn activates kinases like p160ROCK and
4

LIM-kinase, which phosphorylate myosin light chain kinase and cofilin [10, 11], thus
regulating actin dependent cytoskeletal shape. Shape change is mediated via Gqα for ADP
and GI3α for thrombin and TXA2.
Prostacyclin (PGI2) synthesized by the endothelium causes Gsα mediated increase
in adenyl cyclase activity. Also NO from the endothelium can inhibit the hydrolysis of
cAMP by intracellular phosphodiesterases [12]. Taken together these mechanisms elevate
intracellular cAMP levels, which strongly downregulates platelet signaling. Agonists
coupled to Gi family members inhibit cAMP production in platelets, thus allowing
activation to proceed unhindered [13]. Additionally the βγ subunits of these receptors can
activate PLCβ and the γ isoform of PI3K. The effectors for PI3K include Rap1b and Akt
[14]. Signaling downstream of Akt is not completely understood, but deletion of Akt2 in
platelets impairs thrombus formation, stability and platelet secretion [15].
ADP is stored in platelet dense granules and is released upon activation. P2Y1 and
P2Y12 are the primary receptors for this agonist [16]. P2Y1 is Gq coupled and signaling
through this receptor causes Ca2+ mobilization, shape change and thromboxane
generation. P2Y12 is the target of the commonly used anti-platelet drug Plavix [17], and is
a Gi2 coupled receptor that inhibits cAMP production in platelets. A third receptor P2X1 is
an ATP gated channel that allows Ca2+ influx across the plasma membrane [18].
Thrombin is a potent platelet agonist that causes fast mobilization of intracellular
Ca2+, and activation of phospholipase A2 and subsequent thromboxane generation (all
mediated by Gqα) [19]. Also, thrombin can trigger Rho dependent signaling pathways in
platelets (mediated by GI3α) [20], that contribute to actin modeling and shape change.
Thrombin signals through the protease-activated receptor (PAR) family of GPCRs. PARs
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1 and 4 are expressed on human platelets, while PARs 3 and 4 are expressed on mouse
platelets. Thrombin cleaves the N-terminus of these receptors, exposing a new Nterminus that serves as a tethered ligand for these receptors. Synthetic peptides are able to
selectively activate these receptors and mimic the actions of thrombin (SFLLRN for
PAR1, and AYPGKF for PAR4) [21]. Kinetic studies have shown that the human platelet
response to thrombin is biphasic and involves first signaling through PAR1 and
subsequent signaling through PAR4 [22, 23]. In mouse platelets signaling occurs
primarily via PAR4, and is facilitated by PAR3. Conflicting evidence exists Gi signaling
in platelets downstream of thrombin can occur independently of thrombin. In addition to
the PAR receptors, GP1bα has high affinity for thrombin. Absence of this receptor
reduces responses to low doses of thrombin and diminishes PAR1 signaling, suggesting
that this receptor facilitates signaling through the PARs [24, 25].
Ca2+ mobilization activates phospholipase A2 (PLA2), which in turn converts
membrane phospholipids to Arachidonic Acid. TXA2 is produced from membrane
arachidonate by the aspirin sensitive cyclooxygenase (COX-1) enzyme [26].

TXA2

causes Ca2+ mobilization, aggregation, secretion, phosphoinositide hydrolysis and protein
phosphorylation. TXA2 can diffuse across the membrane and activate nearby platelets,
but its activity is limited by the molecule’s short half life (~30sec). Its effects in vitro can
be studied using the stable analog U46619. This agonist signals through the TP receptors
(α and β forms) [26] that signal through Gqα (Ca2+ mobilization) [19] and GI3α (shape
change) [20]. No Gi mediated inhibition of cAMP formation is caused via TP signaling.
The signaling events involved in the initial accumulation of platelets and the
extension of the platelet aggregate are schematically represented in Figure 1.2-1.

6

Figure 1.2-1 Platelet signaling during development and growth of the thrombus.
Platelet activation during thrombosis is governed by several simultaneous activating
signals. Activation by collagen happens predominantly via the receptor tyrosine kinase
GPVI. Subsequent activation involves signaling through the GPCRs P2Y1 and P2Y12
(ADP), PAR1 and PAR4 (thrombin), TP (TXA2) and IP (PGI2). Receptors involved are
shown in red. Under conditions of high shear, VWF allows the platelet to adhere to
collagen via the GP1b receptor.
7

1.2.3 Stabilization of the platelet aggregate
Because of the close proximity of individual platelets, several close contacts are
formed between the surface molecules of individual cells in the growing aggregate. This
sets of additional waves of signaling in the platelets as well and supplies an additional
source of adhesive force between the cells. Further, interactions between the intracellular
domains of αIIbβ3 (bound to its ligands fibrinogen and VWF) and the platelet’s
actin/myosin machinery causes the aggregate to retract upon itself [27], and thus prevent
complete occlusion of the vessel.
Outside-in signaling occurs downstream of the formation of fibrinogen bridges
that link activated platelets together. Several proteins interact with the cytoplasmic
domains of αIIbβ3 to either regulate integrin activation or outside in signaling. Some of
these include talin, myosin, C1B1and the tyrosine kinases Src and Syk. Talin binding is
one of the final events preceding activation. C1B1 can interact indirectly with actin via
PAK. Fibrinogen binding to the extracellular domains of causes a rapid increase in the
activity of Src family members and Syk. These lead to the phosphorylation of the
residues Y773 and Y785 on the β3 cytoplasmic domain of the integrin. These events are
required for full aggregation, spreading and clot retraction. [28]
Platelet Specific Cell Adhesion Molecule (PECAM-1; CD31) is a cell adhesion
molecule capable of homotypic interactions. The C-terminal of PECAM-1 is
phosphorylated at tyrosine residues upon activation and can bind to the phosphatases
Shp-1/2 [29], bringing these enzymes close to their substrates including the Fcγ chain of
GPVI. This limits the extent of collagen signaling [30].
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JAM (Junctional Adhesion Molecule)-A and C are cell adhesion molecules that
localize to platelet-platelet and platelet-leukocyte contacts and mediate adhesive and
signaling interactions between these cells. These molecules support heterotypic
interactions by binding to integrins. Also JAM-A contributes to adhesion by forming
trans interactions involving the N-terminal Ig domain [31, 32]. ESAM (Endothelial Cell
Specific Adhesion Molecule) [33] and CD226 [34] two other members of the CTX
family of immunoglobulin domain containing adhesion molecules detected on active
platelet surfaces. SLAM (signaling lymphocyte activation molecule) [35] and CD84 [36]
are members of the CD2 family of homophilic adhesion molecules expressed on platelets,
and become phosphorylated on activation at platelet-platelet contacts.
Eph kinases are receptor tyrosine kinases that interact in trans with their cell
surface ligands called ephrins triggering bidirectional signaling. Blockade of this
interaction causes reversible platelet aggregation and limits the growth of platelet thrombi
on collagen surfaces. Signaling downstream of these molecules promotes further integrin
activation (by activating Rap1B) and integrin signaling (by phosphorylating the β3
cytoplasmic tail of αIIbβ3) [37]. Similarly growth arrest specific gene - 6 (Gas-6) secreted
from platelet α granules can serve as a ligand for receptor tyrosine kinases Tyro3, Axl
and Mer and cause signaling that promotes platelet plug formation and stability [38].
Aggregation in Gas-6-/- platelets terminates prematurely, and produces a phenotype
resistant to thrombosis [39].
In addition to the numerous proteins secreted from the platelet granules, platelets
shed several surface molecules including GP1Bα, GPVI and P-selectin [40, 41]. Such
shedding has been shown to be mediated by metalloproteases such as ADAM17 and
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serves to limit signaling [40, 42]. CD40 ligand (CD40L) is a membrane protein that
appears on the surface of activated platelets, and gradually releases an 18-kDa exodomain
fragment [43]. The extracellular portion of CD40L can bind to their receptors (CD40) as
well as integrin. Growth of platelet plugs in CD40L-/- show defective thrombus growth
over collagen, decreased stability, and delayed occlusion. These effects are presumably
mediated by integrin since loss of CD40 has no appreciable effect [44].

1.3 The blood coagulation cascade
Under normal conditions in vivo, the intact endothelium inhibits platelet activation
and the chain of plasma reactions known as the coagulation cascade. Upon vascular
damage, exposed collagen initiates platelet activation, and TF initiates the clotting
cascade. The cascade involves a series of sequential enzymatic reactions, wherein at
every step an inactive zymogen is converted into an active enzyme typically by the
product of the previous step, ultimately leading to the formation of thrombin. With the
exclusion of thrombin, such newly formed enzymes have low activity, until they bind to
specific protein cofactors or suitable phospholipid surfaces (typically the active platelet).
This cascade is traditionally divided into “extrinsic” (or Tissue Factor) pathway
and “intrinsic” (or contact) pathway leading to the formation of factor Xa. The portion of
the cascade beyond factor Xa, leading to the formation of thrombin is referred to as the
“common” pathway. These pathways happen in the presence of plasma inhibitors that
limit the activity of the active proteases that are formed. These events are schematically
represented in Figure 1.3-1. Downstream of thrombin, fibrinogen is polymerized during
the process of fibrin formation, and the fibers of fibrin hold the loose platelet aggregate
together. The formed fibrin strands are degraded during the process of fibrinolysis. [45]
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Figure 1.3-1 The reactions of the coagulation cascade generating thrombin.
The Coagulation cascade involves multiple sequential plasma reactions that lead to the
generation of thrombin. Zymogens (red) are converted to active enzymes (green) by the
products of the preceding reactions in the cascade, aided in some cases by active
cofactors (light blue). Several plasma inhibitors (red) serve to inhibit the active proteases.
The cascade is triggered either by the exposure of TF at the site injury (extrinsic cascade)
or by activation of factor XII adsorbed onto negatively charged surfaces (intrinsic
cascade). Both pathways ultimately lead to the formation of thrombin. Thrombin formed
(in addition to other platelet agonists) can activate platelets. The active platelets provide
catalytic surface for several of these reactions. Contact activation can be minimized in
vitro by using Corn Trypsin Inhibitor (CTI) to block XIIa.

1.3.1 The extrinsic pathway
The predominant initiator of the coagulation cascade in vivo is the extrinsic
system, involving exposure of the molecule Tissue Factor (TF) at the site of vascular
damage. TF is normally absent from on cells in contact with plasma, but is present on a
11

variety of cells outside the vasculature [46]. TF exposure, allows it to bind to the
activated form of one of the soluble clotting factors: factor VII. Factor VII is one of a
group of vitamin K-dependent proteins (including factors IX and X, prothrombin and
protein C) that is secreted by the hepatocytes and contains a γ-glutamyl carboxyl acid
(Gla) residue at the N terminal of the molecule. This post-translational modification
allows these molecules to bind calcium subsequently assemble on a phospholipid surface.
Once formed, the TF:VIIa complex can activates factor IX via limited proteolysis.
Alternatively, TF:VIIa can directly activate X and this is the kinetically favored
mechanism in vitro [47]. Activated factor IX can also activate factor X efficiently
provided the cofactor activated factor VIII is present. This leads to the formation of the
“tenase” complex critical for X activation. Absence of factor VIII or IX underlies the
hemorrhagic symptoms of hemophilia A and B respectively [48].
Since all of serine proteases and protein cofactors (excluding TF) in the
coagulation cascade predominantly circulate in plasma as inactive zymogens, it is
puzzling how this cascade can be triggered via the assembly of inert precursors. It is
known that approximately 1 % of total factor VII exists in circulation in the form of VIIa
[49]. Proportions of the active forms of other enzymes are miniscule in comparison.
Exposure of TF leads to the formation of both inactive TF:VII and active TF:VIIa
complexes. Even the minute amounts of TF:VIIa (that can initially exist at circulating
levels of VIIa) can set up autocatalytic feedback and activate VII bound to TF.
Furthermore, a variety of enzymes including factors IXa, Xa, XIIa and thrombin have
been shown to activate VII [50, 51], and this makes the cascade strongly self amplifying.
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1.3.2 The intrinsic pathway
The “intrinsic” ability of plasma to gel when placed in a glass tube, or more
accurately “contact” with negative surfaces (glass, clay, kaolin) gives the intrinsic
pathway its name.
For many years the contact pathway has been considered physiologically
irrelevant because severe deficiency in the initiator of this cascade (Factor XII) causes no
bleeding defect [52]. However recent experiments have revealed that mice deficient in
Factor XII do indeed have a tendency to form unstable thrombi [53, 54]; suggesting that
this often overlooked part of the cascade does indeed have an important physiological
role.
This pathway is triggered by the activation of the zymogen factor XII upon
contact with a negative surface. The heavy chain of factor XII binds to surfaces, leading
to substantial increase in local enzyme concentration, autoactivation and activation of
XIIa dependent prekallikrein (and its cofactor high molecular weight kininogen, HK) and
factor XI. Subsequently, factor IX is activated by the novel dimeric serine protease factor
XIa [55].
Kallikrein in turn cleaves HK to release bradykinin, a potent stimulus which links
the coagulation and inflammatory pathways, and the remaining kinin free kininogen
(activated HK) binds several fold better than intact HK. This allows more prekallikrein to
associate with HK setting up a strong autocatalytic loop. Additionally Kallikrein can
reciprocally activate factor XII [55].
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This pathway is also characterized by negative feedbacks. Factor XIa can cleave
the light chain of HK, which is responsible for the cofactor’s procoagulant activity. This
in turn liberates XIa from the activating surface [56].

1.3.3 The common pathway
Factor Xa formed by either the extrinsic or intrinsic pathway converts
prothrombin to thrombin. Prothrombin is another vitamin K dependent zymogen that
requires calcium to bind to phospholipid surfaces. After cleavage by Xa, the N terminal
Gla portion of prothrombin is removed and thrombin is formed. Thrombin occupies a
central portion in the formation of the haemostatic plug and limits both its own formation
and destruction by acting on multiple substrates including fibrinogen, factors V, VIII, XI,
platelet receptors, and proteins S and C. The rate of thrombin formation is increased by
more than 300,000 fold (in comparison to Xa alone) by the action of the prothrombinase
complex (factors Xa, Va, phospholipid and calcium) on localized prothrombin [57].
Activated factor V is possibly supplied by platelet secretion of

α-granule content

following activation [58].

1.3.4 Coagulation inhibition
Plasma inhibitors serve to limit the extent of both the coagulation and the
fibrinolytic systems. The major plasma inhibitors are C1 inhibitor, ATIII and TFPI.
C1inhibitor is the major inhibitor of the contact system, and accounts for 95% of
the plasma inhibitor capacity of factor XIIa and more than 50% of the inhibitory capacity
of kallikrein [45]. α1-Antitrypsin is the major plasma inhibitor of XIa [59].
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Antithrombin (ATIII) is one in a class of general serine protease inhibitors
(serpins) that limits the action of most active proteases in the coagulation cascade. In
particular ATIII strongly inhibits the actions of thrombin, factors IXa and Xa. ATIII
deficiency is associated with a striking increase in the risk of thromboembolism. The
catalytic site serine of thrombin reacts with an arginine of ATIII to form an inactive
covalent complex. The affinity of ATIII for thrombin is strongly enhanced, by the
binding of a basic group in ATIII to heparin (a highly negatively charged sulfated
polysaccharide that exists on the endothelial surface) [60]. Heparin cofactor II is a serpin
that selectively inactivates thrombin in the presence of heparin or dermatan sulfate [61].
Tissue factor pathway inhibitor (TFPI) is a protein that in association with factor Xa,
inhibits TF:VIIa [62].
α2-Macroglobulin is a secondary inhibitor of several coagulant and fibrinolytic
enzymes including kallikrein, thrombin and plasmin. Enzymes trapped in the cage
structure of this inhibitor are protected from other inhibitors [63]. α2-Antiplasmin is the
primary inhibitor of plasmin and serves to limit the fibrinolytic response till completion
of wound healing [64]. Protein C inhibitor is also a serpin that can function as a
procoagulant molecule by inhibiting the action of protein C [65].

1.3.5 Fibrin formation
The formation of fibrin strands stabilizes the loose platelet aggregate at the site of
injury. Fibrin is formed by the action of thrombin on fibrinogen, a protein present in
abundance both in plasma and platelet granules. Thrombin binding to the central domain
of fibrinogen liberates fibrinopeptides A and B, resulting in fibrin monomer and polymer
formation. Progressive lengthening of the polymer occurs by half overlap, side to side of
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fibrin monomers, thus forming long, thin, fibrin strands. The degree of lateral
polymerization regulates the tensile strength of the clot. Factor XIIIa serves to cross link
these loose fibrin strands and confers resistance to degradation by plasmin [66].
The fibrin mesh holds platelets together and attaches them to the vessel wall, by
binding to platelet receptor glycoproteins and by interacting with other adhesive proteins
like thrombospondin and fibronectin. After binding to platelet binding sites, these
proteins serve as molecular bridges between plasma proteins and the platelet interior,
between platelets and the vessel wall, and between plasma fibrin fibers and the
subendothelial matrix. For instance, fibronectin is crosslinked by XIIIa to fibrin [67], and
its separate binding site for collagen [68] bridges fibrin and the vessel wall. VWF serves
as a bridge between platelet membrane and the subendothelium (via platelet membrane
GP1B and αIIbβ3) [69]. Additionally, platelet αIIbβ3 joins fibrinogen to intracellular actin,
thereby controlling clot retraction and vessel wall constriction [70].
Several mechanisms exist to exist to limit and localize the extent of thrombosis.
Firstly, the shear forces of blood flow tear away loosely attached clumps of platelets [71].
Secondly, thrombin in conjunction with thrombomodulin on the endothelial surface, acts
as a receptor for protein C. Activated Protein C is a potent inhibitor of factors V and VIII
[72]. Soluble pro-coagulant molecules like Xa or thrombin that advect away from the site
of the growing clot are efficiently inhibited by plasma inhibitors like ATIII [60].

1.3.6 Fibrinolysis
Fibrinolysis, along with endothelial cell regrowth and vessel regrowth are repair
mechanisms set in motion following thrombus formation. Similar to the coagulation
cascade, fibrinolysis involves zymogen to enzyme conversions, autoactivation and
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inactivation. The inactive precursor plasminogen is present at high concentrations.
During the initial process of thrombus formation, activated platelets and endothelial cells
release plasminogen activator inhibitors that allow fibrin formation to continue
unhindered. However, once the vessel wall is sufficiently repaired, endothelial cells
release tissue plasminogen activator, which in turn activates plasminogen to plasmin [73].
Plasmin contributes to its own activation by cleaving an activation peptide from
plasminogen, making it more susceptible to surface binding and activation by
plasminogen activators. Also plasminogen bound to fibrin, by lysine binding sites on its
kringle structures has much higher reactivity. The small proportion of plasma fibrinogen
adhered onto fibrin can lead to clot dissolution [74]. There exists a delicate balance
dictated by the position and relative abundance of profibrinolytic plasminogen and
plasminogen activator molecules and antifibrinolytic α2-antiplasmin

molecules

(covalently attached via factor XIIIa action) assembled on the fibrin strands. Soluble
fibrin degradation products like D-dimers are released into the circulation following
fibrinolysis and serve as clinical markers of underlying thrombotic activity [75]. Active
plasmin molecules released into circulation are quickly degraded in solution by α2antiplasmin [76], thus limiting fibrinolysis to the site of the thrombus.
Thus the entire process of clot formation and dissolution is finely regulated by
numerous plasma clotting factors, cellular components including endothelial cells and
platelets, thrombus specific and distributed inhibitory mechanisms, as well as
subendothelial components. This intricate balance of interlinked mechanisms ensures a
robust response that prevents blood loss following injury, but is one that does not occlude
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blood flow by uncontrolled thrombus growth. Disruption of any portion of these
processes can lead to fatal hemorrhagic or thrombotic disorders.

1.4 Outline
Previous studies have often looked at individual parts of the thrombotic response
in isolation. In contrast, this dissertation takes a “systems approach” to thrombosis
integrating experimental and theoretical studies. This work quantitatively characterizes
both the coagulation component of the clotting response leading to the formation of
thrombin via sequential plasma reactions, as well as the cellular component involving
platelet activation. Fibrinolysis has not been considered. High throughput experimental
systems were first developed to efficiently probe the biology of these pathways across
several dimensions. Models were then developed based on these experimental
observations. In the second chapter, a study of the kinetics of thrombin formation in
resting and activated human blood is presented. Thrombin formation is studied in the
presence of a fluorogenic thrombin substrate (Boc-VPR-MCA), and a mechanism based
ordinary differential equation (ODE) model is developed based on the framework of the
Hockin-Mann reaction network. In the third chapter, a study of platelet activation is
presented. “Pairwise Agonist Scanning” (PAS) was developed to predict higher order
interactions amongst several simultaneous signals from a high throughput experiment
sampling of all possible first and second order signals. Data driven Neural Network
models were trained on PAS datasets to make donor specific predictions of platelet
signaling. In the final chapter extensions of this work are suggested.
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Chapter 2
Kinetics of thrombin generation in resting and activated
human blood
2.1 Abstract
Blood function defines bleeding and clotting risks and dictates approaches for clinical
intervention. Independent of adding exogenous tissue factor (TF), human blood treated in vitro
with corn trypsin inhibitor (CTI, to block Factor XIIa) will generate thrombin after an initiation

time (Ti) of 1 to 2 hr (depending on donor), while activation of platelets with the GPVIactivator convulxin reduces Ti to ~20 min. Since current kinetic models fail to generate
thrombin in the absence of added TF, we implemented a Platelet-Plasma ODE model
accounting for: the Hockin-Mann protease reaction network, thrombin-dependent display
of platelet phosphatidylserine, VIIa function on activated platelets, XIIa and XIa
generation and function, competitive thrombin substrates (fluorogenic detector and
fibrinogen), and thrombin consumption during fibrin polymerization. The kinetic model
consisting of 76 ordinary differential equations (76 species, 57 reactions, 105 kinetic
parameters) predicted the clotting of resting and convulxin-activated human blood as well
as predicted Ti of human blood under 50 different initial conditions that titrated increasing
levels of TF, Xa, Va, XIa, IXa, and VIIa. Experiments with combined anti-XI and antiXII antibodies prevented thrombin production, demonstrating that a leak of XIIa past
saturating amounts of CTI (and not “blood-borne TF” alone) was responsible for in vitro
initiation without added TF. Clotting was not blocked by antibodies used individually
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against TF, VII/VIIa, P-selectin, GPIb, protein disulfide isomerase, cathepsin G nor
blocked by the ribosome inhibitor puromycin, the Clk1 kinase inhibitor Tg003, or
inhibited VIIa (VIIai). This is the first model to predict the observed behavior of CTItreated human blood, either resting or stimulated with platelet activators. CTI-treated
human blood will clot in vitro due to the combined activity of XIIa and XIa, a process
enhanced by platelet activators and which proceeds in the absence of any evidence for
kinetically significant blood borne tissue factor.

2.2 Introduction
Blood coagulation is a surface catalyzed protease cascade with autocatalytic
amplification and multiple modes of inhibition [77]. Clotting in vivo is triggered by
exposed tissue factor (TF) during vascular injury or plaque rupture. There is a striking
sensitivity of coagulation to picomolar levels of TF [78]. Considerable uncertainty exists
concerning the relative roles of circulating concentrations of TF [79, 80] and the
mechanism(s) of platelet display of active TF via synthesis [80, 81], de-encryption [82]
or changes in membrane composition [83]. Some of these mechanisms are illustrated in
Figure 2.2-1. The detection of circulating concentrations of activation peptides, such as
F1.2 and fibrinopeptides A and B, inactivation products such as thrombin-antithrombin
(TAT) [84-87] and activated factors such as VIIa and activated Protein C (APC) is proof
of some low level of activated proteases in normal individuals coexisting with flowing
blood in vivo. Exploring this endogenous “engine-idling” active state of blood ex vivo is
central to clinical diagnostics.
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Figure 2.2-1 Triggers of the extrinsic cascade
Although TF exposure at the site of vascular injury is considered to be the predominant
trigger of in vivo coagulation (Also see Figure 1.1-1), several other controversial
explanations have been proposed in existing literature that could account for initiation in
the absence of exogenous TF. “Bloodborne TF”, “Platelet synthesized TF (either by
releasing preformed TF molecules or translating new protein from existing mRNA)”,
“de-encryption” of cryptic TF, and TF independent VIIa activity (using platelet GP1b as
cofactor) have all been proposed as possible mechanisms.
Once initiated with TF, the coagulation cascade proceeds by sequential enzymatic
steps to produce thrombin, which in turn polymerizes fibrinogen to fibrin to form the
protein polymer mesh of the thrombus. Thrombin also has complex regulatory action by
activating platelets and further enhancing thrombin formation by activating V, VII, VIII,
and XI. In vivo, thrombin can limit its own production by binding thrombomodulin and
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converting protein C to activated protein C (APC), which subsequently inhibits Va and
VIIIa. Upon activation, platelets express anionic phospholipids on their surface, an event
that is critical for several surface bound reactions of the cascade [88].
Given the central role of thrombin in clotting, much effort has focused on
experimentally detecting the transients of thrombin generation [89]. ‘Calibrated
Automatic Thrombography’ measures thrombin formation by following the cleavage of
more than 100 μM of the thrombin substrate Z-Gly-Gly-Arg-MCA [90]. However, the
use of this fluorogenic substrate has been shown to interfere with the kinetics of the
cascade by competitive inhibition of thrombin [91]. Furthermore, inhibitory influences of
anticoagulants such as citrate may influence conclusions drawn from experiments with
whole blood [92]. Complications due to artificial material activation of the contact
pathway in vitro can be minimized by the inhibition of the contact system through the use
of CTI to inhibit XIIa [93].
We have built upon the existing Hockin-Mann reaction network of the extrinsic
coagulation cascade [94] to predict the function of blood studied in vitro with contact
pathway inhibition. The Hockin-Mann model is a homogenous ordinary differential
equation (ODE) reaction scheme that assumes a maximally activated platelet at t = 0. The
Hockin-Mann model predicts accurately the initiation times of blood coagulation at
picomolar levels of TF, but breaks down at zero or sub-picomolar levels of exogenously
added TF [95]. Other models have attempted to consider the platelet as a separate entity
which exists in discrete activation states and contributes binding sites once activated for
the catalysis of several coagulation reactions [96, 97]. Such approaches have shed light
on the critical importance of platelet activation mediated changes on the reaction surface

22

area, the fragility of the cascade to thrombin induced activation of the platelet, stochastic
effects at low molecular counts and experimentally observed variability in the initiation
of clotting. However, these models still do not explain why blood drawn into CTI will
clot without exogenous addition of TF.
Quantitatively, the systems biology analysis of blood clotting must account for
strong autocatalytic feedback, nonlinearity of kinetic rates, and extreme sensitivity to
initial conditions, specifically to help predict system outcomes that lead to insufficient or
overactive responses (i.e. bleeding or thrombosis). The present study explores the
stability of normal donor blood (i.e. what tips the balance towards clotting) as indicated
by prolongation or reduction of the clotting time. We have developed and validated a
high throughput assay to measure thrombin production initiation in static blood under
minimal inhibitory influences of fluorogenic substrate and anticoagulant. We used this
assay to examine several possibilities in existing literature that could account for
initiation without exogenous TF and conclude that a leak of XIIa past saturating CTI is
responsible for such initiation. Further, our studies demonstrated blood’s graded
sensitivity to exogenously added TF, IXa and XIa; a dramatic switch like response to
exogenously added Xa; little discernible effect of exogenously added Va; and statistically
significant VIIa activity (independent of TF) when used above nanomolar concentrations.
From a systems biology perspective that seeks to accommodate patient-specific
variations, modeling can help address central questions regarding: (i) the regulation of
response to perturbation, (ii) the stability of blood in vivo or ex vivo in the face of zero or
near-zero levels of active TF or active proteases, and the (iii) safe pharmacological
alteration of blood function.
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2.3 Materials and methods
2.3.1 Materials
The fluorogenic thrombin substrates Boc-Val-Pro-Arg-methylcoumarinamide
(Boc-VPR-MCA) and Z-Gly-Gly-Arg methylcoumarinamide (Z-GGR-MCA) were
obtained from Bachem (King of Prussia, PA). Lipidated recombinant TF (baculovirus
expressed, amino acids 1-263; 43kDa), monoclonal anti-human FVII/VIIa, and TF
ELISA kits were obtained from American Diagnostica (Stamford, CT) and used to
determine the available TF antigen concentration of 18.2 nM. Monoclonal anti human
FXI and FXII were obtained from Enzyme Research Laboratories (South bend, IN).
Monoclonal anti human P-selectin was obtained from R&D Systems (Minneapolis, MN).
Monoclonal anti human Gp1bα was obtained from Lifespan Biosciences (Seattle, WA).
Polyclonal anti human cathepsin-G was obtained from Molecular Innovations (Novi, MI).
Monoclonal anti human PDI was obtained from was obtained from Affinity Bioreagants
(Rockford, IL). Thrombin-antithrombin ELISA kits were obtained from Dade Behring
(Deerfield, Illinois). Active site inhibited VIIa (VIIai) was gifted by Novo-Nordisk,
Denmark. Other reagents included: adenosine diphosphate (ADP), benzamidine
hydrochloride, EDTA, HEPES, NaCl, NaOH, sodium citrate, apyrase,PGE2, Tg003 and
Puromycin (all from Sigma, St. Louis, MO); corn trypsin inhibitor (CTI), Phe-Pro-Argchloromethylketone (FPRCK), human α-thrombin, polyclonal anti-human TF, Xa, Va,
VIIa, IXa, XIa , human plasmas deficient in prothrombin and factors V, VII, XI or XII
(all from Hematological Technologies, Essex Junction, VT); convulxin (CVX,
Centerchem, Norwalk, CT); and black 384-well plates (Corning, Corning, NY). All
reagents were stored and prepared according to the manufacturers’ recommendations.
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The buffer used for all dilutions was HEPES buffered saline (HBS, sterile filtered 20 mM
HEPES and 140 mM NaCl in deionized water adjusted to pH 7.4 with NaOH).

2.3.2 Blood collection and preparation of washed platelets
Unless otherwise noted, blood was collected in a syringe containing 1 part sodium
citrate to 9 parts blood and 50 μg CTI/mL.

To obtain washed platelets for the

experiments in Figure 2.4-10, blood was first centrifuged at 120g for 12 min to obtain
platelet rich plasma (PRP). PRP was then treated with 200μM PGE2 and 1unit/ml
apyrase to prevent activation during subsequent spinning. A platelet pellet was obtained
by centrifuging PRP at 800g for 10 min and this pellet was resuspended in HBS to yield a
final concentration of ~3×108 platelets/ml.

2.3.3 High throughput experimentation
Prior to phlebotomy, all reagents were prepared in a 384-well plate using a
Thermo Multidrop and a Perkin-Elmer JANUS workstation. For all experiments, blood
was added to the whole (or segments) of a well plate using a PerkinElmer Evolution P3.
To ensure a simultaneous activation time, citrated blood was recalcified in all 384 wells
simultaneously, yielding a final added calcium concentration of 10 mM. To detect
thrombin activity with time, we added the fluorogenic substrate (SIIa), Boc-VPR-MCA
(10

μM)

to

every

well

and

detected

the

fluorescence

of

the

released

aminomethylcoumarin (AMC) with Thermo Fluoroskan fluorimeters preheated to 37 °C.
Each well was read once per minute for 4 hr. After 4 hours, 5 U thrombin/well was
added and then the plate was read again once per minute for 20 minutes to determine the
maximal signal. This procedure is illustrated in Figure 2.3-1.
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Figure 2.3-1 High Throughput Experimental Procedure to study coagulation
(A) Experimental protocol. Calcium and the fluorogenic thrombin substrate (SIIa) were
added to the 384-well plate on a Thermo Multidrop. The plate was placed on a PerkinElmer Janus where various concentrations of each individual species were added to each
well. After phlebotomy, the plate was moved to a Perkin-Elmer Evolution P3 where the
blood was added to all wells simultaneously (t = 0). The plate was read in a ThermoElectron Fluoroskan where the fluorescence was measured for 4 hr. The time from vein
to first measurement was under 5 min. (B) Initiation Time. The time required to reach
5% conversion of the fluorogenic substrate was set as the initiation time (Ti). Relative
prolongation or reductions in Ti were used to quantify coagulation initiation. (Thanks to
Bill Denney for his contribution in developing this assay).
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In experiments to study the effect of fluorogenic substrate concentration, BocVPR-MCA or Z-GGR-MCA were used at final concentrations between 1 and 100 μM.
All experiments were carried out in 5x diluted whole blood. Fractional conversion of the
fluorogenic substrate was determined according to:
C=

F − Fmin
Fmax − Fmin

(2.3.1)

where C is the fractional conversion, F is the instantaneous fluorescence at any time, Fmin
is the minimum fluorescence for that well, and Fmax is the maximum fluorescence in that
well during either the experiment or after thrombin addition. The initiation time (Ti) was
set when C rises past 0.05.

2.3.4 Thrombin-Antithrombin (TAT) immunoassays
TAT serves as a measure of the cumulative thrombin production. Citrated blood
was dispensed into all wells of a 384-well plate containing calcium using a PerkinElmer
Evolution P3 liquid handling station. Reactions were manually stopped in columns of the
well plate by adding a ‘stop cocktail’ of 50 mM EDTA, 20 mM benzamidine and 100 μM
Phe-Pro-Arg-chloromoethyl ketone (PPACK) at specific time points [98]. The plate was
spun at 120g for 12 min to separate out plasma, which was subsequently assayed for TAT
by ELISA (Dade Behring).

2.3.5 Simulation
Simulations were performed in Matlab R2008b (version 7.7.0.471) using the
Systems Biology Toolbox 2 (SBTOOLBOX2) with the SBPD extension package ODE
solver with an absolute tolerance of 10-30 and a relative tolerance of 10-7 [99].
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A function of thrombin concentration was fit with a Hill function to published
experimental data that quantified ‘Platelet Activation Status’ by reporting surface
Phosphatidylserine exposure (measured by fold increase in Annexin V binding) in
response to thrombin (IIa) [100] (Figure 2.3-2):
f ([ IIa * (t )]) =

[ IIa * (t )]1.6123
[ IIa * (t )]1.6123 + (2.4279 × 10 −9 )1.6123

(2.3.2)

where [ IIa * (t )] = max ([ IIa(t ' )]) . Since thrombin concentration physiologically starts
t ' [0 t ]

decreasing after monotonically rising to a peak, it was necessary to use the maximum
transient thrombin concentration max ([ IIa(t ' )]) , to ensure that
t ' [0 t ]

f ([ IIa * (t )]) never

decreases once it has reached its maximum magnitude. IIa * (t ) is exactly equivalent to
[IIa(t)] until [IIa(t)] reaches its peak, whereafter [ IIa * (t )] is constant at that maximum
value. This ensures that the platelet stays activated even when thrombin declines.

Figure 2.3-2 Definition of εmax for a given thrombin concentration

Phosphatidylserine exposure measured by fold increase in annexin V binding was
obtained from published values [100] and are shown in blue circles. The maximum
platelet activation state attainable at a given thrombin concentration (εmax) was obtained
by fitting a hill function to this data (green line).
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For a given [IIa], we define the maximum platelet activation state, ε max :

ε max = ε max + (1 − ε max )× f ([ IIa * (t )])
0

0

(2.3.3)

where εmax describes the fractional activation state of the platelet. ε max 0 defines the basal
activation state of the platelet at t=0, and is set to 0.01 in most simulations (assuming a
basal 1% binding strength of coagulation factors to the resting platelet surface). For full
activation of platelets at [thrombin] > ~10 nM, ε max equals 1 and protein dissociation is
minimized (Figure 2.3-2).
The instantaneous platelet activation state ε is governed by the differential
equation

dε
= k (ε max − ε )
dt

(2.3.4)

with the initial condition at t = 0, ε = 0.01 , this solves to,

ε = ε max − (ε max − 0.01) × exp(−kt )

(2.3.5)

The constant k is inversely proportional to the time scale of platelet activation, and was
set to 0.005. This is consistent with the fact that it takes ~ 200 s for platelets to mobilize
calcium from intracellular stores upon stimulation with thrombin or other platelet
agonists [101]. Such a form of the platelet function (ε) ensures that the platelet achieves
its maximum attainable activation state (εmax) not instantaneously, but on a
physiologically relevant timescale. Transients of ε are shown for values of εmax= 0.25,
0.5, 0.75 and 1.0 are shown in Figure 2.3-3.
To account for changes in the reaction rates with platelet activation, we modified
the Hockin-Mann model rate constants as follows,
kmodified = koriginal × (η / ε)
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(2.3.6)

where η was a parameter that was used to alter the magnitude of the rate constant used in
the Hockin-Mann model. Many of the Hockin-Mann model parameters were originally
fitted empirically to global experimental data. For η = 1 and full platelet activation (ε =
1), the modified value becomes the original value. For η ≠ 1, the modifications may be
regarded as further fits to experimental data, consistent with published values of rate
constants (footnotes to Table 2.4-1).

Figure 2.3-3 Representative transients of ε for εmax= 0.25, 0.5, 0.75 and 1.0

The instantaneous platelet activation status (ε) approaches its maximum attainable value
(εmax) on a time scale consistent with the time it takes for the platelet to mobilize
intracellular calcium. Shown are ε transient profiles at various values of εmax.
To estimate the sensitivity of our model’s output to the choice of kinetic
constants, a global sensitivity analysis of the models output thrombin concentration at 0
and 10 pM TF concentration was carried out by the method of weighted averaging of
local sensitivities. The results of this analysis are shown in Figure 2.4-15 A and B;
Table 2.4-3 and Table 2.4-4.
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2.4 Results
We have used a high throughput fluorogenic assay to measure coagulation
initiation in 384-well plates where 5x-diluted, citrated human blood (CTI treated) was
recalcified within 5 min of venipuncture (Figure 2.3-1 A). A level of 5% cleavage of the
fluorogenic substrate Boc-VPR-MCA was used as the coagulation initiation time (Ti). A
large burst in thrombin production was always detected within minutes after Ti. Relative
prolongation or reductions in Ti were used to quantify coagulation initiation in response
to varying conditions (Figure 2.3-1 B). The observed bursts in fluorescence were
completely abolished by the thrombin inhibitor PPACK, and were not observed in
prothrombin deficient (platelet supplemented) plasma (not shown), proving that we were
indeed detecting thrombin and not some other non specific protease mediated cleavage of
the fluorogenic substrate.
The Platelet-Plasma model (Figure 2.4-1, Table 2.4-1 and Table 2.4-1) was built
on the existing framework of the Hockin-Mann model [94] and our experimental
observations.

During the course of thrombin generation in the well plate, platelets

become activated and this activation was modeled using a coarse-grained description of
platelet function by equating platelet activation (ε) to phosphatidylserine (PS) exposure as
a function of thrombin concentration (Figure 2.3-2 and Figure 2.3-3). The complete
topology of the model, its constituent reactions, and initial conditions are shown in
Figure 2.4-1, Table 2.4-1 and Table 2.4-2. (Also see Supporting Information

of [102] for full listing of ODEs and reactions). Justifications for alterations to kinetics
are explained in the footnotes to Table 2.4-1.
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Figure 2.4-1 Schematic of the Platelet-Plasma model.

A Wiring diagram of the Platelet-Plasma model is shown above. Blue portions represent
additions to the Hockin-Mann model [94]. Binding and unbinding equilibriums are
shown in black. Reactions highlighted in pink occur on the activated platelet, and the
respective unbinding reaction rates decrease by two orders of magnitude during the
course of platelet activation. Proteolysis reactions are represented by the green arrows.
Inhibition reactions are shown in red.
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Hockin-Mann
Rxn

Model Expressions

1

TF + VII ↔ TF=VII

2

TF + VIIa ↔ TF=VIIa

3

33

4
5
6
7
8
9

TF=VIIa + VII → TF=VIIa + VIIa
Xa + VII → Xa + VIIa
IIa + VII → IIa + VIIa
TF=VIIa + X ↔ TF=VIIa=X →
TF=VIIa=Xa
TF=VIIa + Xa ↔ TF=VIIa=Xa
TF=VIIa + IX ↔ TF=VIIa=IX →
TF=VIIa + IXa
II + Xa → IIa + Xa

k1

k -1

3.2 x 106
-1

-1

2.3 x 107

3.1 x 10-3

M s

(s-1)

(M)

-1

s

-1

Model Km or Kd

3.1 x 10-3

M s
-1

k cat

-1

s

Platelet-Plasma
η

Model (ε =1) Km or

References

Kd (M)

9.6 x 10-10

10

9.6 x10-9

[103, 104]

1.3 x 10-10

0.01

1.3 x10-12

[105]

2.8 x 10-7

0.01

2.4 x 10-7

[105, 106]

8.6 x 10-7

1

8.6 x 10-7

[107]

4.2 x 10-7

1

4.2 x 10-7

[108]

4.4 x 105
M-1 s-1
1.3 x 107
M-1 s-1
2.3 x 104
M-1 s-1
2.5 x 107
-1

-1

M s

2.2 x 107
M-1 s-1
1.0 x 107
M-1 s-1
7.5 x 103
M-1 s-1

1.05 s-1

6

19 s-1
2.4 s-1

1.8

10

IIa + VIII → IIa + VIIIa

11

VIIIa + IXa ↔ IXa=VIIIa

12
13
14

34

15
16
17
18
19
20

IXa=VIIIa + X ↔ IXa=VIIIa=X →
IXa=VIIIa + Xa
VIIIa ↔ VIIIa1•L + VIIIa2
IXa=VIIIa=X → VIIIa1•L + VIIIa2 + X
+ IXa
IXa=VIIIa → VIIIa1•L + VIIIa2 + IXa
IIa + V → IIa + Va
Xa + Va ↔ Xa=Va
Xa=Va + II ↔ Xa=Va=II → Xa=Va +
mIIa
Xa=Va + mIIa → Xa=Va + IIa
Xa + TFPI ↔ Xa=TFPI

2.0 x 107
M-1 s-1
1.0 x 107
-1

-1

5.0 x 10-3
-1

M s

s

1.0 x 108

1.0 x 10-3

-1

-1

-1

M s

s

6.0 x 10-3

2.2 x 104

s-1

M-1 s-1

8.2

5.0 x 10-10

0.02

1.0 x10-11

[109, 110]

8.2 x 10-8

0.01

8.2 x 10-8

[111]

2.7 x 10-7

0.01

2.7 x10-9

[112, 113]

5.0 x 10-10

0.04

2.0 x10-11

[114]

1.6 x 10-6

0.02

6.5 x 10-7

[115]

4.0 x 10-10

1

4.0 x10-10

[116]

1.0 x 10-3
s-1
1.0 x 10-3
s-1
2.0 x 107
M-1 s-1
4.0 x 108
M-1 s-1
1.0 x 108
-1

-1

M s

0.2 s-1
103 s-1

63.5

1.5 x 107
M-1 s-1
9.0 x 105

3.6 x 10-4

M-1 s-1

s-1

21
22
23
24

TF=VIIa=Xa + TFPI ↔
TF=VIIa=Xa=TFPI
TF=VIIa + Xa=TFPI →
TF=VIIa=Xa=TFPI
Xa + ATIII → Xa=ATIII
mIIa + ATIII → mIIa=ATIII
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25

IXa + ATIII → IXa=ATIII

26

IIa + ATIII → IIa=ATIII

27
28

TF=VIIa + ATIII → TF=VIIa=ATIII

3.2 x 108
-1

-1

1.1 x 10-4

M s

s

M-1 s-1
7.1 x 103
M-1 s-1
4.9 x 102
M-1 s-1
7.1 x 103
M-1 s-1
2.3 x 102
M-1 s-1

MCA-IIa → Boc-VPR + AMC + IIa

M-1 s-1

s-1

XIIa + XII ↔ XIIa=XII → XIIa + XIIa

31

XIIa + PK ↔ XIIa=PK → XIIa + K

[106]

1.5 x 103

6.1 x 103

30

3.4 x10-11

M-1 s-1

1.0 x 108

XII → XIIa

100

5.0 x 107

Boc-VPR-MCA + IIa ↔ Boc-VPR-
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3.4 x 10-13

-1

53.8

6.1 x 10-5

-

5.0 x 10-4
s-1
1.0 x
8

-1

-1

10 M s
1.0 x

108M-1 s-1

750 s-1
3.6 x 103

3.3 x
10

-2

40

-

1

7.5 x 10-6

[117, 118]

-

1

3.7 x 10-5

[117, 119]

32

XII + K ↔ XII=K → XIIa + K

33

PK + K → K + K

34

K → K.Inhibited

35

XIIa + CTI ↔ XIIa=CTI

36

36

XIIa + C1inh → XIIa=C1inh

37

XIIa + ATIII → XIIa=ATIII

38

XI + IIa ↔ XI-IIa→XIa +IIa

39

XIIa + XI ↔ XIIa=XI → XIIa + XIa

40

XIa + XI ↔ XIa=XI → XIa + XIa

41

XIa + ATIII → XIa=ATIII

42

XIa + C1inh → XIa=C1inh

1.0 x
8

-1

-1

10 M s

45.3 s-1

5.7

2.7 x

-

1

5.1 x 10-7

-

104M-1 s-1

[121]

1.1 x 10-2

[122]

s-1
1.0 x 108
M-1 s-1

2.4 s-1

-

-

2.4 x 10-8

3.6 x 103
21.6 M-1

[123]

s-1
-1

-1

M s

1.0 x 108
M-1 s-1
3.19 x
106M-1 s-1
3.2 x 102
M-1 s-1
1.8 x 103
M-1 s-1

[93]
[123]

M-1 s-1

1.0 x 108

[117, 120]

5 s-1
200 s-1

1.3 x
10-4
5.7 x
10-4

-

-

5.0 x 10-8

[124, 125]

-

1

2.0 x 10-6

[120, 124]
[124, 126]
[127]
[127]
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XIa + α1AT → XIa= α1AT

44

XIa + α2AP → XIa= α2AP

45

XIa + IX ↔ XIa-IX→XIa +IXa

46

IXa + X ↔ IXa= X → IXa + Xa
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47

Xa + VIII ↔ Xa=VIII → Xa + VIIIa

48

VIIa + IX ↔ VIIa=IX → VIIa + IXa

49
50
51
52
53

VIIa +X ↔ VIIa=X → VIIa + Xa
Fbg + IIa ↔ Fbg = IIa → Fbn1 + IIa +
FPA
Fbn1 + IIa ↔ Fbn1 = IIa → Fbn2 + IIa
+ FPB
2Fbn1 ↔ (Fbn1)2
(Fbn1)2 + IIa ↔ (Fbn1)2 = IIa →
(Fbn2)2 + IIa + FPB

1.0 x 102

[127]

M-1 s-1
4.3 x 103

[127]

M-1 s-1
1.0 x 108
-1

-1

M s

1.0 x
8

-1

-1

10 M s

1.0 x 108
M-1 s-1
1.0 x 108
-1

-1

M s

1.0 x 108
-1

-1

M s

1.0 x 108
M-1 s-1
1.0 x 108
-1

-1

M s

41 s-1
0.64 s-1
2.1 s-1
0.9 s-1
210 s-1

10

-4

0.023
3.6 x
10

-5

1.6 x
10-6

1

4.9 x 10-7

-

1

6.4 x 10-9

-

1

2.1 x 10-8

-

1

[128, 129]
[111, 130,
131]
[110, 132,
133]

9 x 10-9

[134]

2.1x 10-6

[134]

84

-

7.2 x 10-6

[135]

742.6 s-1

7.4

-

7.5 x 10-6

[135]

6.4 x 10-2

M-1 s-1

s-1

M-1 s-1

7.0 x

-

636 s-1

1.0 x 106
1.0 x 108

7.7

701 s-1

[135]
49

-

7.5 x 10-6

[135]

54
55
56
57

Fbn2 + IIa ↔ Fbn2 = IIa
(Fbn1)2 = IIa + ATIII → (Fbn1)2 = IIa:
ATIII
Fbn1 = IIa + ATIII → Fbn1 = IIa: ATIII
Fbn2 = IIa + ATIII → Fbn2 = IIa: ATIII

1.0 x 108
-1

-1

M s

1.6 x 104
M-1 s-1
1.6 x 104
M-1 s-1
1.0 x 104
M-1 s-1

1.0 x 103
-1

s

-

1.0 x 10-5

[135]
[135]
[135]
[135]
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Table 2.4-1 Reactions used in the Platelet-Plasma model.
Rxn 1. Bach et al.[103] report a decrease in KH from 14.9 to 0.58 nM as %

phosphatidylserine (PS) increases from 0 to 40.
O’Brien et al. [104] report a kassoc of 3.14×105 M-1 s-1 and a kdiss of 6.29×10-4 s-1,
which yields a Kd of ~2 nM. With our choice of η, Kd is comparable to this value.
Rxn 2. Shaw et al.[105] report a decrease in Kd from ~60 pM to ~10 pM as % PS

increases from 10-40. on TF liposomes and a decrease from ~90 pM to ~10 pM as
% PS increases from 10-70 on TF nanodiscs.
Rxn 6. Shaw et al.[105] also report an ~20x decrease in Km from ~400 nM to 20 nM for

X activation as % PS increases from 10 to 40. Baugh et al. [106] report an
experimental Km of 238 nM on 25% PS vescicles.
Rxn 7. The product inhibition of TF:VIIa by Xa is dependent on local Xa concentrations.

Given that Xa and X binding to a PSPC bilayer increases hyperbolically with Kds
of 53.9 and 34.2 nM respectively [107] and that the TF:VIIa:X complex is
strengthened with increasing PS content (see 6), it is reasonable to assume that the
TF:VIIa:Xa complex is also strengthened with increasing PS levels.
Rxn 8. Beals et al. [108] report that the Kd for bovine IX binding to lipid surface at

optimum [Ca2+] decreases from 4.9 to 1.7 μM as % PS increases from 20 to 50.
Given that the formation of TF:VIIa is favoured with increasing PS content (See
2) and analogous to the increased strength of the TF:VIIa:X complex with
increased PS (see 6), we expect that the formation of TF:VIIa:IX will also
increase with increasing PS content.
Rxn 11. Jenkins et al. [109] report a decrease in Kd from 351 nM to 4 nM on PCPS

vesicles. Neuenschander and Jesty [110] report a Kd of 74 pM on activated
platelet surfaces as opposed to 550 pM on equimolar PSPC vesicles. A Kd of 10
pM on the activated platelet was required to fit the shape of the IXa titration in
Figure 2.4-11 B.
Rxn 12. Rawala Sheikh et al. [111] report a decrease in Km from 45μM to 160nM from

using unactivated to activated platelets respectively.
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Rxn 13. Fay et al. [112] report a Kd value of ~260 nM for this interaction at pH 7.4 in the

absence of phospholipids. Fay et al. [113] report that this interaction is stabilized
by the presence of phospholipid. In the Platelet-Plasma model this dissociation
constant changes from 270 nM to 2.7 nM as the platelet activates.
Rxn 17. Lindhout et al. [114] report a decrease in Kd from 3.3 nM in solution to 30 pM

using 10μM 40% PS.
Rxn 18. Rosing et al. [115] report a decrease in Km from 34.5 to 0.21 μM using 7.5 μM

phospholipids.
Rxn 20. Huang et al. [116] report a decrease in Ki from 85.2 to 65.2 pM on using

phospholipids.
Rxn 21. Given that the TF:VIIa:Xa (see 7) and the Xa:TFPI (see 20) complexes are

strengthened on phospholipids, we expect the stabilization of the
TF:VIIa:Xa:TFPI complex with the exposure of phospholipids as the platelet
activates.
Baugh et al. [106] report an off rate 3.6 × 10-4 s-1 for Xa unbinding Xa:TFPI , and
on rates experimentally determined to be 9.0 × 105 M-1s-1, or numerically
estimated to range between 6.8 × 105 and 1.35 × 106 M-1s-1. Their data imply that
these constants are comparable to those for the binding of TF:VIIa:Xa to TFPI (ie
a Kd between 2.66×10-10 and 5.29 × 10-10 M) . The original constants for this
reaction in the Hockin-Mann model were fitted empirically, but their choice of
constants results in a far stronger complex than can be reasonably expected from
literature. Hence we have increased Kd by two orders (η = 100) of magnitude
from their reported value.
Rxn 28. Experimentally determined by fitting initial velocities of AMC release to

standard Michelis-menton kinetics.
Rxn 29.XII activation was coarse grained by assuming a first order dependence on XII

concentration and estimating a rate of production (5×10-4s-1) that would resolve
the disparity between the Hockin-Mann model prediction and the experimentally
observed control.
Rxn 30. Kinetics of XIIa autoactivation (in the presence of negatively charged dextran

sulfate) was from Tankersley et al. [117]. Griep et al. [118] showed that the
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autoactivation (and Kallikrein activation, See 32) of XII is strongly promoted by
negatively charged sulfatides.
Rxn 31. Kinetics of Pre-Kallikrein activation by β-XIIa (in the presence of dextran

sulfate) was from Tankersley et al. [117]. Pre-Kallikrein activation by XIIa was
shown to be facilitated by negatively charged phosphoinositides [119].
Rxn 32. Kinetics of XII activation by Kallikrein (in the presence of dextran sulfate) was

from Tankersley et.al [117]. Walsh and Griffin [120] showed that this reaction is
sped up by the presence of activated platelets.
Rxn 33. Kinetics of second order Kallikrein autoactivation was from Tans et al. [121].
Rxn 34. The pseudo first order rate constant for the inhibition of Kallikrein in plasma (by

C1 inhibitor, α2-macroglobulin and ATIII) was obtained from Van-Der-Graaf et

al. [122].
Rxn 35. Hojima et al. [93] report a Ki of 24 nM for the inhibition of XIIa by CTI.
Rxns 36 and 37. Kinetics of XIIa inhibition by C1inhibitor and ATIII were from Pixley

et al. [123]. C1 inhibitor is the primary inhibitor of XIIa. ATIII inhibition
(although minor) was considering for consistency with other inhibitory reactions.
Rxn 38. Rate constants (in solution) for this reaction are from Gailani et al. [124] .Some

controversy exists over the physiological surface for this reaction. Oliver et al.
[125] showed that this reaction happens physiologically on the activated platelet
surface. However several seminal papers by Baglia-Walsh et al. in the laboratory
of Peter N. Walsh which originally proposed that this mechanism happens on the
active platelet have subsequently been retracted. We therefore chose not to
include a dependence of this reaction on ε.
Rxn 39. Rate constants (in solution) for this reaction are from Gailani et al. [124]. Walsh

and Griffin [120], showed that this reaction is sped up by the presence of
activated platelets.
Rxn 40. Several authors describe this mechanism of XI auto-activation (See for example

[124, 136]). However, following the retraction of (Baglia et al. JBC 2000) we are
not aware of an experimental report of the kinetics of this reaction. Kramoroff et

al. [126]estimate the second order rate constant of this reaction to be 3.19 μM-1s-1
by optimizing an ODE model of the intrinsic cascade to experimental
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measurements of APTT. They consider either XI autoactivation or XI activation
by thrombin (but not both possibilities) as plausible mechanisms for XI activation
(in addition to activation by XIIa), thus their estimated value is likely an
overestimate. We utilized a value 4 fold lower than the value they report for this
constant, since we consider thrombin activation of XI in addition to
autoactivation. This was in keeping with the experimental titration of XIa (Figure
2.4-11 C) where we have noticed strong sensitivity to even minute amounts of

XIa.
Rxns 41 - 44. Rate constants are for inhibition of XIa in plasma are from Wuillemein et

al. [127]
Rxn 45. Rate constants (in solution) for this reaction are from Walsh et al. [128]. Gailani

et al. [129] propose a mechanism by which this reaction could happen on the
platelet surface facilitated by the dimeric form of factor XI.
Rxn 46. Rawala - Sheikh et al. [111] report a reduction in Km from 45 μM to 390 nM

from unactivated to thrombin activated platelets. In later publications from the
same lab, Scandura and Walsh [130] report a Km of 16nM and a kcat of 5.1×10-4
for the activation of X by IXa alone on SFLLRN activated platelets in a model
where platelet bound IXa interacts with zymogen X, and Wilkinson et al. [131]
report a Km of 6.4 nM and a kcat of 7.0×10-4 .
Rxn 47. Rate constants were obtained from Leipold et al. [132] using catalytic

efficiencies reported in Lollar et al. [133]. Activation of VIII by Xa, unlike
activation by thrombin (reaction 10) was reported to be markedly dependent on
the presence of either phospholipid or active platelet surface [110].
Rxn 48. Rate constants for this reaction were from Komiyama et al. [134]. Unlike the

activation of X by VIIa alone (see 49) the Km for this reaction was reported to be
relatively constant over a wide range of added PCPS concentrations, thus unlike
other unbinding reactions in the model there was no dynamic change in reaction
rate with platelet activation.
Rxn 49. Rate constants for this reaction were from Komiyama et al. [134]. The authors

report a decrease in Km from 1.48 to 0.25 μM with PCPS levels increasing from
1.4 to 21 μM.
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Rxns 50-57. Kinetics of fibrin polymerization are taken from Naski et al. [135]

Reactions 1-27 comprise the original Hockin-Mann Model.
For reactions 1-27, parameter values were from the Hockin-Mann model when a
reference is not cited.
Except for reaction 13, ε wherever applicable operates on the off rate usually defined as
k-1. For reaction 13, ε operates on k1 which is the actual unbinding rate of the VIIIa
complex. The notation for this reaction is kept consistent with its description in the
Hockin-Mann Model.
On-Rates were assumed to be diffusion limited (with a k1 of 1.0 x 108 M-1 s-1) [96], and
the corresponding off-rate was calculated from Km using K m =

koff + kcat
kon

.

Supporting Information of [102] provides a complete description of the ODEs for all 76

species in the assembled reaction network, along with the definition of every reaction
rate. Essentially all of the model parameters (rate constants and initial conditions) are
known or estimated from literature (Table 2.4-1). The use of η clarifies changes from the
original Hockin-Mann rate constants that are justified by more recent literature
measurements (See Table 2.4-1 footnotes). Only, the rate of XIIa leakage was estimated
(i.e. fitted) based on the difference between simulation and experiment at 0 added TF.
To estimate the sensitivity of our model’s output to the choice of kinetic
constants, a global sensitivity analysis of the models output thrombin concentration at 0
and 10 pM TF concentration was studied by the method of weighted averaging of local
sensitivities (Figure 2.4-15 A and B; Table 2.4-3 and Table 2.4-4). Local sensitivity of

Ti to 10 fold variations in important parameters (determined from the global sensitivity
analysis) across the entire range of titrated TF concentrations is shown in Figure 2.4-16.
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Species
TF

Hockin-Mann Model Initial

Platelet-Plasma Model Initial

Concentration (M)

Conditions (M)

0

0

VII

1.0 x 10

TF=VII

0

VIIa

1.0 x 10

-8

1.0 x 10-8
0

-10

1.0 x 10-10

TF=VIIa

0

0

Xa

0

0

IIa

0

0

X

1.6 x 10-7

1.6 x 10-7

TF=VIIa=X

0

0

TF=VIIa=Xa

0

IX

9.0 x 10

TF=VIIa=IX

0

IXa

0

0
-8

9.0 x 10-8
0
0

II

1.4 x 10

-6

1.4 x 10-6

VIII

7.0 x 10-10

7.0 x 10-10

VIIIa

0

0

IXa=VIIIa

0

0

IXa=VIIIa=X

0

0

VIIIa1-L

0

0

VIIIa2

0

0
-8

2.0 x 10-8

V

2.0 x 10

Va

0

0

Xa=Va

0

0

Xa=Va=II

0

0

mIIa

0

0

TFPI

2.5 x 10-9

2.5 x 10-9

Xa=TFPI

0

0

TF=VIIa=Xa=TFPI

0

0

ATIII

3.4 x 10-6

3.4 x 10-6

Xa=ATIII

0

0

mIIa=ATIII

0

0

IXa=ATIII

0

0

IIa=ATIII

0

0
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TF=VIIa=ATIII

0

0

Boc-VPR-MCA

-

1.0 x 10-5

Boc-VPR-MCA=IIa

-

0

Boc-VPR

-

0

AMC

-

0

XII

-

3.4 x 10-7

XIIa

-

0

XIIa=XII

-

0

PK

-

4.5 x 10-7

XIIa=PK

-

0

K=XII

-

0

K

-

0

CTI

-

4.2 x 10-6

XIIa=CTI

-

0

C1inh

-

2.5 x 10-6

XIIa=C1inh

-

0

XIIa=ATIII

-

0

XI

-

3.1 x 10-8

XI=IIa

-

0

XIa

-

0

XIIa=XI

-

0

XIa=ATIII

-

0

XIa=C1inh

-

0

α1AT

-

4.5 x 10-5

α2AP

-

1.0 x 10-6

XIa=α1AT

-

0

XIa= α2AP

-

0

XIa=IX

-

0

IXa=X

-

0

Xa=VIII

-

0

VIIa=IX

-

0

VIIa=X

-

0

Fbg

-

9.0 x 10-6

Fbg=IIa

-

0

Fbn1

-

0
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Fbn1=IIa

-

0

(Fbn1)2

-

0

(Fbn1)2=IIa

-

0

Fbn2

-

0

Fbn2=IIa

-

0

(Fbn1)2=IIa=ATIII

-

0

Fbn1=IIa=ATIII

-

0

Fbn2=IIa=ATIII

-

0

Table 2.4-2 Initial conditions of species in the Platelet-Plasma model.

The initial conditions for the first 34 values in Table 2.4-2, were set to the values used in
the Hockin Mann model [94]. The level of Boc-VPR-MCA was set to 10 μM (this is the
level of fluorogenic substrate we use in our experiment). The level of CTI was set to 4.2
μM corresponding to the concentration of 50 μg/ml used in the phlebotomy syringe. XII,
XI Pre-Kallikrein , C1-Inhibitor, α1AT, α2AP and Fibrinogen are set to their plasma
concentrations [127, 137, 138].

2.4.1 Validation

of

experimental

methods

to

detect

thrombin

dynamics
Calibrated Automatic Thrombography (CAT) [90] measures the initiation,
propagation and destruction phases of the thrombogram. In seeking to trace the complete
profile, CAT uses a thrombin substrate Z-GGR-MCA that binds weakly (Km = 305 μM)
and that is consumed slowly (kcat = 1.86 s-1) and requires high concentrations (416 μM) to
quantify the complete profile. However, fluorogenic substrates can act as competing
substrates for thrombin, thereby slowing down positive feedback. Z-GGR-MCA can also
serve as a competitive substrate for Xa. The magnitude and importance of such inhibitory
mechanisms of Z-GGR-MCA are still debated [91, 139]. Since thrombin has a strict
requirement for proline in the P2 position [140], we compared Z-GGR-MCA with the
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highly selective thrombin substrate Boc-VPR-MCA (Km = 61 μM, kcat = 53.8 s-1) used at
[SIIa] < Km to detect coagulation initiation.
Titrations of the fluorogenic substrates Boc-VPR-MCA and Z-GGR-MCA were
carried out at 0 and 1 pM added TF (Figure 2.4-2 A and Figure 2.4-2 B) to determine
the initiation time (Ti). Since increasing substrate will take increasing time to be
consumed, the 5% conversion criterion (see Methods) cannot be used as the metric to
quantify coagulation initiation. We defined instead, the time when the second derivative
of fluorescence was maximized as Ti for this experiment.

Without addition of TF

(Figure 2.4-2 A), the use of Z-GGR-MCA prolonged Ti by 10 to 20 min at all

concentrations from 1 to 100 μM in comparison to Boc-VPR-MCA. At 1 pM added TF
(Figure 2.4-2 B), both fluorogenic substrates were found to be inhibitory to some degree

as demonstrated by a prolongation in Ti with increasing substrate concentration.
However, Z-GGR-MCA caused a prolongation of Ti from 13.1 to 33.8 min as substrate
concentration was increased from 1 to 100 μM, while Boc-VPR-MCA prolonged Ti from
4.1 to 14.0 min as fluorogenic substrate concentration was increased from 1 to 100 μM.
Thus, Boc-VPR-MCA used at up to 100 μM provided smaller Ti (less inhibition) when
compared to Z-GGR-MCA even when used at 1 μM.
Thrombin-antithrombin (TAT) formation provided an independent method to
validate the fluorogenic assays (Figure 2.4-2 C and Figure 2.4-2 D). Saturation of the
detector (at maximized gain to detect low substrate concentrations) prevented the testing
of 416 μM Z-GGR-MCA typical of CAT, thus the use of 100 μM Z-GGR-MCA in this
comparison.

In the absence of added TF (Figure 2.4-2 C) clotting initiation was

observed in ~90 min as indicated by a change from baseline levels of TAT. The addition

47

of 10 μM Boc-VPR-MCA or 100 μM Z-GGR-MCA slowed the formation of TAT with 0
or 1 pM TF addition compared to reactions without fluorogenic substrate (Figure 2.4-2 C
and Figure 2.4-2 D). In the presence of 1 pM TF (Figure 2.4-2 D), clotting initiated at

[TAT] ~ 10 nM at a time between 5 to 10 min in the absence of substrate or with 10 μM
Boc-VPR-MCA present. However, clotting initated at [TAT] ~ 10 nM at a time between
10 to 30 min with 100 μM Z-GGR-MCA present.

TAT formation in the propagation

phase of thrombin production was inhibited by the presence of 100 μM Z-GGR-MCA
substrate.

Importantly, we have verified that [TAT] at the time of Ti detected by the

fluorogenic assay with 10 μM Boc-VPR-MCA was 10 to 20 nM which was in excellent
agreement with the initiation phase of coagulation as defined by the time it takes to
generate 10 nM thrombin [141].
The use of a more selective substrate Boc-VPR-MCA at a low concentration of 10

μM (used for the remainder of this study) allows for accurate detection of only the
initiation phase and not the entire thrombogram, due to the rapid consumption of the
substrate much before the complete conversion of prothrombin. However, the time taken
for onset of initiation of thrombin generation is one of the most important characteristic
of a thrombogram, and the use of the substrate at low levels allows for accurate detection
of this metric without appreciable competitive inhibition of thrombin.
This was the basis for adding the thrombin detection chemistry (Reaction 28,
Table 2.4-1) to the Hockin-Mann topology.

In keeping with our experimental

observation, thrombin formation is slightly inhibited by thrombin occupying the
fluorogenic substrate and thus unavailable to generate positive feedback upon the
zymogens V, VII, VIII, XI or activating the platelet.
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Figure 2.4-2 Validation of experimental protocol.
(A) A titration of the fluorogenic substrates Boc-VPR-MCA (blue circle) and Z-GGRMCA (green square) with 0 added TF showed a mild inhibitory influence of Z-GGRMCA. *s indicates statistically significant difference (p<0.05) between initiation times
detected with the two different substrates. (B) A titration of the fluorogenic substrates
Boc-VPR-MCA and Z-GGR-MCA with 1 pM added TF showed inhibitory influence of
both substrates where Boc-VPR-MCA was found to be the better substrate to detect
initiation and exhibited little inhibition at 10 μM concentration. (C) TAT formation with
0 added TF, in the absence and presence of fluorogenic substrates showed less inhibitory
influence of Boc-VPR-MCA on initiation defined by a burst in TAT compared to ZGGR-MCA. Absolute [TAT] after initiation is decreased in the presence of either
substrate. (D) TAT formation with 1 pM added TF, in the absence and presence of
fluorogenic substrates showed decreased [TAT] during the propagation phase of
coagulation in the presence of either substrate. Initiation detected by TAT correlated well
with Ti determined by our fluorogenic assay. In panels C and D, * indicates [TAT]
significantly greater than baseline levels (p<0.05) and # indicates statistically significant
differences compared to no substrate (blue). Experiments in panels A, B, C and D were
carried out with blood from the same phlebotomy. (E) TF titration done in blood
anticoagulated with CTI alone (green), Citrate + CTI (red) and Citrate alone (blue).
Dashed lines indicate controls with no added TF. No significant difference was detected
in titrations done with and without citrate, showing no evidence of inhibition by the
anticoagulant. Effects of the contact factor pathway were apparent only below 100 fM
added TF.

The nonspecific effects of citrate [92] and CTI [142] were also evaluated by performing a
titration of TF into blood drawn into CTI alone, CTI-citrate, or citrate alone (Figure
2.4-2 E). Recalcification was done to adjust the concentrations of Ca2+ in each of these

citrated blood samples to 10 mM. The time difference between recalcification of all the
samples to the same [Ca2+] and the drawing of uncitrated blood (which was free to
coagulate in the presence of physiological Ca2+ concentrations) was less than 3 min. It
has recently been suggested that coagulation studies done with recalcified citrated blood
are potentially influenced by inhibitory effects of calcium citrate [92]. Similarly, CTI has
been reported to interfere with factor VIII coagulant activity [142]. We detect no
significant difference in Ti upon carrying out titrations of TF in blood anticoagulated with
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CTI alone or CTI-citrate, indicating little inhibitory influence of citrate on the initiation
of coagulation. In the absence of added CTI, the effects of contact pathway-induced
production of XIIa were apparent only below 100 fM added TF as suggested by a
lowering of Ti in the absence of CTI. It should be noted that citrated blood is maintained
for < 5 min prior to recalcification in the current study.

2.4.2 Coagulation initiation without added TF
CTI additions beyond 32 μg/ml have been reported to saturate prolongations of
clot times due to contact activation in otherwise unstimulated blood [77].

We

reproducibly observe (Figure 2.4-3) that blood drawn into 50 μg/ml CTI will still clot
between 60 to 120 minutes without addition of TF, for all donors tested. Prior activation
of platelets with CVX will lower initiation time to ~20 minutes.

Figure 2.4-3 Coagulation initiation in the absence of externally added TF.

Blood drawn into 50 μg/ml CTI and without added TF, will still reproducibly clot in ~75
minutes. Prior activation of platelets with CVX will lower initiation time to ~20 minutes.
Shown are the multiple replicates tested under the same conditions with the same
phlebotomy.
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Similar results were obtained with other platelet agonists such as PAR1 peptide
agonists or ADP (data not shown). Since contact activation is thought to be completely
inhibited by the use of CTI, it was reasonable to hypothesize that TF from some “blood
borne” source or other proximal triggers of prothrombinase formation were responsible
for such initiation.

2.4.3 Evaluating ‘blood-borne’ TF and other mechanisms that could
lead to initiation of clotting in blood drawn into CTI without
exogenous TF addition
To evaluate the effect of phlebotomy as a source of vessel wall derived TF,
experiments were conducted with the first 10 ml, 10-20 ml, 20-30 ml and 30-40 ml of
blood (Figure 2.4-4). If TF was indeed produced from the phlebotomy, an increase in
initiation time would be expected with subsequent volumes of blood drawn after the
initiation of phlebotomy. Clotting initiated in the first 10 ml of resting blood in ~75 min.
For all subsequent volumes clotting initiated at ~90 min and no further increase in
initiation times was observed. Initiation occurred in 25 min in CVX pretreated blood for
all volumes after the blood draw. The amount of TF due to phlebotomy appears minor
and has no role in blood activated with CVX. In subsequent experiments, the first 10 ml
of blood drawn was discarded.
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Figure 2.4-4 TF from phlebotomy

To evaluate the effect of phlebotomy, experiments were conducted ±CVX using the first
10 mls, 10-20 mls, 20-30 mls and 30-40 mls of blood. No steady increase in Ti was noted
showing that TF from phlebotomy was not leading to eventual initiation.
P-selectin is expressed on the platelet surface upon activation and induces
procoagulant PS exposure [143] and TF synthesis in monocytes [144]. TF-containing
microparticles (MPs) have been reported to be generated by interactions between Pselectin and PSGL-1. Furthermore the presence of P-selectin on activated platelets helps
to recruit these MPs to the developing thrombus [145].

However, the addition of a

function-blocking P-selectin antibody caused no change in the time when a thrombin
burst was detected, in the absence or presence of CVX (Figure 2.4-5). VIIa can bind
weakly to activated platelet surfaces and support thrombin generation independently of
TF [146]. Weeterings et al. have reported recently that GP1bα can bind rFVIIa with a Kd
of ~20 nM and this interaction enhanced TF-independent thrombin generation [147].
However, neither antibodies against VII/VIIa (Figure 2.4-7 B), nor antibodies against
GP1bα (Figure 2.4-5) had any effect on the initiation of thrombin formation with or
without CVX stimulation.
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Figure 2.4-5 Studying the effect of P-Selectin and GP1bα on initiation

Addition of antibodies against P-selectin or Gp1bα did not prolong initiation either in the
absence or presence of high dose CVX
Protein disulfide isomerase (PDI) has been suggested as a possible trigger for
tissue factor dependent fibrin generation. PDI originating from adhering platelets [148]
can activate ‘encrypted or cryptic’ [82] functionally inactive TF by changing the disulfide
status of the Cys186-Cys209 pair on the TF molecule [149]. Fibrin formation, following
infusion of TF microparticles were shown to be strongly inhibited by an anti-PDI
antibody in vivo [150]. However, in our hands an anti-PDI antibody had no significant
effect in prolonging Ti with or without CVX treatment (Figure 2.4-6), suggesting that TF
de-encryption via PDI was not a mechanism at play. This is consistent with earlier reports
that: (1) exogenously added PDI or anti-PDI antibodies had no effect on TF-VIIa
coagulant activity shown by MDA-MB231 cells stimulated with HgCl2; or (2) PDI
silencing with PDI shRNA had no effect on procoagulant activity [151].
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Figure 2.4-6 Studying the effect of PDI and Cathepsin G on initiation

Addition of antibodies against PDI or cathepsin G did not prolong initiation either in the
absence or presence of high dose CVX.
The integrin Mac-1 (CD11b/CD18) on neutrophils or monocytes can bind FX
which can be converted to Xa by cathepsin G. Inflammatory stimuli or Mac-1
engagement of its ligands (including fibrinogen and FX) stimulates degranulation and
release of cathepsin-G [152]. Such a mechanism of X activation could lead to initiation in
the absence of TF. However, the addition of a anti-cathepsin G antibody had no effect in
prolonging the time at which a burst in thrombin production occurred with or without
CVX treatment (Figure 2.4-6).
We note that in all experiments utilizing antibodies and without prior platelet
activation there was slight reduction (relative to the control where no antibody was
added) in the time taken for initiation to occur. For instance, sheep IgG by itself reduces
Ti (Figure 2.4-5) from 91.82±13.35 (control) to 70.08±10.57 min. Such effects were
possibly mediated by non specific Fcγ-R mediated platelet activation [153] and were not
apparent when the platelets were already fully activated with CVX.
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Figure 2.4-7 Effect of TF translation and activity
(A) The ribosome inhibitor puromycin; the Clk1 kinase inhibitor Tg003; (B) antibodies against
TF, VII/VIIa; or (C) VIIai did not prolong initiation either in the absence or presence of high dose
CVX. This shows that initiation is unaffected by either ‘bloodborne’ or platelet synthesized TF on
the time scales of our experiments.

Platelets may have the capacity to rapidly splice TF pre-mRNA to a mature
transcript and rapidly translate TF protein intracellularly [154]. We added Tg003 and
puromycin to inhibit Cdc2-like kinase (Clk)1 and ribosomal function, respectively, two
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platelet functions reported to be responsible for splicing TF pre-mRNA and rapid TF
mRNA translation [154]. A level of 10 μM Tg003 and 5 μM puromycin had no effect on
the initiation (Figure 2.4-7 A), either in the absence or presence of CVX. This suggests
that the capacity of platelets to splice TF pre-mRNA and rapidly express TF protein does
not contribute to clotting initiation at least on the time scales of the experiment. Also, the
addition of 20 μg/ml anti-TF, 20 μg/ml anti-VII/VIIa (Figure 2.4-7 B) or 1 μM active site
inhibited factor VIIa, VIIai (Figure 2.4-7 C) caused no increase in Ti with or without
CVX activation of the platelets. This further suggests that in whole blood endogenous TF
mediated mechanisms are not responsible for clotting initiation.

2.4.4 Evaluating the role of CTI
In the absence of evidence for kinetically-significant blood borne TF, we
evaluated the efficacy of CTI (Figure 2.4-8). Without inclusion of CTI in the syringe or
in the well plate, clotting initiated in 57.3 ± 9.9 min.

When 10 μg/ml CTI (final

concentration) was included in the well plate, initiation occurred in 77.4 ± 7.0 min due to
inhibition of XIIa production. When the same final concentration was achieved (after a
5x final dilution of blood in the well plate) by including 50 μg/ml CTI in the phlebotomy
syringe, initiation time was markedly prolonged to 110.0 ± 17.0 min. Liquid handling of
citrated blood after phlebotomy takes ~3 minutes before recalcification and this result
points to the significant production of XIIa during this initial period. When very high
concentrations (100 μg/ml) of CTI were achieved by including CTI in the syringe (50
μg/ml, diluted 5x in the well plate) and 90 μg/ml preexisting CTI in the well plate,
initiation occurred in 96.6 ± 15.1 min and was not prolonged further. Thus, the inhibitory
effect of CTI saturates, pointing to the possibility of a XIIa leak past CTI.
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Figure 2.4-8 Saturation of the effects of CTI

To evaluate the possibility of leakage past CTI, experiments were conducted with no
CTI, CTI addition in well plate, CTI addition during phlebotomy and large quantities of
CTI during phlebotomy as well as in well plate. The inclusion of 50 μg CTI/ml whole
blood (before a 5x dilution in the well plate) produced saturating effects.

2.4.5 Anti-XI and XII used simultaneously prevent initiation in resting
blood
Combined addition of 50 μg/ml of anti-XI and anti-XII to diluted whole blood
(with CTI) completely abolished initiation (Figure 2.4-9) demonstrating that for
conditions lacking platelet activation a steady leak of XIIa activity past CTI was the most
proximal trigger of platelet activation and subsequent clotting of minimally perturbed
blood in vitro. Interestingly, anti-XII when used alone did not prevent initiation (not

shown), suggesting that inspite of our best attempts at preventing XII activation in diluted
whole blood (CTI and anti-XII used together), some XIIa is still formed on the time scale
of our experiments, necessitating the inhibition of XI activity as well. Also, anti-XI by
itself did not prevent initiation in whole blood (not shown), suggesting strong
autocatalytic amplification by very minute amounts of XIa formed inspite of the use of
the inhibitory XI antibody. Despite the efficacy of high dose CTI in conjunction with
anti-XI and anti-XII in preventing activation in resting blood, there was no effect of these
antibodies on Ti when blood had been treated with CVX. The levels of thrombin
produced during the initial moments of the propagation phase of thrombin production
(after Ti) were however diminished as demonstrated by lowered rates of fluorescence
increase. This was possibly a consequence of the inhibition of thrombin- mediated
feedback on FXI after initiation [155].
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Figure 2.4-9 Effect of anti-XI and anti-XII.

Addition of 50 μg/ml of anti-XI and anti-XII will completely prevent initiation of clotting
in resting blood showing that initiation is a result of leak past saturated effects of CTI.
However, on CVX activated platelets initiation is still unaffected by the presence of both
CTI and these antibodies. Initial thrombin production during the propagation phase is
however diminished due to abolition of thrombin feedback on FXI. Insert shows initial
rates of thrombin formation in the presence of these antibodies.

2.4.6 Preventing initiation in CVX treated blood
Unlike the case of resting blood, initiation could not be prevented in blood
pretreated with CVX by the use of antibodies against XI and XII. To probe further the
mechanism responsible for such initiation, we supplemented CTI-treated regular plasma
and CTI-treated plasmas deficient in factors VII, XI and XII with washed platelets.
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Thrombin generation in these samples as well as samples of plasma that had been treated
with antibodies against TF, VII, XI, XII, or XI/XII/VII was studied following CVX
activation (Figure 2.4-10). Antibodies against TF had no detectable effect. Thrombin
formation was not completely inhibited by blocking any single factor individually, but
was inhibited in samples where the activities of XI, XII and VII were simultaneously
inhibited (Figure 2.4-10, last row of subplots). In particular clotting was completely
inhibited in 6 out of 8 wells in XI-deficient plasma treated with antibodies against XI, XII
and VII. Inhibition of VIIa activity alone is insufficient (initiation times are almost
unchanged in VII-deficient plasma treated with a VII antibody) because XIa formation
beyond the XIIa leak past CTI, is still sufficient to trigger thrombin formation. Inhibition
of XI activity (XI-deficient plasma with an XI antibody) has pronounced inhibitory
effect, but was still insufficient with VIIa being functionally active on the active platelet.
Thus upon activated platelets, in addition to blocking factors XI and XII, VIIa activity too
must be inhibited to prevent thrombin generation.
It should be noted that immunodepleted plasmas deficient in coagulation factors
have <1% normal activity of the particular factor, but are still not completely devoid of
the depleted protein. This explains why initiation is prolonged further by antibodies
against a protein that had already been immunodepleted in plasma. For instance thrombin
generation in anti-XI treated, XI- deficient plasma is inhibited compared to that observed
in XI-deficient plasma alone. The use of deficient plasmas offers a “cleaner inhibition”
because the protein being targeted for inhibition is largely absent from the onset, as
opposed to reliance on the inhibitory antibody to exert its effect before the protein is
functionally active.
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Figure 2.4-10 Prevention of initiation on CVX activated platelets.

CTI-treated regular plasma or plasma deficient in factors VII, XI or XII were
supplemented with washed (plasma free) platelets. These samples were left untreated or
were treated with antibodies against TF; VII; XI; XII or XI, XII and VII simultaneously;
and tested for thrombin generation without exogenous TF addition after activating
platelets with 25 nM CVX. Simultaneous inhibition of XI, XII and VII activity was
required to completely abolish thrombin generation.
Thrombin formation, once clotting is initiated by a single activator for instance by
the addition of TF or Xa (See Figure 2.4-11) yields relatively small variations in
initiation time when tested in multiple replicates. However, given the strongly
autocatalytic nature of the cascade, complete abolition of a triggering mechanism is much
more challenging. Even small localized diffusional or binding limitations of the
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inhibitory antibody will allow individual molecules that bypass the inhibitors to trigger
the cascade. This accounts for the relatively large variations we observe in trying to
inhibit initiation upon activated platelets, where thrombin formation occurs stochastically
past inhibitory antibodies against targeted coagulation proteins.

2.4.7 Titrations of TF and active proteases into blood
Addition of exogenous lipidated TF was used to initiate coagulation via the
extrinsic pathway. Concentrations from 0.5 fM to 5 pM were added to whole blood
(Figure 2.4-11 A). Added TF resulted in a continual, statistically significant reduction

of initiation time over a wide dynamic range of 3 orders of magnitude of concentration
from 20 fM to 20 pM. Distinct from flow experiments where a concentration threshold
exists between 2 and 20 molecule-TF/μm2 [156], no switch-like regime was detected
under static conditions. This suggests that the barrier to be overcome in the flow system
to exceed the threshold is not a chemical inhibition barrier since such a barrier would be
present under stasis as well. The observation is consistent with Fogelson and Tania [157]
who note the barrier responsible for the threshold under flow is a physical one dependent
on competition between flow-mediated removal and rate of production of procoagulants.
Next, we investigated the individual components of prothrombinase (XaVa
complex) on coagulation initiation (Figure 2.4-11 B). Addition of Va showed negligible
effects with minimally decreased initiation time from 0.3 nM to 4 nM added Va (>10% of
the plasma concentration of V). This relative insensitivity indicated that Va was not a
limiting during coagulation initiation, in agreement with previous studies that show that
Va may be present in platelets or be rapidly displayed or produced during activation
[158]. In contrast, Xa additions produced a marked switch-like action by moving from a
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negligible change in Ti at 10 pM to nearly saturating effect at 100 pM, a concentration
that is <0.1% of the plasma concentration of X. This switch-like behavior was consistent
with the well understood rate limiting role of Xa [94].
Further, we explored reactions proximal to thrombin production by addition of
increasing amounts of Factors VIIa, IXa and XIa to blood (Figure 2.4-11 C). The
nominal concentrations of endogenous VIIa (1 % of VII) prior to exogenous addition in
5x blood is 20 pM [159].

Using 5x final blood dilution, we extended these

concentrations to reach an effective concentration of VIIa above 1 nM. VIIa has no
significant effect until above 1 nM, approximately 10% of the circulating amount of VII.
For comparison, high dose rVIIa therapies use up to ~17 nM final concentrations [160].
The dynamic range for added IXa extended from below 5 pM to above 500 pM and that
for XIa extended from below 2 pM to above 200 pM. The upper end of these ranges are
less than 1% of the circulating IX and XI concentration respectively [161]. Similar to
results for TF, the addition of IXa or XIa in this assay did not display a switch-like
regulatory function, i.e. changing from no effect to full effect over some narrow
concentration range, but rather displayed a broad dynamic response over a wide range of
concentrations.
Baseline low level protease activity can exist even in healthy individuals (the
“engine idling” theory). Knowledge of the upper bounds of these proteases defines the
levels of these enzymes that allow blood to remain in a stable state (flowing normally) in
spite of their presence. Experimentally measured values of active proteases for a patient
that are significantly different from these values might indicate underlying coagulation
disorders or heightened sensitivity to weak triggers of clotting.
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Figure 2.4-11 Titration of TF and active proteases into blood.
(A) Effect of exogenous TF on initiation time. TF was titrated from 0.5 fM to 5 pM in
5x diluted blood. The black solid line is the simulated initiation time for the HockinMann model (with SIIa) and the blue dashed line is the prediction of the Platelet-Plasma
model. The light green solid line is the experimental control with no added TF. (B)
Addition of prothrombinase components. Xa (red) and Va (green) was added to 5x
diluted blood. The black solid line is the simulated initiation time for the Hockin-Mann
model (with SIIa). The red and green dashed lines are the prediction of the Platelet-Plasma
model for Xa and Va, respectively. The light green solid line is the experimental control
with no added proteins. (C) Addition of VIIa, IXa and XIa. Various concentrations of
VIIa (green), IXa (red) and XIa (blue) were added to blood at 5x dilution. The dashed
lines of the corresponding color are simulations done with the Platelet-Plasma model.
The light green solid line is the experimental control. (Experiments courtesy Bill Denney)

2.4.8 Platelet-Plasma model of thrombin production in human blood
The Hockin-Mann model was used to simulate these tirations and was found to be
quite accurate for TF concentrations above 1 pM, but diverged dramatically at
concentrations below 1 pM (Figure 2.4-11 A, black solid line) of added TF. We have
shown experimentally, that a leak of XIIa past saturating levels of CTI is responsible for
eventual intiation. This prompted us to include the contact factor pathway to HockinMann topology.
Upon contact with anionic surfaces a conformational change occurs in the
zymogen FXII, resulting in the formation of active FXIIa. The exact mechanism for XII
surface adsorption, conformation change and activation remain ambiguous and cannot be
modeled easily.

We therefore coarse grained surface mediated XII activation by

assuming a first order dependence on XII concentration (Reaction 29, Table 2.4-1) and
estimating a rate of production (5×10-4s-1) that would resolve the disparity between the
Hockin-Mann model prediction and the experimentally observed control (green) at 0 TF
(without disrupting its predictive ability at high TF).
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It should be noted that this

estimated rate of XIIa production was based solely on observations in our experimental
surfaces (Corning 384-well plates) and may well be different on other surfaces. The small
amount of XIIa that is initially formed auto-activates upon negative surfaces in vitro
(Reaction 30, Table 2.4-1). Formed XIIa further activates Pre-Kallikrein to active
Kallikrein (Reaction 31, Table 2.4-1), which in turn reciprocally activates XII (Reaction
32, Table 2.4-1) and Pre-Kallikrein (Reaction 33, Table 2.4-1). Both Kallikrein and

XIIa are inhibited by plasma protease inhibitors (Reaction 34, 36-37; Table 2.4-1).
Further, XIIa is inactivated by CTI included at high concentrations specifically to inhibit
contact activation (Reaction 35, Table 2.4-1). Despite the efficacy of CTI, it is a
reversible inhibitor of XIIa; and thus there is always some active XIIa beyond CTI
resulting from the unbinding of the XIIa=CTI complex. Such XIIa that has “leaked past”
CTI can in turn activate XI (Reaction 39, Table 2.4-1). Thrombin feedback on XI has
also been considered (Reaction 38, Table 2.4-1) as a mechanism for XI activation.
We have experimentally observed (Figure 2.4-11 C) strong sensitivity of blood to
very minute doses of XIa (even 2 pM of added XI reduced Ti significantly from that of
the control). Also complete abolition of clotting without exogenous TF, required
inhibition of XI activity in addition to XII (Figure 2.4-9 and Figure 2.4-10) suggesting
that the very little XIa that is formed downstream of XIIa is able to strongly self amplify
(especially if the pro-coagulant surface of the activated platelet is readily available). With
inhibition by ATIII, C1-inhibitor, α1-antitrypsin and α2-antiplasmin (Reaction 41-44;
Table 2.4-1), such sensitivity could not be adequately explained by just XIIa mediated

activation and thrombin feedback on XI. Therefore we also included the mechanism of
XI auto-activation [136] on negatively charged surfaces to the topology of the network
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(Reaction 40, Table 2.4-1). Following the retraction of Baglia and Walsh, JBC 2000 we
are not aware of experimental reports on the kinetics of this reaction. However,
Kramoroff et.al [126] estimate the second order rate constant of this reaction to be 3.19
μM-1s-1

by optimizing an ODE model of the intrinsic cascade to experimental

measurements of APTT. They consider either XI autoactivation or XI activation by
thrombin (but not both possibilities) as plausible mechanisms for XI activation (in
addition to activation by XIIa), thus their estimated value is likely an overestimate. We
utilized a value 4-fold lower than the value they report for this constant, since we
consider both mechanisms.
The XIa that is formed activates IX (Reaction 45, Table 2.4-1). Unlike the
original Hockin-Mann topology, IXa in the absence of its cofactor is now able to activate
some factor X (Reaction 46, Table 2.4-1) albeit very inefficiently. This minute amount
of Xa contributes to the activation of VIII (Reaction 47, Table 2.4-1), in addition to the
VIII activation by thrombin in the Hockin-Mann structure (Reaction 10, Table 2.4-1).
VIIIa once formed dramatically raises the efficacy of IXa and hence subsequent thrombin
formation. Thus such participation of Xa in VIII activation (in addition to its ability to
directly convert prothrombin) helps it to function in simulation as the dramatic switch
like controller of the cascade we observed experimentally (Figure 2.4-11 B).
VIIa above 1 nM concentrations is able to produce significant lowering of Ti
independently of TF (Figure 1.1-1 C). Furthermore, with platelet activation, inhibition of
VII activity was required (in addition to the inhibition of XI and XII activity) to
completely block thrombin generation (Figure 2.4-10). This suggests that VIIa activity
independent of TF, is effective at high concentrations and on the activated platelet. This
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prompted us to include VIIa’s ability to convert IX and X (independent of TF) in the
structure of the model (Reactions 48-49; Table 2.4-1).
Fibrinogen can act as an efficient sink for thrombin in experiments conducted in
whole blood, and thus limit its ability to generate positive feedback by converting other
zymogens or activating platelets. The thrombin catalyzed formation of fibrin I and fibrin
II, release of fibrinopeptides A and B and the irreversible entrapment of thrombin in
complexes with fibrin and antithrombin are described in (Reactions 50-57; Table 2.4-1)
using published kinetics [135].
With these additions to the structure of the Hockin-Mann topology, we could now
obtain quantitative agreement between experimental and simulated titrations of the
procoagulant proteins TF, Va, VIIa, IXa, Xa and XIa into 5x diluted blood. The original
Hockin-Mann topology could predict finite Ti for only high dose TF/ Xa (Solid lines in
Figure 2.4-11 A and B).

Although there is evidence to suggest that TF dependent reactions (Table 2.4-1,
Reactions 1, 2, 6-8 and 21) are sped up on acidic phospholipids (See Comments in

footnotes to these reactions in Table 2.4-1), no ε dependence was used for these reactions
in our simulations of the TF titration in Figure 2.4-11 A. This is because TF was already
added in lipidated form in these experiments, and thus the TF-VIIa assembly or activity
will not be affected by changing lipid composition upon the platelet surface.
The Kuharsky-Fogelson model [96] for thrombin formation under flow in the
presence of collagen activated platelets shows [Xa] remaining at levels of about 10 pM
throughout the duration of simulation. In the Hockin-Mann model with a TF stimulus of
5 pM, Xa concentrations are 10-100 pM during the times that substantial thrombin
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formation first occurs and subsequently this rises by about 10-fold. Our results, along
with the modeling predictions in these papers suggest why it is necessary that clotting be
sensitive to low levels of Xa in vivo. Namely, if levels produced under flow (where Xa
can be rapidly convected downstream) are to be efficacious at all, they must produce
substantial effects at very low levels (~10 pM), despite the presence of much higher
concentrations of X, or the system’s ability to produce much larger concentrations of Xa
under conditions of stasis.

Figure 2.4-12 Simulated transients of selected species during coagulation with TF.

Shown above are the time courses of thrombin, Xa, Xa:Va, Va and the platelet’s
activation state (ε) for coagulation triggered with 5pM TF in whole blood. Before
initiation sufficient catalyst quantities are built up by the minute (subnanomolar levels) of
thrombin being formed. Concentrations of all species increase steeply beyond initiation
(and full platelet activation) during the propagation phase of the thrombogram. Note, the
shift in equilibrium of Va towards Xa:Va following platelet activation. Thrombin
concentrations eventually start decreasing because of destruction of the free enzyme by
ATIII and consumption of limited reserves of prothrombin inspite of the presence of
sufficient prothrombinase catalyst.
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Similar to Kuharsky-Fogelson (Figure 7 of reference [96]), we show in Figure
2.4-12 simulations for the concentrations of thrombin, Xa, Xa:Va, and Va for a stimulus

of 5 pM TF (Also, compare to Hockin-Mann, Figure 8B of reference [94]). We found
free Xa concentrations growing to about 20 pM during the initial instants followed by a
much more substantial burst (that increases Xa levels by ~3 orders) following platelet
activation. The Va concentrations grow steadily, but beyond full platelet activation (~10
nM thrombin), there is a dramatic shift in the equilibrium towards Xa:Va and thus the
amount of free Va drops rapidly, as prothrombinase levels rise steeply.

2.4.9 Simulations of clotting times in whole blood
Our high throughput experimental system allows us to efficiently study
coagulation reactions under various perturbations with multiple replicates. However,
reaction volumes in our 384-well plate systems are only 50 μl, preventing us from
studying undiluted whole blood. Automated liquid handling can dispense with high
precision volumes of 5 μl, but for lower volumes experimental variability is high. Since
each individual well must contain several reagents (calcium, fluorogenic substrate,
platelet agonists, antibodies and coagulation proteases) other than human blood, there is a
limitation to the volume of blood that can be used in each well.
De Smedt et al. [162] have recently reported that anticoagulant pathways
(particularly the TFPI and APC mediated) are more affected by dilution than the
procoagulant pathways. However, they did not observe any significant effect of dilution
on the duration of the initiation phase, both for TF and Kaolin stimulated coagulation
reactions in PPP upto dilutions of 12x (detectable effects on endogenous thrombin
potential and peak height of the thrombograms were however reported). Blood at 5x
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final dilution is below this limit of 12x dilution beyond which linear scaling of initial
conditions with the dilution factor might not be sufficient to account for the kinetics of
thrombin generation initiation, and provides a tractable system for extensive high
throughput experimentation. In simulating such experiments, the initial conditions of all
species were divided by 5 to account for the dilution in each well.

Figure 2.4-13 Simulating clotting times in whole blood.

The very small reaction volumes in a 384 well plate prevent us from studying coagulation
reactions in whole blood (See text). To simulate the kinetics of initiation in whole blood
we simulated clotting times for additions of TF, thrombin (IIa), IXa , Xa or
combinations of all 3 proteases at low and high doses reported by Butenas et al. [163] in
the Mann laboratory. We found good qualitative agreement between experimental
clotting times (blue) and initiation times predicted by the Platelet-Plasma model (green).
The Hockin-Mann (with fluorogenic thrombin substrate, SIIa) model (red) predicts finite
initiation times only in the presence of high dose TF or Xa.
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To test the ability of the model to predict perturbations in whole blood, we
simulated clotting times (a good measure of the time to generate a burst in thrombin) for
additions of either TF; IXa, Xa, thrombin; or all 3 proteases together reported by Butenas

et al. [163]. We found good agreement between experimentally reported values of
clotting time and predicted initiation times across all conditions (Figure 2.4-13). The
original Hockin-Mann model could predict finite Ti in the presence of high dose TF/ Xa,
or when low dose thrombin, IXa and Xa were present simultaneously.

2.4.10

Simulating platelet activation

The Hockin–Mann model assumes a fully activated platelet at t=0.

In the

Kuharsky-Fogelson model [96] or the Cellular Potts model [164], platelets can exist
either in discrete “unactivated” or “activated” states. We do not consider platelets
explicitly, but all reaction rates reported in literature to be dependent on platelet
activation are altered by a single function (ε) of thrombin concentration (See Methods).
As the platelets are activated by thrombin, they expose anionic phospholipids like PS on
their surface, and the “platelet activation status” ε increases from a basal state of 0.01 to
1.00. The unbinding rates of all enzyme-substrate complexes are set to their literature
values at saturating PS levels, but are all divided by ε. Thus, as the platelet activates the
unbinding rates dynamically decrease by two orders of magnitude, consistent with the
notion that the platelet surface becomes more procoagulant. In the Kuharsky-Fogelson
model of intravascular thrombosis under flow, reaction rates depend on the availability of
fully activated platelets (contributing maximal platelet binding sites for the coagulation
factors). Since binding sites change with the concentration of activated platelets, the
local effective reaction rates change as well. For modeling isotropic coagulation in a well
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plate, we account for a continuum of platelet activation states by thrombin and assume an
excess of PS once platelets fully activate (as opposed to discrete saturable binding sites in
the Kuharsky-Fogelson model).
Reactions that have been reported in literature (See Table 2.4-1 footnotes) to be
accelerated by acidic phospholipids are upregulated in the model when platelets are
activated by thrombin as ε increases (and dissociation rates decrease). Platelets provide
the negative surfaces for coagulation factor assembly in vivo, yet most current
enzymology studies of coagulation enzyme kinetics in vitro use artificial phospholipid
surfaces since standardizing platelet surfaces for kinetic assays is difficult.
In reality, surface adsorption of procoagulant molecules might also alter the
catalytic efficiency (kcat), but for the sake of simplicity all kcat values are set to their
reported values at saturating PS levels (with the assumption that loose enzyme substrate
complexes will hardly be formed in the first place and thus rarely get converted). The
assumption that all unbinding rates change by two orders of magnitude is also made for
simplicity. (In reality some enzyme substrate complexes are dramatically strengthened on
exposed PS surfaces, while others show only weak dependence. See Table 2.4-1

footnotes.)
We make the assumption that the amount of active surface available upon
activation of platelets at normal platelet counts (3×106 platelets per 50 μl reaction well for
5×diluted blood with a platelet count 3×108 platelets/ml) is sufficient for coagulation
reactions to proceed at their most optimal rates. Thus, like the Hockin-Mann model we
assume an excess of phospholipid surfaces once the platelets are activated. Yet, our
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approach accounts for the fact that surface reactions occur at a rate dependent on the
extent of platelet activation rather than being fixed at the highest level at t = 0.
As a pseudohomogeneous and single phase model of coagulation, we do not treat
platelets as separate entities (or account for free and plate bound species). Thus, the fact
that each platelet may have a limited number of specific binding sites is not considered.
Our approach assumes that sufficient binding sites are available in 5×diluted blood, an
assumption that may not be valid at greater dilutions. Also, we assume that coagulation in
a well plate is well mixed, lacks spatial gradients, and is not transport-controlled. In
contrast, intravascular thrombosis occurs under conditions with (1) substantial gradients
of reactive species and platelet binding sites, (2) significant effects of convective
transport on soluble species, and (3) intrathrombic diffusion limitations.
Setting the initial activation state ε max 0 , allows us to control in simulation the basal
level of activation of the platelet (Figure 2.4-14 B). For ε max 0 = 0.01 (akin to assuming
1% PS exposure on the surface of unactivated platelets), we obtain a burst in thrombin
production (and hence fluorogenic substrate cleavage) at ~75 min in the Platelet-Plasma
model. To simulate experiments where coagulation reactions occur upon pre-activated
platelets, ε max 0 is set to a value of 1.0 (with the assumption that the fully activated
platelets have exposed all of their PS) giving Ti ~15 min. These values are in good
agreement (Figure 2.4-14 A) with the mean initiation times obtained upon unactivated
platelets (solid lines) and activated platelets (dashed lines) for the 4 donors shown in
Figure 2.4-3.
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Figure 2.4-14 Simulating platelet activation.
(A) Mean substrate conversion across all replicates for the donors shown in Figure 2.4-3.
Substrate conversion traces without platelet activation are shown in solid lines and
conversion traces upon activated platelets are shown in dashed lines. (B) Setting the
initial activation state ε max 0 allows us to simulate platelet activation and its dynamic

(

)

effect on all platelet dependent unbinding rates (see methods). The red line indicates
simulations of substrate conversion without prior platelet activation ε max 0 = 0.01 . The
blue dashed line indicate simulations of substrate conversion upon instantaneously fully
activated platelets at t = 0. ε max 0 = 1.0

(

(

)

76

)

We note that the rate of thrombin production (substrate conversion) in simulation
beyond Ti increases more sharply than actually observed in experiment.

Thrombin

concentrations at Ti are ~10 nM, corresponding to a fully activated platelet (Figure 2.3-2)
beyond Ti. This suggests that a method of prothrombinase inhibition (that has not been
considered in our reaction topology) may exist once platelets are activated. Inhibition of
XaVa in vitro in the absence of endothelial thrombomodulin is poorly understood.
Further experiments will be required to pinpoint this inhibitory mechanism, but for the
present the Platelet-Plasma model is a reliable indicator of the time taken to generate a
burst in thrombin in vitro.

2.4.11

Sensitivity analysis of the Platelet-Plasma model

We estimated global parameter sensitivities for the Platelet-Plasma Model’s
output for 10 pM added TF (Figure 2.4-15 A and Table 2.4-3) and 0 added TF (Figure
2.4-15 B and Table 2.4-4) input stimuli by the method by the method of weighted

averaging of local sensitivities [165]. In this method local parameter sensitivities in
output ‘y’, for a parameter ‘j’ (j = 1, …, 105) at a point ‘i’ in parameter space is first
calculated by introducing a 2% increment in the parameter pj :
sij =

∂y / y
∂p j / p j

(2.4.1)

We define ‘y’ to be the thrombin concentration at the initiation time (Ti) of the
nominal parameter set. Note Ti cannot be used as the output during sensitivity analysis
because 5% conversion of the fluorogenic substrate is not achieved in some perturbed
parameter sets. Local sensitivities were calculated at multiple random points ‘i’ in a very
large parameter space where each of the 105 parameters has a spread of half an order of
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magnitude around their nominal value. In total 10,000 points were explored (10,000 ×105
simulations) and global sensitivity indices were determined by calculating a weighted
average of local sensitivities. Similar to Bentele et al. [165] we use the BoltzmannDistribution exp (-E / kbT) for weighting, in which E is the difference in thrombin
concentration between the nominal and perturbed states and kbT is a scaling factor (we
use minimum E for scaling). Based on the assumption that parameter sets resulting in
output values close to the experimental observation are the most probable, this approach
statistically amplifies the sensitivities of parameter sets that result in outputs close to the
nominal solution. For ease of visualization sensitivity indices were normalized between
0 and 1 and the values for ranked according to decreasing sensitivity.
Other methods of global sensitivity analysis like ‘Sobol’s method’ [166] or the
‘Extended FAST method’ [167] provide non-biased sampling over the entire parameter
space . Such methods were attempted (not shown) and provide similar rank orderings of
sensitivities. However convergence was not achieved in a feasible amount of time.
For 10 pM added TF (Figure 2.4-15 A and Table 2.4-3), the rate of binding of
TF to VIIa was found to be the most sensitive, followed by the rate of binding of X to
TF:VIIa. Interestingly, thrombin production was also found to be strongly sensitive to TF
independent VIIa binding to IX, as well as VIIa ‘s ability to convert X by itself.
Reactions regulating prothrombinase formation (Ranks 7 and 8) were also found to be
sensitive. Contact activation (XIIa) mediated reaction rates were generally too slow too
have any appreciable effect, although thrombin feedback on XI was found to be
moderately sensitive (Ranks 17 and 18).
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Figure 2.4-15 Global sensitivity analysis of the Platelet-Plasma model

79

Rank

Parameter

Rank

Parameter

1

'k_on_TF_VIIa'

54

'k_on_Fbn1_binding_IIa'

2

'k_on_X_TF_VIIa'

55

'k_off_X_VIIa'

3

'k_off_IX_VIIa'

56

'k_off_IXa_X'

4

'k_on_IX_VIIa'

57

'k_on_IXa_X'

5

'k_cat_VII_Xa'

58

'k_off_Xa_VIII'

6

'k_cat_V_IIa'

59

'k_off_Fbn1_2_unbinding_Fbn1_IIa'

7

'k_on_Xa_Va'

60

'k_cat_Xa_VIII'

8

'k_off_Xa_Va'

61

'k_on_TF_VIIa_Xa_TFPI'

9

'k_cat_II_Xa'

62

'k_cat_VII_IIa'

10

'k_cat_mIIa_Xa_Va'

63

'k_on_IXa_ATIII'

11

'k_on_II_Xa_Va'

64

'k_off_XIIa_XI'

12

'k_off_Xa_TF_VIIa'

65

'k_off_VIII_HC_LC_IXa'

13

'k_cat_X_TF_VIIa'

66

'k_cat_XIIa_producing_Kallikrein'

14

'k_on_TF_VII'

67

'k_on_bXIIa_binding_PreKallikrein'

15

'k_on_TFPI_TF_VIIa_Xa'

68

'k_on_wall_XIIa_production'

16

'k_off_TF_VII'

69

'k_off_XII_unbinding_Kallikrein_XII'

17

'k_off_XI_IIa'

70

'k_off_XII_XIIa'

18

'k_on_XI_IIa'

71

'k_on_Xa_VIII'

19

'k_cat_off_mIIa_Xa_Va'

72

'k_on_CTI_XIIa'

20

'k_off_TFPI_TF_VIIa_Xa'

73

'k_cat_XI_IIa'

21

'k_off_II_Xa_Va'

74

'k_off_X_IXa_VIIIa'

22

'k_on_IIa_ATIII'

75

'k_on_Fbn1_2_destruction_by_ATIII'

23

'k_on_Xa_ATIII'

76

'k_cat_XIIa_XI'

24

'k_on_Fbg_binding_IIa'

77

'k_off_CTI_XIIa'

25

'k_off_Fbg_unbinding_Fbg_IIa'

78

'k_on_XI_autoactivation'

26

'k_plt_delay'

79

'k_off_VIII_HC_LC_IXa_X'

27

'k_off_Boc_VPR_AMC_IIa'

80

'k_off_VIII_HC_LC'

28

'k_on_Boc_VPR_AMC_IIa'

81

'k_off_Fbn2_IIa_dissociation'

80

29

'k_on_IX_TF_VIIa'

82

'k_on_Fbn2_IIa_association'

30

'k_off_IX_TF_VIIa'

83

'k_on_XII_binding_Kallikrein'

31

'k_on_mIIa_ATIII'

84

'k_on_C1inh_inhibition_of_XIIa'

32

'k_cat_IIa_producing_Fbn1'

85

'k_on_Fbn2_IIa_destruction_by_ATIII'

33

'k_cat_IX_TF_VIIa'

86

'k_on_XIa_IX'

34

'k_on_TF_VIIa_ATIII'

87

'k_on_ATIII_inhibition_of_XIIa'

35

'k_off_Xa_TFPI'

88

'k_on_XIa_inhibition_by_alpha1AT'

36

'k_on_Xa_TFPI'

89

'k_on_Kallikrein_autoactivation'

37

'k_on_IXa_VIIIa'

90

'k_on_C1inh_inhibition_of_XIa'

38

'k_cat_VIII_IIa'

91

'k_cat_IIa_producing_Fbn2'

39

'k_on_X_IXa_VIIIa'

92

'k_on_XIa_inhibition_by_alpha2AP'

40

'k_cat_Boc_VPR_AMC_IIa'

93

'k_on_VIII_HC_LC'

41

'k_off_Fbn1_unbinding_Fbn1_IIa'

94

'k_cat_X_VIIa'

42

'k_off_TF_VIIa'

95

'k_on_XIIa_XI'

43

'k_off_X_TF_VIIa'

96

'k_on_XII_XIIa'

44

'k_on_Fbn1_2_dimer_association'

97

'k_cat_XIa_IX'

45

'k_on_Xa_TF_VIIa'

98

'k_cat_Kallikrein_producing_XIIa'

46

'k_off_IXa_VIIIa'

99

'k_cat_IIa_producing_Fbn2_2'

47

'k_cat_IXa_X'

100

'k_on_Kallikrein_inhibition'

48

'k_cat_X_IXa_VIIIa'

101

'k_cat_XIIa_production'

49

'k_on_Fbn1_IIa_destruction_by_ATIII'

102

'k_off_XIa_IX'

50

'k_on_X_VIIa'

103

'k_off_bXIIa_unbinding_PreKallikrein_XIIa'

51

'k_cat_IX_VIIa'

104

'k_on_ATIII_inhibition_of_XIa'

52

'k_on_Fbn1_2_binding_IIa'

105

'k_off_Fbn1_2_dimer_dissociation'

53

'k_cat_VII_TF_VIIa'

Table 2.4-3 Rank order of sensitivities at 10 pM added TF
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Rank

Parameter

Rank

Parameter

1

'k_on_XI_autoactivation'

54

'k_off_VIII_HC_LC_IXa'

2

'k_on_IIa_ATIII'

55

'k_off_Xa_TFPI'

3

'k_on_C1inh_inhibition_of_XIa'

56

'k_on_XII_binding_Kallikrein'

4

'k_on_XIa_inhibition_by_alpha1AT'

57

'k_cat_Kallikrein_producing_XIIa'

5

'k_on_ATIII_inhibition_of_XIa'

58

'k_cat_XIIa_producing_Kallikrein'

6

'k_cat_II_Xa'

59

'k_on_bXIIa_binding_PreKallikrein'

7

'k_off_XIa_IX'

60

'k_off_XII_unbinding_Kallikrein_XII'

8

'k_on_XIa_IX'

61

'k_on_C1inh_inhibition_of_XIIa'

9

'k_cat_XIa_IX'

62

'k_off_bXIIa_unbinding_PreKallikrein_XIIa'

10

'k_off_XIIa_XI'

63

'k_on_Kallikrein_inhibition'

11

'k_cat_VIII_IIa'

64

'k_on_mIIa_ATIII'

12

'k_on_Fbg_binding_IIa'

65

'k_cat_XI_IIa'

13

'k_on_CTI_XIIa'

66

'k_on_Xa_VIII'

14

'k_on_Fbn2_IIa_destruction_by_ATIII'

67

'k_cat_Xa_VIII'

15

'k_cat_XIIa_XI'

68

'k_off_Xa_VIII'

16

'k_on_XIIa_XI'

69

'k_on_IXa_ATIII'

17

'k_off_CTI_XIIa'

70

'k_off_Fbn1_2_unbinding_Fbn1_IIa'

18

'k_off_Fbn2_IIa_dissociation'

71

'k_on_Fbn1_2_binding_IIa'

19

'k_on_wall_XIIa_production'

72

'k_on_ATIII_inhibition_of_XIIa'

20

'k_off_Fbg_unbinding_Fbg_IIa'

73

'k_off_VIII_HC_LC_IXa_X'

21

'k_on_Fbn2_IIa_association'

74

'k_on_Kallikrein_autoactivation'

22

'k_on_Fbn1_2_dimer_association'

75

'k_cat_IIa_producing_Fbn2_2'

23

'k_off_Fbn1_unbinding_Fbn1_IIa'

76

'k_on_Fbn1_2_destruction_by_ATIII'

24

'k_cat_IIa_producing_Fbn1'

77

'k_off_Fbn1_2_dimer_dissociation'

25

'k_on_X_IXa_VIIIa'

78

'k_cat_VII_Xa'

26

'k_on_IXa_VIIIa'

79

'k_on_VIII_HC_LC'

27

'k_cat_IXa_X'

80

'k_cat_X_VIIa'

28

'k_off_IXa_X'

81

'k_off_XII_XIIa'

82

29

'k_on_Fbn1_binding_IIa'

82

'k_cat_VII_IIa'

30

'k_cat_IIa_producing_Fbn2'

83

'k_on_X_VIIa'

31

'k_on_IXa_X'

84

'k_cat_XIIa_production'

32

'k_cat_V_IIa'

85

'k_on_XII_XIIa'

33

'k_cat_X_IXa_VIIIa'

86

'k_off_X_VIIa'

34

'k_on_XIa_inhibition_by_alpha2AP'

87

'k_off_IX_TF_VIIa'

35

'k_on_Boc_VPR_AMC_IIa'

88

'k_on_TF_VII'

36

'k_on_Xa_ATIII'

89

'k_off_TF_VII'

37

'k_off_Xa_Va'

90

'k_on_TFPI_TF_VIIa_Xa'

38

'k_off_II_Xa_Va'

91

'k_on_TF_VIIa_Xa_TFPI'

39

'k_on_II_Xa_Va'

92

'k_on_Xa_TF_VIIa'

40

'k_off_VIII_HC_LC'

93

'k_off_TF_VIIa'

41

'k_on_Xa_Va'

94

'k_cat_IX_TF_VIIa'

42

'k_on_XI_IIa'

95

'k_off_Xa_TF_VIIa'

43

'k_cat_mIIa_Xa_Va'

96

'k_on_TF_VIIa_ATIII'

44

'k_cat_off_mIIa_Xa_Va'

97

'k_off_TFPI_TF_VIIa_Xa'

45

'k_off_IXa_VIIIa'

98

'k_on_IX_TF_VIIa'

46

'k_cat_IX_VIIa'

99

'k_on_TF_VIIa'

47

'k_off_Boc_VPR_AMC_IIa'

100

'k_off_X_IXa_VIIIa'

48

'k_plt_delay'

101

'k_on_Fbn1_IIa_destruction_by_ATIII'

49

'k_off_XI_IIa'

102

'k_off_X_TF_VIIa'

50

'k_cat_Boc_VPR_AMC_IIa'

103

'k_cat_X_TF_VIIa'

51

'k_off_IX_VIIa'

104

'k_on_X_TF_VIIa'

52

'k_on_IX_VIIa'

105

'k_cat_VII_TF_VIIa'

53

'k_on_Xa_TFPI'

Table 2.4-4 Rank order of sensitivities at 0 added TF
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Figure 2.4-16 Effect of variation of important parameters across a TF titration.

The experimental values of Ti for a titration of TF are shown in blue. The experimental
value of the control is shown in green. Simulated values of Ti are shown by the blue
dashed line. Important individual parameters were locally perturbed by either 10× (red
dashed lined) or 0.10× (black dashed line) and the resulting simulated titrations are
shown above. This local sensitivity analysis was performed for the 3 most globally
sensitive parameters (subplots 1-3) in the absence of added TF (Figure 2.4-15 B and
Table 2.4-4), the estimated rate of XIIa produced from the wall (subplot 4), as well as for
the 4 most globally sensitive parameters (subplots 5-8) in the presence of 10pM added TF
(Figure 2.4-15 A and Table 2.4-3).
84

In the absence of external TF (Figure 2.4-15 B and Table 2.4-4), regulation of XIa
activity resulting from its production by autoactivation or inhibition by C1-inhibitor,
alpha1- antitrypsin or ATIII was found to be the most sensitive. The estimated XIIa
production rate was moderately sensitive (Rank 19) but not the most crucial determinant
of contact activation in the presence of CTI. This is in accordance with our observation
that very minute amounts of XIIa, leakage past CTI can strongly self amplify via XIa. On
the slow timescales of activation in these simulations, inhibition of thrombin activity by
ATIII or by its binding to fibrinogen was also found to be important. On expected lines,
no sensitivity to TF mediated reactions was observed.

2.5 Discussion
Human blood is the only living tissue that is routinely and easily obtained for in
vitro research and clinical diagnostics. Blood is fully amenable to high throughput

functional phenotyping and strong genotype-phenotype linkages are the basis of
significant human disease. The platelet and the plasma form the basis for hemostasis and
have been modeled from a bottom-up systems biology approach [94, 96, 97, 168] with
the distinct advantage of relatively well defined reaction topology and freedom from
genome-wide transcriptional complexity.
We have developed a high throughput assay that allowed us to study thrombin
generation in diluted blood, across several conditions simultaneously with multiple
replicates at each condition. The use of diluted blood in this assay is a limitation of the
small reaction volumes in a 384-well plate and scales the initial concentrations of all
species by the final dilution factor. The presence of an externally added fluorogenic
substrate for the purpose of detection represents a subtle alteration of thrombin-mediated
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feedback of its own generation by competitively occupying thrombin’s active site. We
evaluated the commonly used thrombin substrates Z-GGR-MCA and Boc-VPR-MCA
(Figure 2.4-2 A, B, C and D). The latter substrate was found to have acceptably small

inhibitory effects on Ti at a concentration of 10 μM. In contrast, Z-GGR-MCA at a
concentration of 100 μM was found to markedly hinder Ti for 1 pM TF triggered
coagulation. The use of 416 μM of this substrate in the ‘Calibrated Automatic
Thrombography’ assay may be necessitated by the objective of tracing the ‘complete’
thrombogram. The use of 10 μM Boc-VPR-MCA suffices for the purpose of detecting
coagulation ‘initiation’ and reduces assay interference. Also, the use of citrate as an
anticoagulant was not found to have any significant influence on clot initiation times and
permitted us to have a well defined activation time (t=0) for the coagulation reaction
space defined as the time of recalcification of all the wells. Effects of the contact factor
pathway were significant at concentrations less than 100 fM TF and were subsequently
prevented by the use of CTI (Figure 2.4-2 E).
We and others have consistently observed that CTI-treated human blood clots in
the absence of added TF in vitro. In keeping with the notion of “blood borne TF” it is
tempting to attribute such clotting initiation to platelet-dependent sources [81, 154]. We
explored several possible mechanisms with neutralizing antibodies against TF, VII/VIIa,
PDI, P-selectin, GPIb, and cathepsin G but none had affect on thrombin generation.
Similar to the experiments of Butenas et al. [169], we have not found any evidence for
functional TF in static whole blood (a closed system).
CTI inhibits β XIIa [170] and has relative specificity for this form of XIIa [171].
The β form of XIIa does not bind to surfaces and has little ability to activate XI, although
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it does activate Pre-Kallikrein (which in turn amplifies XIIa production). The
effectiveness of CTI in prolonging APTT is probably a result of prevention of XIIa
amplification by Kallikrein produced by β XIIa. The surface bound α form of XIIa is the
main activator of FXI and the intrinsic coagulation system [172]. Such XIa produced by α
XIIa on negative surfaces could get past CTI and lead to contact activation.

We have

demonstrated that in resting whole blood XIIa can leak past even very high
concentrations of CTI, eventually leading to a significant burst in thrombin production
(Figure 2.4-8). Without CVX activation, the combined use of CTI, anti-XII and anti-XI

block all proximal triggers of clotting in the 4 hr assay (Figure 2.4-9). With CVX
activation, VIIa activity on the active platelet alone (independent of TF) is kinetically
significant, but the local activity of single molecules of XIa (formed downstream of a
XIIa leak past CTI) in the proximity of the active platelet surface, can lead to efficient
thrombin production (Figure 2.4-10).
We highlight a recent report by Back-Nilsson et al. [173] where the authors
showed that the levels of XIIa-AT, XIa-AT and Kallikrein-AT complexes were not
affected by CTI treatment if contact activation of XII is allowed to occur on activated
platelet surfaces. In contrast, if contact activation is allowed to occur on artificial
negative surfaces like glass or kaolin, the formation of XIIa inactivation complexes is
completely abolished by CTI (Back et al. Figures 1-3). Thus, there exists strong evidence
that CTI is ineffective against XIIa formed on active platelet surfaces. Several reports
attribute in vitro thrombin generation following platelet activation to endogenous TF.
Caution must be exercised in interpreting such results because contact activation still
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occurs upon active platelet surfaces even in the presence of CTI (and antibodies against
XII and XI).
Initiation times obtained by titrations of active proteases provide estimates of
upper limits for endogenous active proteases. Activation peptides of several proteases
have indeed been detected in blood indicating that these proteases do exist in active form
albeit in concentrations low enough to have little effect on physiologic time scales [8487]. Our experimental titrations (Figure 2.4-11) bounded the initial conditions of active
proteases (or TF) in blood to: <~500pM Va, <1 nM VIIa, <1 pM IXa, <10 pM Xa, <1 pM
XIa and <~40 fM of pre-synthesized TF. Titrations of added thrombin are difficult to
deconvolute using fluorogenic thrombin substrates. Circulating thrombin levels must be
<100 pM to maintain platelets in an unactivated state (Figure 2.3-2). With respect to
initial conditions of active proteases at t=0, we attempted to search the initial condition
space of blood using Simulated-Annealing and Particle-Swarm optimization algorithms
to find the best fit of initial conditions, subject to the above upper bounds for non-zero
initial levels of Va, VIIa, IXa, Xa, XIa and bloodborne TF. Despite more than 100,000
simulations, no acceptable fit was obtained by optimization of initial conditions alone.
Importantly, adjustment of XIa (t=0) was insufficient to maintain an “engine idling”
model of blood consistent with the results in Figure 2.4-11, Figure 2.4-13 and Figure
2.4-14. It was necessary to include a source term that generated XIIa at a rate slow

enough to have little effect on short time scales in the presence of high concentrations of
active proteases, but fast enough to limit Ti to that of the control. TF independent VIIa
activity was found to be appreciable at high concentrations and upon active platelet
surfaces and was therefore also considered as a proximal trigger of coagulation initiation.
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The estimation of a rate of XIIa production (Reaction 29, Table 2.4-1) allows us
to extend the predictive capacity of the Hockin-Mann model to low concentrations of TF.
Further we were also able to simulate titrations of Va, VIIa, IXa, Xa and XIa in 5x
diluted blood (Figure 2.4-11); clotting times observed with additions of TF, IXa, Xa and
thrombin in whole blood (Figure 2.4-13); and the observed consequences of platelet
activation (Figure 2.4-14). However, the Platelet-Plasma model remains a coarse grained
platelet and pseudo-homogeneous model. No distinction is made explicitly between bulk
and surface phases and binding of reactants onto the platelet surface is not considered
separately. Net conversion rates were sped up as the platelet activates by decreasing the
unbinding of the enzyme-substrate complex (representing the role of anionic lipid
exposure), but no explicit attempt was made to model the change in exposed surface area
and chemistry, and its effect on reaction rates. For the sake of simplicity, a single
functional form (ε) was assumed for the changes in rates as the platelet activates,
resulting in a two order change in rate of all desorption reactions on the platelet surface.
We have shown recently that it is possible to construct donor specific models of platelet
calcium mobilization as a function of combinatorial agonist concentrations at the site of
the thrombus [101]. To incorporate donor specific descriptions of platelet function in
models of coagulation, the correlation between intracellular calcium and PS exposure
must be defined.
The present study indicates the future feasibility of a full description of blood
accounting for intracellular platelet metabolism and heterogeneous reactions on the
dynamic platelet surface. In keeping with the static environment in a well plate and the
absence of endothelium, no consideration was made of fluid flow, mass transfer from the

89

bulk onto the platelet surface or thrombomodulin/APC mediated pathways. Our model
extends the topology of the Hockin-Mann structure to better simulate in vitro clotting
initiation of whole blood under diverse initial conditions, however the assumption of a
well mixed static system is not appropriate for simulations of thrombosis under flow in
vivo.

Our high throughput measurement system allows us to rapidly and reproducibly
quantify the duration of the initiation phase across numerous conditions from a single
blood draw. This has the potential to efficiently identify coagulation pathologies. For
instance, an extended duration of this metric for a donor would indicate propensity to
bleeding diseases like hemophilia while a shortened metric would indicate predisposition
to thrombosis. Titration experiments with added proteases provide a higher dimensional
examination of blood function than simply measuring the clotting time after addition of
high doses of TF.
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Chapter 3
Pairwise agonist scanning of human platelets reveals
the

high

dimensional

response

to

combinatorial

mediators of thrombosis
3.1 Abstract
Prediction of cellular response to multiple stimuli is central to evaluating patientspecific clinical status and to basic understanding of cell biology. Cross-talk between
signaling pathways cannot be predicted by studying them in isolation and the
combinatorial complexity of multiple agonists acting together prohibits an exhaustive
exploration of the complete experimental space. Here we describe pairwise agonist
scanning (PAS), a strategy that trains a neural network model based on measurements of
cellular responses to individual and all pairwise combinations of input signals. We apply
PAS to predict calcium signaling responses of human platelets in EDTA-treated plasma
to six different agonists (ADP, convulxin, U46619, SFLLRN, AYPGKF and PGE2) at
three concentrations (0.1, 1 and 10 × EC50). The model predicted responses to
sequentially added agonists, to ternary combinations of agonists and to 45 different
combinations of four to six agonists (R = 0.88). PAS could distinguish between the
phenotypic responses of platelets from ten healthy male donors and even showed promise
in stratifying donors based on ethnicity and gender. Further, PAS was performed in the
presence of external calcium for the 3 agonists ADP, CVX and U46619, both without
pharmacological intervention and with inhibitors against targeted pathways. This was
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used to train patient specific neural network models of regular response, as well as
response to therapy, and forms the basis of the platelet activation module in a multiscale
Lattice Kinetic Monte Carlo model of thrombosis. Training neural networks with pairs of
stimuli across the dose-response regime represents an efficient approach for predicting
complex signal integration in a patient-specific disease milieu. Finally this approach can
be extended to study not just human platelets, but also murine platelet phenotypes (both
regular and genetically modified) across a broad range of conditions using very small
volumes of blood.

3.2 Introduction
Since cells can respond to numerous signals and integrate their response to dosedependent combinations of these inputs, efficient methods are needed to survey such high
dimensional systems. The evaluation of response to pairs of stimuli offers a direct and
rapid sampling of a response space that can be built-up into a higher level predictive tool
through the use of neural networks. Central to cardiovascular disease, platelets are cells
that respond in a donor specific manner to multiple signals in vivo and their activation in
response to thrombotic signals is central to the thrombotic risks and events surrounding
1.74 million heart attacks and strokes, 1.115 million angiograms and 0.652 million stent
placements in the United States each year [174].
During

a

clotting

event,

platelets

experience

diverse

signaling

cues

simultaneously. After capture of the flowing platelet via glycoprotein GPIb-IX-V binding
to von-willebrand factor, exposed collagen activates glycoprotein VI (GPVI)-dependent
tyrosine kinase signaling leading to phospholipase Cγ2 activation, which in turn triggers
calcium mobilization and α2β1 and α2bβ3 integrin activation. ADP is released from dense
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granules to activate the G-protein coupled receptors (GPCR) P2Y1 and P2Y12, while
thromboxane A2 (TxA2) is synthesized by platelet cyclooxygenase 1 (COX1) and binds
platelet TP receptors. Tissue factor at the site of the damaged vascular wall leads to the
production of thrombin which cleaves the platelet GPCR protease activated receptors
PAR1 and PAR4 on the platelet surface. These activating signals occur in the context of
inhibitory signals from endothelial nitric oxide and prostacyclin.
While these diverse signaling events occur simultaneously in vivo during
thrombosis, most in vitro studies examine single agonists in isolation. ADP[175],
thrombin[176], collagen[177] have been investigated in detail, yet these studies do not
capture the highly heterogeneous and dynamic thrombotic environment. Platelet signaling
varies spatially and temporally in growing thrombi[178]. Few experimental or
computational tools are available for building a global understanding of how a cell
integrates multiple stimuli present at varying levels.
We have developed a high-throughput experimental platform that measures the
human platelet response to all pairwise combinations of six major agonists. Agonists
tested in this study were: convulxin (CVX; GPVI activator), ADP, the thromboxane
analog U46619, PAR1 agonist peptide (SFLLRN), PAR4 agonist peptide (AYPGKF),
and PGE2 (activator of IP receptor).

The method yields high-resolution time-series

measurements of intracellular calcium which is the convergent node of these platelet
signaling pathways (Figure 3.2-1) and is critical to granule release, exposure of
phosphatidylserine, actin polymerization, shape change, and integrin activation[179]. We
first tested the platelet response to all pair-wise combinations of 6 agonists at 3 separate
doses (0.1, 1, 10×EC50). These 135 calcium traces trained a 2-layer neural network (NN)
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to successfully represent an individual’s platelet phenotype.

The Pairwise Agonist

Scanning (PAS) method demonstrates that sampling all dual orthogonal "axes" (every
agonist pair) can successfully predict the dynamic responses and cross-talks of a higher
dimensional system (6 agonists in this case).

Figure 3.2-1 Signaling pathways in human platelets converge on calcium

Platelets integrate signals from numerous simultaneous thrombotic inputs. The signals
considered in this study include Collagen (CVX), thromboxane (U46619), thrombin
(AYPGKF and SFLLRN), ADP and PGE2. All of these signals regulate the levels of
cytosolic calcium and an elevation of calcium concentration precedes several responses
including integrin activation, granule release and shape change. (Also see Section 1.2 and
Figure 1.2-1).

3.3 Materials and methods
3.3.1 Materials
The protease activated receptor-1 (PAR-1) agonist peptide SFLLRN (thrombin
receptor agonist peptide, TRAP) and the PAR-4 agonist peptide AYPGKF were obtained
from Bachem (King of Prussia, PA). Convulxin (CVX), was obtained from Centerchem,
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(Norwalk, CT). Thrombin and GGACK were obtained from Haematologic Technologies
(Essex Junction,VT). Clear, flat bottom black 384-well plates were obtained from
Corning (Corning, NY). ADP, U46619, PGE2, EDTA, HEPES, the fibrin polymerization
inhibitor Gly-Pro-Arg-Pro (GPRP), NaCl, NaOH, apyrase, indomethacin and sodium
citrate were all from Sigma (St. Louis, MO). Fluo-4 NW Calcium assay kits were
obtained from Invitrogen (Carlsbad, CA). The buffer used for all dilutions was HEPES
buffered saline (HBS, sterile filtered 20 mM HEPES and 140 mM NaCl in deionized
water adjusted to pH 7.4 with NaOH).

3.3.2 Platelet preparation
Whole blood was drawn from healthy male volunteers according to the University
of Pennsylvania Institutional Review Board guidelines, into citrate anticoagulant (1 part
sodium citrate to 9 parts blood). All donors affirmed to not taking any medications for the
past 10 days and not consuming alcohol for the past 3 days before phlebotomy. After
centrifugation at 120g for 12 min to obtain platelet-rich plasma, 2 ml of platelet-rich
plasma was incubated with each vial of Fluo4-NW dye mixture reconstituted into 8 ml of
buffer for 30 min.

3.3.3 High throughput experimentation
An ‘agonist plate’ containing varying combinatorial concentrations of platelet
agonists was prepared on a PerkinElmer Janus (PerkinElmer Life and Analytical
Sciences) using 10× stock solutions of ADP, CVX, SFLLRN, AYPGKF and U46619. A
separate ‘platelet plate’ containing dye-loaded platelets was prepared on a PerkinElmer
Evolution.
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Figure 3.3-1 High throughput experimental procedure

An agonist plate containing combinatorial agonist combinations and a platelet plate
containing dye-loaded platelets were separately assembled. Agonists were dispensed onto
platelet suspensions and fluorescence changes were measured to quantify platelet calcium
concentrations [Ca2+]i. [Ca2+]i transients can be represented as overlapping plots (lower
right) or parallel heat maps (lower left). RFU, relative fluorescence units.
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Final platelet rich plasma (PRP) concentrations were 12% by volume (6 μl/well)
after agonist addition, and 5 mM EDTA was included in every well. Agonists (10
μl/well) were dispensed after a 20-s baseline read from columns of the ‘agonist plate’
onto the corresponding columns of the ‘platelet plate’ on a Molecular Devices
FlexStation III. Fluo4 fluorescence was measured at excitation 485 nm and emission 535
nm for 4 min in every column of the plate. The fluorescence F(t) was scaled to the mean
baseline value for each well F0(t) and relative calcium concentrations were quantified as
F(t)/F0(t). An entire 384-well plate was read in ~90 min.

3.3.4 Agonist selection
The number of agonists tested in a PAS experiment is limited to 6 by the need of
testing all the 154 conditions in duplicate in a single 384-well plate. Agonists were
chosen to be representative of physiological signaling cascades. Convulxin is a selective
GPVI activator [180] and under static conditions this receptor is the predominant
determinant of collagen induced signal strength [181] . In contrast, the soluble
monomeric form of collagen interacts only with α2β1, which regulates platelet adhesion
but has little direct effect in mediating signaling [182, 183]. “Horm” collagen
preparations are insoluble making them poorly suited for automated liquid handling.
Although ADP stimulates both P2Y1 and P2Y12, the latter receptor has minor effect on
calcium mobilization [184], allowing us to use the physiological agonist ADP instead of
specific P2Y1 ligands. Thrombin signals through two separate Gq coupled receptors
PAR1 and PAR4 both of which produce temporally separate calcium signals [185, 186].
This prompted us to use selective PAR agonist peptides (SFLLRN and AYPGKF) to
distinguish the separate signal contribution of both these receptor pathways. Moreover
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thrombin stimulation of unwashed PRP requires inhibition of fibrin and FXa formation
(See Figure 3.4-21). Washing or gel filtering platelets is a processing step that decreases
throughput in a large scale experiment and often causes residual platelet activation in the
absence of PGE2 or other PGI2 analogs. The use of a short lived prostaglandins like PGI 2
[187] is unsuitable for assembly of agonist plates (requiring ~120 min) and plate reading
(requiring ~90 min). In contrast, prostaglandins of the E series are chemically stable
prompting us to use PGE2 as an agonist causing elevation in intracellular cAMP.
Similarly, for reasons of stability during the course of the experiment the thromboxane
analogue U46619 was used instead of its physiological equivalent TxA2 [188].

3.3.5 Choice of synergy score
To quantify cross talks between agonist combinations, the ‘Synergy score’ was
defined as the difference between the observed and the predicted additive response. For
ease of visualization this difference was scaled to the maximum synergy score observed
in an experiment (or simulation) giving a metric that ranges from -1 (antagonism) to +1
(positive synergy). A similar synergy metric was previously defined as the ratio of the
observed and the predicted additive response to demonstrate synergistic calcium
signaling between C5a and UDP in RAW264.7 cells and bone marrow derived
macrophages[189]. The use of a ratio rather than a difference is prone to numerical
errors for small values of the predicted additive response.

3.3.6 Neural network model construction, training and simulation
Neural network modeling and analysis was performed using the Neural Network
Toolbox for MATLAB (The MathWorks). Training data consisted of (i) the dynamic
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inputs, which represent the combination of agonist concentrations present at each time
point for a particular experiment. Because the concentration of agonists remains
essentially constant throughout each experiment, these values were generally a constant
vector of concentration values repeated at 1-s intervals. (ii) The dynamic outputs, which
represent the experimentally measured calcium concentrations, also interpolated at 1-s
intervals. To normalize the input data, agonist concentrations of 0, 0.1, 1 and 10 × EC50
were mapped to the values (–1, –0.333, +0.333, +1) before introducing them to the
network, so as to fall within the working range of the hyperbolic tangent sigmoid transfer
function, which was used for all processing nodes. Output values (fluorescence
measurements) were normalized between –1 and +1, so that the basal concentration of
calcium at t = 0 was defined to be 0. After training all 420 possible one- and two-layer
neural networks with between 1 and 20 nodes in each processing, or ‘hidden’, layer and
testing each network for accuracy, a final neural network topology with a six-node input
layer (representing the six agonists), two processing layers (eight nodes/four nodes) and a
single-node output layer (representing the intracellular calcium concentration) [190] was
most optimal (best predicted the ‘net’ output response [Ca2+]I for a given multivariate
input using the fewest neurons) and thus selected to predict successive time points from
all 154 Ca2+ release curves gathered experimentally (Figure 3.4-3). For the sake of
simplicity and because we already obtain reasonably accurate time series predictions of
[Ca2+]i, more processing layers or >20 neurons in each layer were not tested.
The work training, testing and utilizing the predictions of the Neural Network
model in Section 3.4 was done in collaboration with Jeremy Purvis.
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Figure 3.3-2 Dynamic neural network used to train platelet response

A constant sequence of input signals (agonist concentrations) is introduced to the twolayer, 12-node network at each time point. Processing layers integrate input values with
feedback signals to predict [Ca2+]i at the next time point
From a purely biological perspective, the model architecture is arbitrary and no
particular meaning should be inferred from the narrowing of eight nodes in the first layer
to four nodes in the second processing layer. Moreover, this neural network model
(Figure 3.3-2) does not correspond to an actual signaling network (Figure 3.2-1) but
does provide a highly efficient framework for use as an independent signaling module in
multiscale models of thrombosis under flow. From a mathematical perspective this
architecture represents a multivariate regression to obtain optimal good fits of highdimensional data and allow extrapolation onto experimentally unexplored spaces.
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NARX (nonlinear autoregressive network with exogenous inputs) models are
recurrent dynamic networks with feedback connections enclosing multiple layers of the
network, and are well-suited for predicting time series data [191] because they process
inputs sequentially, that is, at successive time points. Calcium outputs before the current
instant were fed back to hidden layers using a delay line spanning 128 s. Initial states of
the delay line were set to 0, corresponding to the steady state of the platelet before
agonist stimulation. Such a structure allows the network output to progress over time,
using the ‘memory’ of the previous 128 s in calculating the current output. Training was
performed using Levenberg-Marquardt back-propagation until the performance of the
model (mean squared error between the simulated and experimentally measured PAS
responses.) did not improve >1 × 10−5. During training, the pairwise agonist data (154
time-course traces) was divided into training, validation and testing vectors. Validation
and testing vectors were each generated by randomly selecting 23 (15%) of the 154
pairwise time-course traces. The training vectors were used to directly optimize network
edge weights and bias values to match the target output. The validation set was used to
ensure that there is no overfitting in the final result. The test vectors provide an
independent measure of how well the network can be expected to perform on data not
used to train it
Mathematically, the output y at an instant t, for an input vector I of the
concentrations of the six inputs species can be compactly described by
⎛
⎞
⎜
⎟
⎛
⎞
⎜
⎟
⎜
⎟
y(t ) = f ⎜ L3(1×4) × f ⎜ H 2( 4×8) × yh (8×1) + L 2( 4×8) × f H 1(8×8) × yh (8×1) + IW (8×6) × I ( 6×1) + b1(8×1) + b2( 4×1) ⎟ + b3(1×1) ⎟
14444444244444443
⎜
⎟
⎜
⎟
(8×1)
⎜
⎟
1⎝44444444444444424444444444444443⎠
( 4×1)
1⎝4444444444444444444244444444444444444443⎠

)

(

(1×1)
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where IW is the matrix of input weights, L 2 and L3 are the weight matrices that operate
on the ‘inputs’ coming from the first and second processing layers respectively. H 1 and
H 2 are matrices that contain history coefficients that weigh the history vector
y h (containing the output of the system 1, 2, 4, 8, 16, 32, 64 and 128 s prior to the current

instant). b1 , b 2 and b 3 are bias vectors that add constant biases to each weighted input
and weighted histories to produce the ‘net input’ to each transfer function. f is the
hyperbolic tangent function that operates on a vector of ‘net inputs’ to yield the
corresponding transformed output. Numbers in parentheses show the sizes of relevant
matrices or vectors. The NARX model presented here, represents a nonlinear regression
model with input stimuli and system history. The use of simple 1st and 2nd order
polynomial terms (with lower number of optimizable parameters) did not produce
acceptable fits (not shown), necessitating the use of the NARX architecture. A 3rd order
polynomial was not attempted since it requires 316 fitting parameters, far exceeding the
number of parameters in the neural network model.
It should be noted that each trained neural network model produces a
deterministic prediction of platelet activation. Experimental variations are inherent in
replicates of donor-specific training data (Figure 3.4-17), and the tightness of the
measured mean will determine the predictive quality of such a donor-specific neural
network model.
Busch et al.[192] used a continuous time recurrent neural network (CTRNN), to
describe the fold expression kinetics of 9 “top ranked” genes involved in the sustained
migration of keratinocytes after hepatocyte growth factor (HGF) treatment. Utilizing the
NN weights for a signaling network, they define the modulation and control elements of
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the response [192]. Also, previous studies have used Partial Least Squares Regression
Analysis (PLSR) to understand the interplay of molecular mechanisms during signaling
[193, 194]. PLSR measures multiple intermediate signaling molecules at various time
points for a relatively small number of inputs, and identifies principal components that
capture the phenotype of the system. In comparison, the PAS approach offers less
mechanistic dissection, but provides rapid (a 2-hr experiment) and efficient prediction of
dynamic input-output relationships at numerous (~102) physiologically relevant
conditions. Geva Zatorsky et al. [195] have recently reported similar utility of sampling
the effects of drug pairs in predicting the dynamics of response to three or four drug
combinations in lung cancer cells.

3.4 Results
3.4.1 Defining the dynamic range of individual agonists
To determine appropriate dynamic ranges for the 6 agonists (Figure 3.2-1), each
compound was first tested individually. Dose response curves were constructed in terms
of the peak fluorecense signal at each agonist dose (Similar dose responses were obtained
for the integrated signal). This allows us to define the complete dynamic range for each
agonist and to determine their half maximum response (EC50) values (Figure 3.4-1). The
inhibitory response of PGE2 was studied by concomitantly stimulating the platelet with
60 μM SFLLRN. These dose responses were determined both in the absence and
presence of external calcium. The removal of external calcium does not affect the ability
of the studied receptors to signal, as no appreciable difference in EC50s were noted with
or without external calcium (Figure 3.4-1 a and b).
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Figure 3.4-1 Single agonist dose response curves

Single agonist dose response curves were constructed for platelet responses to the
agonists ADP, CVX, U46619, SFLLRN, AYPGKF and the antagonist PGE2. All
conditions are for a single donor with 8 replicates per agonist dose. EC50 levels were
determined by fitting a 4 parameter curve (dashed lines) to the peak calcium signal. EC50
levels were almost unchanged in (a) 1.5 mM extracellular Calcium (with 15 μM
Indomethacin to prevent autocrinic amplification via TXA2) or (b) 5 mM EDTA. Values
shown are mean ± standard deviation.
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3.4.2 Supression of autocatalytic signal amplification
To eliminate the sensitivity of cells to confounding autocrine effects of soluble
mediators that are dependent on platelet concentrations and transport processes, we
conducted all experiments in 5 mM EDTA, which chelates extracellular calcium. Inspite
of the absence of external calcium the ability of the receptors studied to signal is not
affected (Figure 3.4-1 a and b). Although such an experimental design does not capture
the contribution of store operated calcium entry, it offers several operational advantages
by (i) lowering background fluorescence without extensive platelet washing, (ii)
preventing thrombin production, (iii) inhibiting granule release [196, 197] as well as
TxA2 formation [198], and (iv) inhibiting integrin mediated signaling downstream of Ca2+
release [199]. Thus, the resulting traces of Ca2+ are directly dependent only on receptor
mediated release from intracellular stores. The operational advantages of using EDTA,
however, prevent prediction of important physiologic phenomena like granule release,
integrin activation and outside-in signaling
To test whether the intracellular Ca2+ signal detected was being influenced by
endogenously released agonists, we studied the effects of 2 units/ml apyrase (which
hydrolyzes released ADP) or 15 μM indomethacin (which inhibits production of TxA2 ) .
Both these inhibitors had no effect on individual responses (Figure 3.4-2, and Table
3.4-1 and Table 3.4-2), suggesting that endogenous agonists have no effect on the Ca2+

signal. This confirms that the resulting traces of Ca2+ are directly dependent only on
receptor-mediated release from intracellular stores.
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Figure 3.4-2 Addition of Apyrase and Indomethacin.

Possible secondary autocrinic amplifications by secreted ADP or synthesized
thromboxane were evaluated by adding the ADP hydrolyzing enzyme apyrase or the
COX inhibitor indomethacin. No statistically significant reduction in (a) the peak calcium
signal or (b) the integrated calcium signal was noted upon stimulation with either 0.1, 1,
or 10x EC50 levels of CVX, U46619, SFLLRN, AYPGKF or PGE2. *s represent
conditions where the use of the inhibitor produced a significant reduction (P Value
<0.05). The PValues for all the comparisons carried out are listed in Table 3.4-1 and
Table 3.4-2. Values shown are mean ± standard deviations.
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Dose

15μM

2 Units/ml

Both Inhibitors

(×EC50)

Indomethacin

Apyrase

added

0.1

0.6039

0.6504

0.6504

1

0.3312

0.4686

0.4091

10

0.3961

0.5314

0.3496

0.1

0.7857

0.0325*

0.4091

1

0.6039

0.9794

0.9794

10

0.3961

0.9535

0.9535

0.1

0.3961

0.6504

0.5314

1

0.8355

0.9924

0.9957

10

0.5346

0.5314

0.7576

0.1

0.0087*

0.0898

0.2944

1

0.2684

0.5909

0.2944

10

0.6039

0.9102

0.8799

0.1

0.6039

0.9102

0.8452

1

0.6039

0.803

0.3496

10

0.3312

0.7056

0.5909

Agonist
CVX

U46619

SFLLRN

AYPGKF

PGE2+60μM SFLLRN

Table 3.4-1 Comparison of peak signals in the presence and absence of inhibitors
against autocatalytic signal amplification pathways

P Values comparing the peak calcium signal in the presence of various inhibitors
(columns 3, 4 and 5) with no added inhibitor at various agonist doses (column 2). *s
indicate significant reductions in peak signal and were noted in 2 out of 45 conditions
tested.

107

Dose

15μM

2 Units/ml

Both Inhibitors

(×EC50)

Indomethacin

Apyrase

added

0.1

0.5346

0.6504

0.7056

1

0.2684

0.5314

0.4091

10

0.3961

0.5314

0.4091

0.1

0.1234

0.0325*

0.5314

1

0.2684

0.8799

0.934

10

0.1234

0.987

0.987

0.1

0.1645

0.5314

0.4686

1

0.8355

0.9957

0.9957

10

0.1645

0.6504

0.5314

0.1

0.0152*

0.0076*

0.0898

1

0.4654

0.8452

0.2424

10

0.7316

0.9102

0.8799

0.1

0.6039

0.9102

0.934

1

0.4654

0.8799

0.2424

10

0.5346

0.5909

0.5909

Agonist
CVX

U46619

SFLLRN

AYPGKF

PGE2+60μM SFLLRN

Table 3.4-2 Comparison of integrated signals in the presence and absence of
inhibitors against autocatalytic signal amplification pathways

P Values comparing the integrated calcium signal in the presence of various inhibitors
(columns 3, 4 and 5) with no added inhibitor at various agonist doses (column 2). *s
indicate significant reductions in peak signal and were noted in 3 out of 45 conditions
tested.

Each experimental condition was tested in replicates of 6. The non-parametric WilcoxonMann-Whitney test was used to test whether the use of either Indomethacin/ Apyrase or
both inhibitors added together resulted in a significant reduction in signal compared to
the control experiment where no inhibitors were added. The tests were conducted at 5%
significance level. Statistically significant reductions in signal were obtained with these
added inhibitors in only ~5% of the conditions tested.
108

Lack of detectable secondary autocatalytic amplification is expected since diffusion
would reduce platelet surface ADP levels by 1000-fold within 2 sec following release of
all dense granules [200]. Also assuming release of 75% of platelet dense granule ADP
content of 1.74 μmoles/1011 platelets [201] into an instantaneously isotropic reaction
volume of 50 μl containing 12% PRP results in a final ADP concentration of 494 nM, a
concentration less than the EC50 levels of ADP. In vivo, platelets are concentrated 5-10
fold near the vessel wall due to drift caused by red blood cell accumulation at the vessel
center [202]. Furthermore, during thrombosis, platelet concentrations in deposited
aggregates can increase 10 to 50-fold over platlet-rich plasma levels. At such close
confinement during thrombosis, autocatalytic amplifications caused by secreted ADP and
TxA2 will become significant. However in the controlled, dilute (12% PRP), and
unstirred environment inside the well plate containing EDTA which attenuates secretion,
we observed only primary effects of receptor mediated calcium release from cell stores.

3.4.3 Pairwise Agonist Scanning
We tested all 135 pairwise combinations of low (0.1×EC50), moderate (1×EC50),
and high (10×EC50) agonists concentrations (Figure 3.4-3 a). The pairwise agonist
synergy score (Sij) is the scaled difference between the integrated calcium transient (area

under the curve) for the combined response and the integrated area for the individual
responses (Figure 3.4-3 b) (Sij>0, synergism; Sij=0, additivity; Sij<0, antagonism).
Neural network (NN) models are remarkable in learning patterns of inputs and
predicting outputs by optimizing the weights of intermediate connections, akin to a
platelet’s ability to respond to multiple thrombotic signals through coupled biochemical
reactions. Motivated by the notion that a living cell is essentially a neural network whose
connection weights have been selectively adjusted during evolution [203], we took a
“top-down” approach [204] to model platelet signaling. A NN model was trained on these
154 time-course traces (135 pairwise responses, 18 single agonist responses, 1 control)
and captured both the time-course behavior (R=0.968 for correlation between time
points) and the pairwise agonist synergy (R=0.884 for correlation between Sij scores
(Figure 3.4-4) with excellent accuracy (Figure 3.4-3 a and b).
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Figure 3.4-3 Pairwise Agonist Scanning (PAS)
(a) Pairwise agonist scanning (PAS) All 154 binary combinations of the agonists CVX,
ADP, U46619, SFLLRN, AYPGKF and PGE2 at concentrations of 0, 0.1, 1 and 10x
EC50 were combined on the same plate (in replicates of 2) and the dynamic response of
the platelet to each combination was recorded. The NN model was trained on this dataset.
(b) Pairwise agonist synergy scores, which reflect the gain or loss in calcium response
due to agonist cross talk, were calculated for both experimental and predicted time course
traces. EC50: PGE2, 24.6 μM; AYPGKF, 112 μM; SFLLRN, 15.2 μM; U46619, 1.19 μM;
ADP, 1.17 μM; CVX, 0.00534 μM.

Figure 3.4-4 Predicted versus measured synergy scores for a PAS experiment

Predicted versus measured synergy scores for the 135 conditions in a PAS experiment
that contained binary agonist pairs (Figure 3.4-3). This fit is a measure of the “adequacy”
of training of the NN on the binary interaction dataset. The strong correlation shows that
the NN was suitably trained by the data, but does not yet demonstrate the predictive
capability of the model.
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3.4.4 Platelet responses to ternary agonist stimulation

Figure 3.4-5 Ternary agonist stimulation

Measurement and prediction of the platelet response to all 64 ternary combinations of
ADP, SFLLRN and CVX at 0, 0.1, 1 and 10 × EC50. The neural network model was
trained only on pairwise interactions but successfully predicted ternary interactions.
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Figure 3.4-6 Predicted versus measured synergy scores for ternary stimulation

Predicted versus measured synergy scores for the 27 conditions in the ternary experiment
(Figure 3.4-5) that contained 3 agonist combinations. This fit is a measure of the de-novo
predictive capacity of the NN model (trained exclusively on the binary interaction
dataset) on ternary agonist space.
Next, we measured all 64 ternary combinations of the agonists ADP, SFLLRN,
and CVX at 0.1, 1, and 10×EC50 concentrations (Figure 3.4-5). A CVX response requires
GPVI multimerization [180] and is characterized by a slow rise to a large peak signal
followed by a slow decline. In contrast, Gq–coupled responses (ADP or SFLLRN)
produce rapid bursts that are quickly brought down to baseline. Increasing CVX for a
fixed ADP level resulted in a steady increase in calcium concentrations on longer
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timescales. In contrast, increasing ADP for a fixed CVX level bolstered early calcium
release. A moderate dose of both ADP and CVX (for 0 and low SFLLRN) produced a
response that almost instantaneously plateaued at a steady level above baseline.
The NN model, trained exclusively on the pairwise interaction data set (Figure
3.4-3 a), successfully predicted all experimentally observed trends in the ternary

interactions among the three agonists studied. Both the time-course behavior (R = 0.844)
and ternary agonist synergy scores (R = 0.881) (Figure 3.4-6) were accurately
reproduced for the 27 unique ternary conditions in this experiment that were not present
in the training set. Thus, the pairwise interaction data presented in Figure 3.4-3 captured
additional information about the interactions amongst 3 agonists.

3.4.5 Sequential addition of the platelet agonists ADP, SFLLRN, CVX
We also explored the effect of adding the agonists ADP, SFLLRN and CVX in
various sequential combinations (Figure 3.4-7). Several interesting behaviors were
accurately predicted by the NN model. Preceding a large dose of ADP with prior
treatment with low dose of ADP (Figure 3.4-7, panel 12) desensitized the calcium signal
expected from a large dose of ADP (as in Figure 3.4-7, panel 1). This behavior has been
observed previously [205] and is attributed to the internalization of P2Y1. The temporal
sequence ADP-SFLLRN-CVX (Figure 3.4-7, panel 1) produced three distinct calcium
bursts, whereas the ADP response was completely abolished in the sequence SFLLRNADP-CVX (Figure 3.4-7, panel 3). This behavior points to mechanisms of cross-down
regulation of the ADP signaling cascade by component(s) of the PAR1 cascade.
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Figure 3.4-7 Measured and predicted platelet responses to sequential additions of
ADP, SFLLRN and CVX.

The effect of ADP, SFLLRN and CVX added in various temporal sequences was tested.
The NN model trained exclusively on binary interactions could predict several of the
experimentally observed trends of cross down regulation and desensitization between the
ADP, SFLLRN and CVX cascades.
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Prior addition of CVX abolished detectable responsiveness to both ADP (Figure
3.4-7, panel 5) and SFLLRN (Figure 3.4-7, panel 6) again pointing to a mechanism

where components of the GPVI signal are able to down regulate the Gq-coupled ADP or
SFLLRN signal. Additions of any two of these agonists in combination followed by the
third agonist confirm the observation that any mixture containing CVX down-regulates
responsiveness to both ADP (Figure 3.4-7, panel 9) and SFLLRN (Figure 3.4-7,
panel 8). CVX-mediated calcium mobilization events were unaffected by pretreatment

with either ADP (Figure 3.4-7, panel 2) or SFLLRN (Figure 3.4-7, panels 4 and 3), or a
binary combination of these agonists (Figure 3.4-7, panel 7). Activation of GPVI or
thrombin receptors phosphorylates the ITIM domain of platelet PECAM [206]. ITIM
phosphorylation inhibits response via phosphatases like SHP-2 [207]. Such inhibitory
mechanisms, or even the existence of agonist selective stores [208], may explain the lack
of ADP/SFLLRN response after prior CVX stimulation and the lack of ADP response
after prior SFLLRN stimulus. Simulation traces containing CVX did not decay as
observed experimentally after ~260s (Figure 3.4-7, panels 2, 4-10). Such a limitation
was expected because the NN was trained on measurements spanning only 260s (Figure
3.4-3 a) and not the entire duration (upto 900s). Importantly, the NN captured such cross-

talks of sequential additions despite being trained on purely synchronous interactions.

3.4.6 Sequential

additions

mimicking

the

in

vivo

thrombotic

environment
Platelets at the site of injury are likely to encounter specific sequences of
thrombotic signals. These are illustrated in Figure 3.4-8 A. The effects of thrombin can
be approximated by considering SFLLRN+AYPGKF to be its equivalent in simulation.
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Figure 3.4-8 Sequential additions mimicking the in vivo thrombotic environment
(A) Various sequences of thrombotic signals likely to be encountered by platelets during
in vivo thrombosis. (B) Comparisons between experiment and simulations studying
sequential additions of CVX, ADP and thromin (or SFLLRN + AYPGKF)
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In a realistic thrombotic setting, the platelet is likely to first get activated upon an
exposed collagen surface. Subsequently, platelets adhered to collagen will encounter
either thrombin (formed on the active platelet surface downstream of the coagulation
cascade) or ADP (released from activated platelets).Platelets that do not directly adhere
to the exposed collagen surface might get activated by thrombin or ADP (or sequences of
these agonists) and subsequently stick on to collagen adhered platelets or form larger
aggregates in solution. These conditions are illustrated in Figure 3.4-8 A. We mimic
these 4 conditions by making selective sequential additions (similar to Figure 3.4-7) of
the collagen analogue CVX, the physiological agonist thrombin as well as preassembled
mixtures of SFLLRN and AYPGKF peptides all at 10x EC50 in Figure 3.4-8 B. We
show that the signals generated by thrombin for these selective additions are similar to
those generated by a mixture of high dose PAR1+PAR4 peptides. A PAS trained NN for
donor A, qualitatively reproduces these sequential additions of PAR1+PAR4 peptides (to
approximate the function of thrombin). The results we obtained are similar to those
already reported (Figure 3.4-7). Prior GPVI activation abolishes detectable
responsiveness to ADP or thrombin. Thrombin (or PAR1+PAR4) abolishes subsequent
response to ADP (presumably by cross down regulation of the ADP cascade by PAR1 as
was already reported in Figure 3.4-7). In contrast, prior ADP stimulation does not
abolish subsequent detectable responsiveness to thrombin (or PAR1+PAR4). We note
that the NN was not trained using thrombin as an agonist and peptides have weak μM
affinity to PARs compared to the intramolecular signaling that is generated by thrombin
cleavage of the PARs. Differences between thrombin and preassembled mixtures of
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SFLLRN and AYPGKF were noted when a CVX stimulus followed these inputs. These
effects are discussed in Section 4.2.

3.4.7 Predicting the global 6 dimensional human platelet response
To fully test and utilize the predictive power of the NN model, we made in silico
time-course and synergy predictions for the complete 6-dimensional agonist space
consisting of 4077 unique agonist combinations of 2 to 6 agonists at 0.1, 1, or 10×EC50
concentrations. For comparison, the full distribution of synergy predictions for all 4077
agonist combinations is shown as a vertical heat map in Figure 3.4-12. Based on these
predictions (Figure 3.4-9), we selected 45 combinations of 4, 5 or 6 agonists that
displayed a range of predicted synergy scores from strong synergy to strong antagonism
and tested them experimentally (Figure 3.4-10). To prevent any bias in the selection we
selected conditions that had maximal dissimilarity in the types and concentrations of
agonists.

Figure 3.4-9 Predicted distribution of synergies scores.

The complete distribution of predicted synergy scores in all 4077 conditions that
comprise the 6 dimensional agonist space of the agonists PGE2, AYPGKF, SFLLRN,
U46619, ADP and CVX. This space was probed at the indicated positions to sample both
ends of the synergy spectrum.
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Figure 3.4-10 Measurement and prediction of response in the full agonist space.

45 conditions (containing 4-6 agonists) spanning the entire synergy spectrum were
chosen from amongst the NN model’s predictions of the complete experimental space.
These were tested experimentally along with 19 controls.
We found strong agreement between both predicted and measured calcium
transient shapes (R=0.845) in Figure 3.4-10 and Figure 3.4-11, as well as between
predicted and measured Sij scores (R=0.883, slope=1.08) (Figure 3.4-12).
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Figure 3.4-11 Probing the complete agonist space.

Experimentally observed mean (blue) and NN predicted (red) [Ca2+]i time courses for 45
out of the 4077 possibilities (shown in Figure 3.4-9) in the complete 6 dimensional
agonist space. Each experiment was done in replicates of 6. Experimental error bars
corresponding to standard deviations are shown at only 17 points along a time course for
the sake of visual clarity. The 45 conditions tested were chosen to span antagonism,
additive interaction and positive synergy.
Conditions containing high levels of all agonists showed especially low measured
synergy due to saturation of calcium release. The highest synergy was observed for
agonist combinations that contained high levels of the thromboxane analog U46619 with
no PGE2 present (Figure 3.4-12, orange bar).
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Figure 3.4-12 Predicted versus measured distribution of synergies for conditions
containing 4-6 agonists and spanning the complete agonist space.

Predicted versus measured synergy scores for the 45 conditions in Figure 3.4-10 (upper
left). Distribution of synergy scores for all 4,077 possible experimental conditions (upper
right). Experimental conditions for the 45 sampled combinations of agonists, arranged in
order of increasing synergy (bottom). The orange bar denotes the three most highly
synergistic conditions, which all contained high U46619, no PGE2 and low levels of other
agonists.
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Given that only 8 of 45 conditions had maximal U46619/PGE2 ratio, this ordering
of the top 3 conditions was highly significant (p <0.004), considering there are 14,190
possible ways to order the first 3 conditions of which only 56 combinations would
contain high U46619 and low PGE2. Thus, the NN model trained on pairwise data
facilitated discovery of a high dimensional synergy that occurs at high U46619/PGE2
ratio (at low levels of ADP, SFLLRN and submaximal levels of AYPGKF) consistent
with the known cardiovascular risks of COX2 inhibitors that prevent endothelial
production of prostacyclin without affecting platelet production of thromboxane [209].
This points to a ‘high-dimensional’ COX2 inhibition risk of high concentrations of
thromboxane, in the absence of PGI2, potentiating the effects of other agonists.

Figure 3.4-13 Effect of input silencing on predictive ability

The NN model’s predictive ability of response to multiple agonists does not amount to
prediction of the response to a dominant pair in the input set of agonists. To illustrate the
ability of the model to integrate all of the inputs in its prediction and not just rely on
certain input species, we systematically silenced each input to the model. Single inputs
were silenced first, followed by pairs, triples, etc. The performance of such models that
considered only smaller input sets (comprised of a lower number of input species) was
evaluated across all high dimensional input sets tested.
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The results of this analysis are presented above. Presence of a particular agonist is
indicated by a black fill in a respective input set. In all but two cases, the overall
predictive power decreased as inputs were silenced. This shows that the NN model
utilizes information from all inputs to gain accuracy. Any suppression of 1, 2, 3, 4, or
more inputs drives down the accuracy. In fact, deletion of data down to only 2 inputs (if
a pair is often able to predict as well as the full input set) shown in red reduces the
predictive power severely to zero correlation between experiment and the NN. This data
demonstrates that no single pair embedded in the experiment that predicts all the tested
outputs better than the full input test.
We note that there were two smaller subsets that yielded better prediction than the
complete input set. Also there were cases where reducing the number of inputs markedly
(for instance even up to two inputs for the two left most red columns) does not make
much difference to the overall prediction. It is generally impossible however, to have a
priori knowledge of which input to exclude to get better predictive ability than the full
input set. Given that there is a strong trend for predictions to do better when given
multiple inputs (despite these few exceptions) we conclude that the NN integrates
information from all input species.
To investigate whether smaller subsets of inputs, such as dominant pairs, could
account for the network’s predictive accuracy, we retrained the neural network on
different subsets of inputs. This typically, but not always, reduced predictive accuracy
(Figure 3.4-13), suggesting that the neural network does not exclusively rely on smaller

subsets of inputs.

3.4.8 Donor specific platelet responses
To investigate the reproducibility of the PAS procedure and to investigate the
potential for using it to stratify individuals’ platelet responses, PAS was performed twice
within two weeks of each other (with 2 replicates of every condition in an individual
experiment) for 10 healthy male donors to construct donor specific synergy maps (Figure
3.4-14). Donors (Ages: 22-30 years) spanned several ethnic groups (3 Western

Europeans, 2 Asians, 2 Indians, 1 Caribbean, 1 African American and 1 African).
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Figure 3.4-14 Donor specific platelet agonist synergisms.

PAS was performed twice for 10 healthy male donors to construct 135 parameter donor
specific synergy maps
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Figure 3.4-15 Donor specific PAS clustering patterns

Ten healthy donors were phenotyped for platelet calcium response to all pairwise agonist
combinations. Repeat experiments were conducted within 2 weeks. Donors (ages, 22–30
years) spanned several ethnic groups (three Western Europeans, two Asians, two Indians,
one Caribbean, one African American and one African). The magnitudes of synergy in
each of the 20 donor-specific synergy maps were arranged as columns of the synergy
matrix. These vectors were clustered according to similarity using a distance-based
clustering algorithm.
The 135 conditions containing pairs of agonists in a single PAS experiment make
up the synergy map for each donor experiment (Figure 3.4-14) and individual columns of
the synergy matrix (Figure 3.4-15). To demonstrate reproducibility and donor specificity,
a simple hierarchical cluster tree was generated using the Euclidean distances between
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donor experiments (columns of the synergy matrix). A total of 7 out of the 10 donor pair
vectors (Donor pairs D, C, A, H, E, F and I) self clustered, demonstrating that in spite of
intra donor variations in synergy, pronounced inter donor variations allow us to
distinguish donors. This pattern of clustering was found to be highly significant (p <
8×10-7) by randomizing observed donor synergies (Figure 3.4-16) considering the fact
that 5 donor pairs (the highest number of donor pair clusterings by random chance) self
clustered in only 8 out of 10 million random permutation tests.

Figure 3.4-16 Randomization of donor specific synergisms.

The synergy scores for each donor (values in the columns of the synergy matrix shown in
Figure 3.4-15 were randomized to test whether the clustering of the ‘observed’ donor
specific synergy vectors was significant. We found that the experimentally observed
clustering of 7 donor pairs (red line) out of 10 was highly significant. A P-Value less than
8×10-7, under the null hypothesis that the donor clustering pattern was by chance alone,
was obtained.
127

Donors separated into at least 2 major subgroups with the cluster of donor
experiments D1, D2, J2, C1, C2, B1 and B2 characterized by relative lack of synergy
(red) in comparison to other experiments. The cluster of experiments A1, A2, H1, H2, J1,
E1, E2, F1, F2, G1, I1, I2 and G2 had marked synergy between moderate doses of
SFLLRN and all doses of U46619/ADP, as well as marked synergy for moderate U46619
and high CVX. Mild positive synergisms such as those between low doses of SFLLRN
and U46619/ADP, as well as those between ADP and CVX further classify this latter
cluster into smaller sub clusters comprising of donors A1, A2, H1, H2 and J1; and donors
E1, E2, F1, F2, G1, I1 and I2 . PGE2 was found to be antagonistic to all Gq-coupled
agonists (ADP, U46619, SFLLRN and AYPGKF) for all donors, in accordance with the
known ability of PGE2 to raise cAMP levels [210]. Experiments A1, A2, J1 and I1, I2
were distinguished by positive synergisms at high dose PGE2 and moderate to high dose
CVX; positive synergy was also noted between low dose PGE2 and high dose CVX for
experiments A1, A2, H1, H2, E1, E2, F2 and G1 possibly via EP3 mediated signals [211]
which are known to mediate pro-aggregatory actions.
In a single PAS experiment there are 135 conditions containing 2 agonists. These
were tested in duplicate on the same plate giving 2 measurements of the 135 synergy
scores (using the mean single agonist integrated areas in a plate to calculate synergy).
PAS experiments were repeated twice within two weeks for an individual donor, giving
us 4 measurements of an experimental synergy score. The standard errors in synergy
scores across all 135 conditions were uncorrelated with the magnitude of synergy and are
measures of the experimental uncertainty and day-to-day fluctuations in mean synergy
values at these conditions. The mean uncertainty for a representative donor (donor A)
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was ± 0.0523 for Sij ranging from –1 to 1 (uncertainties across all 135 conditions are
shown in Figure 3.4-17). The mean standard error in synergy scores for all ten donors
ranged from ±0.0347 to ±0.0627 (Table 3.4-3).

Figure 3.4-17 Experimental uncertainty in mean synergy score (Donor A).

Shown above are the mean synergy scores ± standard errors for all 135 conditions for
both donor A experiments. The mean standard error across all 135 conditions for each
donor was 0.0523. These values were calculated for all the 10 donors studied and are
reported in Table 3.4-3.
Since all experiments were performed in diluted platelet rich plasma and not
‘pure’ platelet suspensions, we tested whether the observed clustering patterns were
dependent on platelet independent plasma components. We performed two separate PAS
scans of platelets from a donor (separate from the donors reported in Figure 3.4-15). In
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the first experiment for donor K (experiment K1), a PAS scan was performed identically
to the procedure described in the manuscript using autologous plasma (as in Figure
3.4-3). In experiment K2, platelet rich plasma from donor K was supplemented with an

equal volume of plasma (platelet free) from donor E (whose PAS scans have been
reported in Figure 3.4-15). Both donor K experiments yield very similar PAS scans, and
as shown above, both donor K experiments self clustered. Importantly K2 does not
cluster with donor E replicates. This demonstrates that the PAS profiles are platelet cell
autonomous and not dependent on plasma components.
Donor

Mean standard error in synergy scores

A

0.0523

B

0.0627

C

0.0331

D

0.0432

E

0.0347

F

0.0356

G

0.0498

H

0.0494

I

0.0443

J

0.0469

Table 3.4-3 Mean standard error in synergy scores.

The mean standard error in synergy score was calculated as explained in Figure 3.4-17.
These values are a measure of the experimental uncertainty in determining donor specific
synergisms.
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Figure 3.4-18 Platelet cell autonomous clustering pattern.

The observed pattern of self-clustering was platelet signaling dependent (and not related
to donor plasma), as the PAS scans of an individual donor’s platelets with autologous
(Experiment K1) or heterologous plasma (Experiment K2) self-clustered.

3.4.9 Dose dependence of binary synergies
To evaluate the dependence of binary synergy scores on the doses of the both of
the agonists present in the binary mixture, we plotted the distributions of synergy at each
dose combination (Figure 3.4-19). All experimentally observed pairwise synergy scores
(4 synergy scores per condition per donor × 10 donors) at the 9 possible binary
concentration pairs (at 0.1, 1 and 10 × EC50) were binned according to their binary
synergy values.
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Figure 3.4-19 Dependence of synergy scores on agonist pair concentrations.

Shown above are the probability distributions of binned synergy scores at each
concentration pair. Responses with synergy scores less than -0.1 were classified as
antagonistic, those greater than 0.1 were classified as synergistic and scores between -0.1
and 0.1 were classified as additive. Shown in the top left is a summary of the cumulative
probabilities of antagonism, additive responsiveness and synergy at each condition.
Highest probabilities of synergy were observed when both agonists were at moderate
doses. At low doses of both agonists, responses were generally additive. When high doses
of both agonists were present the synergy distributions were skewed towards antagonism
in accordance with the notion of saturation of signaling pathways.
In general across all conditions and donors, the highest probability of pairwise
synergy was observed when moderate doses of both agonists were used. Low doses of
both agonists produced additive responses, whereas high doses of both agonists skewed
synergy distributions toward antagonism.
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3.4.10

Intra and inter donor variability of phenotype

Figure 3.4-20 Intra and inter donor variability of phenotype

Variations in synergy scores both within the same donor and across donors were
evaluated. (A) Intra-donor variability was calculated as the mean of the standard error
in synergy scores across all conditions and (B) Inter-donor variability was calculated as
the standard error of mean synergy scores across all conditions.
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We have conducted an analysis of intra-donor and inter-donor variability (Figure
3.4-20). We found that the source of intra-donor variability was similar, but not identical

to the source of inter-donor variability. For example, ADP-CVX interactions were a
strong source only of intra-donor variability.

In contrast, high PAR4 agonist in

combination with ADP, U4619, and SFLLRN were sources of only inter-donor variation.
To calculate intra-donor variability (panel A), the standard errors at each of the
135 conditions containing binary mixtures was first evaluated. Next the means of these
standard errors were calculated across all 10 donors. The conditions were plotted on the
binary synergy map with the color indicating the magnitude of the relative variability. To
calculate inter-donor variability (panel B), the mean synergy at each of the 135
conditions (across all 4 replicates) was first calculated. The standard error of this mean
synergy measurement at a particular condition was then calculated across all 10 donors.
This gives us an indication of the spread of measured values for a particular condition in
the donor cohort. The conditions were again plotted on the binary synergy map.
Conditions containing PGE2 in general had the lowest intra donor variability.
Conditions containing moderate CVX had the highest intra donor variability. Such
variability is a measure of the likelihood of experimental noise at a particular condition.
Conditions containing PGE2 had the least inter donor variability as well, thus pointing to
highly conserved modes of interaction. Conditions that were identified to have high inter
donor variability inspite of low intra donor variability are the most useful in
distinguishing the two major donor clusters (Figure 3.4-15). Some of these conditions
were (i) high AYPGKF, low/moderate ADP; (ii) high AYPGKF, moderate/high U46619;
(iii) moderate SFLLRN, high U46619.
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3.4.11

Synergy between thrombin and thromboxane pathways

Figure 3.4-21 Synergism between thrombin and thromboxane.

Noting marked synergism between SFLLRN and U46619, and some synergisms between
AYPGKF and U46619, for all donors, we tested for synergism between the physiological
agonist thrombin and U46619. A complete binary interaction map spanning 7
concentrations of either agonist was studied. for 2 separate donors. All conditions were
tested in replicates of 6 and mean responses were used to calculate synergy scores.
Experiments were conducted in EDTA and also included 15 μM Indomethacin, 2 units/ml
Apyrase and 100 μM GGACK to prevent autocatalytic amplification by thromboxane,
ADP or Xa. 500 μM GPRP was included to prevent fibrin formation with added
thrombin. It should be noted that our experiments were conducted in 12% ‘unwashed’
platelet rich plasma in the presence of ~300 nM concentration of the physiological
thrombin inhibitor antithrombin III. This might account for the fact that relatively high
levels of thrombin (greater than ~10 nM) were required to observe detectable response to
thrombin. Such an experimental design has no effect on receptor mediated pathways but
produces a right shift in thrombin dose response. As anticipated, we observed synergisms
between low and moderate doses of these agonists prior to saturation of their receptor
signaling pathways.
All donors showed some synergism between low and moderate doses of SFLLRN
and U46619. Except for experiment B2, synergy was also found between AYPGKF and
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U46619 for all donors. Moreover, synergistic/additive interactions were noted also
between low and moderate doses of SFLLRN and AYPGKF. These results strongly
suggested a mechanism of synergy between thrombin and thromboxane. To test this,
binary synergy maps of the physiological agonist thrombin and U46619 were constructed
for donors A and E (Figure 3.4-21) over 7 doses spanning the active concentration
ranges. Marked synergisms were noted at low and moderate doses of these agonists as
expected from conserved synergy between SFLLRN/AYPGKF and U46619 (Figure
3.4-15). High doses saturated signaling pathways abolishing synergism. To our

knowledge, this is the first report of conserved synergy between thrombin and
thromboxane mimetics.

3.4.12

Dominance of pairwise effects in platelets

The PAS approach works because individual and binary interactions dominate,
and they are sampled across the full dose range of inputs. We expect the method to break
down when ternary interactions in excess of summing binary interactions become strong.
We show that the residual ternary synergy (∆(ABC) = SABC – SAB – SBC – SAC) was ~0 in
each of 27 responses of platelets to different ternary combinations of CVX, ADP and
SFLLRN and was minimized in the neural network model training (Figure 3.4-22).
The PAS approach works because unitary and binary interactions dominate and
they are no feedbacks, which would otherwise expand the repertoire of participating
factors. With these “pure inputs” (which are not broad intracellular perturbations like
ionophores or phosphodiesterase inhibitors), the network architecture (Figure 3.2-1)
necessitates rapid convergence to a common second messenger. Because of the speed of
signaling and the known cell circuitry, it is difficult to envision realization of greater than
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second order synergies in such a situation. Thus observed ternary synergies appear to be
well approximated by the linear superposition of the individual pairwise synergies. Since
residual ternary interactions were undetectable, even higher ordered residuals are likely
very small and potentially difficult to evolutionarily select. This exact result of unitary
and binary interactions dominating with few detectable ternary interactions was reported
for multiple cytokine stimulation of RAW264.7 cells [212].
In general, knowledge of pairwise interactions alone cannot be expected to predict
response to several simultaneously present stimuli (>2). However, certain characteristics
of platelets and the conditions under which they were studied made such an approach
feasible in this instance. These include (i) the relative abundance of binary interactions in
signaling systems with minimized ternary interactions (ii) the efficient utilization of
system history (Figure 3.4-23); (iii) the dense sampling of interactions across a full doseresponse range; (iv) known intracellular wiring that rapidly converges on Ca2+, without
the possibility of higher order effects from genetic regulation or other interactions on
long time scales; and (v) choice of well-characterized extracellular ligands and careful
design to avoid autocatalytic feedback.
Thus, the PAS approach is powerful for training NN models of signaling systems
that accommodate multiple binary interactions where ∆(ABC) or higher ordered residuals
are small. In systems where third order interactions are important “ternary” agonist
scanning might be necessary, however this will require added experimental complexity.
“Pairwise” agonist scanning is the bare minimum that can be expected to quantify
interactions between multiple simultaneously acting signaling pathways over and above
the strictly additive interactions between pathways.
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Figure 3.4-22 Minimization of residual ternary synergy.

The PAS trained NN model has complete knowledge about all unitary and binary
interactions that occur in the platelet, since these conditions were exhaustively sampled in
the experimental training set. However, information about higher order interactions are in
general unknown, and thus successful predictions can be made in a system only if such
higher order interactions are relatively unimportant.
Our experiment with ADP/CVX/SFLLRN measured platelet response to simultaneous
activation of two GPCRs and an immune receptor homologue (GPVI). Above, we
investigate the binary synergy score (SAB=AB-A-B), the trinary synergy score (SABC =
ABC-A-B-C), and the “residual” ternary synergy which measures the synergy in excess
We show that the
of the binary synergies [∆(ABC) = SABC-SAB-SBC-SAC].
experimentally measured residual ternary synergy ∆(ABC) is essentially zero in 27
different tests of platelet response to the 3 agonists used at 0.1, 1, and 10X EC50. By
determination of SAB, SABC, and ∆(ABC) from the predicted calcium responses obtained
from the neural network, we show that ∆(ABC)NN is also minimized during the NN
training. If ∆(ABC) ~ 0, then it is highly unlikely that higher ordered residuals such as
∆(ABCD..) are large. In such a situation, sampling the pairwise interactions
experimentally and using this data to train the NN allows the NN to make accurate
prediction of n-tuples.
Multiple signals acting simultaneously in vivo is not unique to platelets. Hsueh et. al.
recently reported the binary to quintinary interactions between 5 ligands (IFN-β, TGF-β,
IL-6, ISO and 8 Br-cAMP) of a single receptor (TLR4), resulting in secretion of 4
cytokines (G-CSF, IL-6, IL-10, and TNF-α) in macrophage like RAW 264.7 cells [212].
They found that almost all pairwise interactions result in non-additive interactions (akin
to Figure 3.4-3 and Figure 3.4-15 in the present study). Instances of higher order
interactions resulting in unique outcomes that not captured by “binary interactions” were
less common (~33% of total combinations with the majority being explicable by ternary
interactions). Hsueh et. al. made no consideration of dose dependence of the input
signals, nor was any attempt made to distinguish between the responses of the same type
originating from different human individuals.
Thus the two actual biological systems tested to date (human platelets and cultured
RAW264.7 cells) satisfy the requirement that response to combinatorial agonists is build
upon unitary and binary interactions. Since ternary interactions can be easily measured
experimentally, this guides the use of PAS in other systems. This approach can be
expected to work in systems where residual third or higher order interactions are
minimal.
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3.4.13

Utilization of system history in making output predictions

Figure 3.4-23 Use of system history in making output predictions.

The importance of history on predictive ability was evaluated by systematically
decreasing the length of system history utilized in making predictions about the current
instant.
The NARX model utilizes system history in making predictions of the output
value [Ca2+]i at the current instant. Without any history, there is no notion of “dynamics”,
and the system can at best predict outputs proportional to the magnitude of input.
However these outputs are constant over the duration of the experiment, unlike the actual
calcium transients experimentally observed. With very little history (2 s), the model does
not “remember” its unperturbed steady state value (0) and hence calcium traces
continually rise to a peak value, but never decrease.

The NN performs reasonably well

with as little as 8 s of calcium concentration history, although oscillations are produced,
as the network progressively utilizes less information about its initial steady state, and
heavily relies on just its “short term memory”, repeatedly replicating the initial trend. As
additional delay lines were removed from the network, the frequencies of these
oscillations were decreased and the network gradually captured experimentally observed
dynamics. Thus the long-term system history inputs (e.g., 32, 64, 128 s) dampen these
short-term oscillations.
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3.5 Discussion
Studying the combinatorial effects of pairs of agonists in low, moderate and high
concentrations allowed a rapid, donor-specific phenotypic scan that was predictive of
responses to 6 multiple agonists. Importantly, a single 384-well plate of data was
sufficient to train a NN model (Figure 3.4-3) that was capable of making accurate
predictions of the global 6-dimensional agonist reaction space (Figure 3.4-9), which is
difficult to probe experimentally but fundamental to the processes of thrombosis.
Synergies between platelet agonists are dependent not just on agonist pairs and
doses, but also vary from donor to donor (Figure 3.4-15). The synergistic effects of
epinephrine on other platelet agonists is well documented [213, 214]. Synergy has also
been reported between ~EC50 levels of SFLLRN-AYPGKF, AYPGKF-ADP and
SFLLRN-ADP [215]. Such unique patterns of synergisms could be used to distinguish
donors and be correlated with certain risk factors. In contrast, certain synergisms, such as
those observed between U46619 and thrombin receptor agonist peptides, were consistent
across donors and suggest conserved modes of interaction amongst these cascades.
We note that in multi-dimensional agonist space emblematic of the thrombotic
milleu, highest synergy was observed for combinatorial mixtures containing high U46619
and no PGE2 (Figure 3.4-12). This points to the “high dimensional risk” of large
concentrations of thromboxane, in the absence of PGI2, potentiating the effects of other
agonists. Aspirin is approximately 170-fold selective to COX-1 mediated thromboxane
production, compared to endothelial COX-2 mediated

PGI2/PGE2 synthesis. Thus,

selective inhibition of thromboxane, without affecting prostacyclin may account for its
efficacy in protecting against thrombotic events when diverse platelet activators are
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present [216]. In contrast Rofecoxib (Vioxx), by a selective inhibition of COX-2
mediated prostacyclin production, increases cardiovascular risk [217].
This study also introduces the use of neural network models for predicting
dynamic cellular signaling data. This application of neural networks offers several unique
benefits as a modeling strategy. First, NNs are “dense” modeling structures (few
parameters) that do not require a detailed knowledge of the kinetic structure of a system.
By comparison, a detailed ordinary differential equation (ODE) model of ADPstimulated calcium mobilization via P2Y1 in the platelet required almost 80 reactions and
over 100 kinetic parameters to describe just this one single pathway [168]. We estimate
that an ODE model that describes the signaling mechanisms of the 6 agonists (Figure
3.2-1) in this study on a similar level of detail would require over 500 parameters, most

of which are currently unavailable. Second, NN models may be trained to match an
individual donor’s signaling response. We have demonstrated in Figure 3.4-15 the subtle
but consistent variation in the platelet calcium response among healthy donors. This
offers a predictive capability that may be used to assess risks associated with an
individual’s platelets. A major goal of blood systems biology is to predict patient specific
risks and to simulate thrombus formation under realistic hemodynamic conditions of flow
[96, 218]. Platelet activation in prior simulations has been course grained by assuming
discrete states of activation or arbitrary rules governing transitions between states. The
speed of NN calculations of [Ca2+]i will allow large scale, donor-specific simulations
with 103 to 105 activating platelets under conditions of flow. Such a model can be
incorporated into lattice kinetic Monte Carlo simulations of particle motion in convective
and dispersive flow fields [219] (Section 3.7).
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Figure 3.5-1 ODE model of platelet calcium mobilization following an ADP stimulus

An ODE based molecular signaling model (77 reactions, 132 rate constants, 70 species)
of platelet phosphoinositide and calcium regulation during homeostasis and P2Y1
activation was developed (top) [168]. This model was able to simulate experimentally
obtained calcium dose response to ADP (bottom).
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Clinically, we anticipate PAS profiles to depend on such variables as ancestry,
age, sex, pharmacology, and cardiovascular state, all of which requires further testing. In
contrast to PAS, other current measurements of platelet phenotype provide the coarsest
measure of differences among healthy donors. For instance, platelet aggregometry for
359 subjects could classify them as “hypo and hyper” reactive to platelet agonists [220];
and flow cytometry of 26 individuals was able to classify them as high, medium or low
responders. A combination of genetic variations may underlie differences in platelet
phenotype, however linking genotype (1327 SNPs) to phenotype (flow cytometric
measurement of P-Selectin exposure and fibrinogen binding) in 500 individuals [221]
demonstrated weak association probabilities.
Platelets are ideal “reduced” cellular systems for quantifying the effects of
multiple signaling pathways because they are anucleate, easily obtained from donors,
amenable to automated liquid handling, and biochemically well-characterized. In spite
of the distinction from the in vivo platelet environment, the simplified in vitro conditions
using EDTA were useful for the dissection of signaling pathways ‘decoupled’ from
confounding autocrine effects of soluble mediators that are highly dependent on local
platelet concentrations and prevailing transport processes. However, the operational
advantages of using EDTA prevent direct prediction of important physiologic phenomena
like granule release, integrin activation, and outside-in signaling.
Further expansion of the PAS set to include epinephrine, soluble CD40L,
serotonin, and nitric oxide donors would essentially map a major portion of the entire
platelet response space. The use of PAS with orthogonal pharmacological agents
(indomethacin, P2Y12 inhibitors, selective PAR antagonists, quanylate cyclase or
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adenylate cyclase inhibitors) would allow further assessment of individual clinical risk or
sensitivity/resistance to therapy. The PAS method demonstrates that sampling all dual
orthogonal "axes" (every agonist pair) can successfully predict the dynamic responses
and cross-talks of a higher dimensional system (6 agonists in this case).

3.6 Extension 1: Phenotyping of female donors
All of the donors shown in Figure 3.4-15 were male donors. To test for
correlations between the gender of the donor and PAS clustering pattern, we carried out
pairwise agonist scans for 10 female donors (donors L to U) and compared the clustering
patterns of all donors (male and female) together Figure 3.6-1. All female donors were
between the ages of 20 and 26, were from either Asian or Caucasian ancestry; and
affirmed before phlebotomy that they had not consumed alcohol for 3 days prior to the
blood draw, were not under any medications, and were not currently using birth control
hormone. Similar to the experiments with male donors a repeat experiment for every
female donor was carried out within a period of two weeks.
All of the experiments beyond donor K were conducted with the same stocks of
reagants for the 6 inputs tested. We also tested a male donor (donor V) with these same
stocks. Donor V did not consent to a second blood draw, thus only a single experiment
(V1) is shown for this donor in Figure 3.6-1.
3 of the 10 female donors self clustered (donors R, M and O). The number of
male donors self clustering remain unaltered (7 out of 10). The comparatively reduced
magnitude of self clustering for female donors can probably be explained by the fact that
the female donors tested did not have as diverse a genetic background as the male donors.
Moreover, the likelihood of self clustering can be expected to drop sharply as the number
145

of donors tested (columns in the synergy matrix) goes on increasing, for an unchanged
number of conditions at which phenotypes were tested (the 135 conditions at which
synergy between platelet agonists were measured comprising the rows of the synergy
matrix). The probability of donor experiment self clustering can be expected to improve
if the number of experimental conditions tested increases (either testing of ternary and
higher order synergies in addition to the pairwise interactions, or the testing of the binary
interactions amongst more signaling pathways). However this will require added
experimental complexity, and is limited by technological limitations of current automated
liquid handling protocols. The total number of donors self clustering (male and female)
still remains highly significant (11 of 21) and to our knowledge PAS shows the most
promise in “stratifying” individual donor platelet phenotypes amongst other currently
available platelet phenotyping approaches (aggregometry or flow cytometry).
We did not observe a clear pattern in Figure 3.6-1 where female donors clustered
separately from male donors. Because hierarchical clustering was inadequate in
distinguishing platelet phenotypes on gender, we determined the principal components of
the synergy matrix. Principal component analysis (PCA) is a method of dimensionality
reduction where an orthogonal basis set of “principal components” is identified
(consisting of linear combinations of the original variables), such that much of the
variance in the original data is explained by variation along the first few principal
components. We deteremined the principal components of the 135 dimensional synergy
matrix and plotted up donor phenotypes along the first two principal components for ease
of visualization (Figure 3.6-2). The first 2 principal components account for the most
variation in the original data (PC-1 accounts 20.74 % of the variance and PC-2 13.98 %).
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Figure 3.6-1 Dependence of synergy clustering pattern on donor gender

10 healthy female donors (donors L to U) were tested twice each within a period of two
weeks. Their PAS synergy profiles were arranged in columns of the synergy matrix (in
addition to those for all male donors), and the columns of this matrix were clustered.
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Figure 3.6-2 Scatter of donor phenotypes along first two principal components of
synergy matrix.

The columns of the synergy matrix in Figure 3.6-1 correspond to donors of varying
gender and ethnicity. To determine whether the experimentally measured synergy
profiles were correlated with any of these factors, we determined the principal
components of the 135 dimensional synergy matrix. Donor phenotypes were projected
along the first two principal components.
Although the first two principal components account for only about 35% of the
variance of the original synergy phenotypes in the synergy matrix, the second principal
component showed remarkable promise in distinguishing phenotypes on gender. 15 of the
20 female donor phenotypes had negative values of the second principal component and
21 out of 23 male phenotypes had positive values of the second principal component.
The first principal component is correlated with donor ethnicity (phenotypes with large
positive values of PC1 were Caucasian, whereas large negative values of PC1 were
obtained for donors of African descent).
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3.7 Extension 2: Platelet activation module in patient specific
multiscale models of thrombosis under flow
The process of thrombosis involves discrete particles (platelets) moving in a
convective field. At the site of the growing thrombus these particles can attach to the wall
(exposed collagen). Such platelets that attach to the wall will eventually activate fully and
release autocatalytic activators like ADP and TXA2, as well as contribute catalytic
surface for thrombin formation. This sets up a boundary layer around the growing clot
where released species like ADP, TXA2 exist at appreciable concentrations. Unactivated
platelets can activate in this layer around the growing thrombus according to the
prevailing local concentrations of agonists. Two activated platelets in the viscinity of the
growing clot can aggregate together either in solution, or an activated platelet in solution
can deposit onto anto an activated platelet on the growing thrombus (Figure 3.7-1 A).
Flamm et al have a developed Lattice Kinetic Monte Carlo (LKMC) algorithm
that is capable of simulating convection and diffusion of particles in complex flow fields
[219], as well as particulate aggregation for defined rates [222]. Kinetic Monte Carlo
algorithms are efficient at predicting system evolution given the rates of governing
stochastic processes involved [219]. For the problem at hand, the spatial and temporal
growth of the thrombus can be simulated from the rates of convection, diffusion, platelet
activation, and activated platelet aggregation/disaggregation. This is the basis for a
multiscale model of thrombosis (Figure 3.7-1 B): where (i) the velocity field is obtained
by either a Lattice Boltzman solution, or from solution of the full Navier Stokes equation
using commercial CFD packages, (ii) the local concentrations of agonists can be obtained
from finite element or finite difference solution of the convection-diffusion equation.
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Figure 3.7-1 Multiscale systems model of thrombosis: Contribution of the platelet
activation module
(A) The process of thrombosis involves discrete platelet particles moving in a flow flow
field that can attach to the exposed injury, activate in the growing cloud of active
agonists, or bind to other active platelets in solution or at the thrombus site.
(B) Multiscale model of thrombosis: An LKMC algorithm is able to simulate the
evolution of the growing clot given rates of all events involved in the process
(convection, diffusion, activation, aggregation and disaggregation). The rates of platelet
activation are supplied by donor specific PAS trained NN models for calcium
mobilization. (Image courtesy Matt Flamm)
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Given the local concentration of agonists at any position and time, a PAS trained
neural network model can predict the level of calcium mobilization in the platelet.
Integrated platelet calcium can be used as a measure of the activation status of the platelet
and governs the “stickiness” of a given platelet for other platelets, as well as its potential
to release autocrine activators. The advantage of this approach is that neural network
models can be trained on an individual donor’s PAS dataset, thus yielding donor specific
models of thrombosis.
For initial comparisons between in vitro experiments studying platelet thrombus
formation and their corresponding LKMC simulations, we do not consider the effects of
thrombin. In the absence of thrombin, or endothelium produced prostacyclin, the effects
of three of the inputs in the original PAS set: the PAR peptides SFLLRN and AYPGKF,
and the prostacylin mimic PGE2 can be ignored. For the 3 remaining inputs (ADP, CVX
and U46619) complete testing of all single and pairwise mixtures requires testing of 37
conditions. We tested these conditions in replicates of 4, both for regular platelets and for
platelets treated with the antiplatelet pharmacological agents MRS2395 (P2Y12 inhibitor)
(Figure 3.7-2 for donor W) and Illoprost (prostacyclin analogue) (Figure 3.7-3 for
donor D). All experiments in this section were conducted in the presence of 2 mM

extracellular calcium, and contained 28 µM Indomethacin to prevent autocatalytic
amplification by secreted thromboxane. Since the platelet suspensions contained external
calcium in these experiments, the level of signal (and background) was higher. This
permitted us to use a lower concentration of 6 % PRP as opposed to 12 % PRP used for
PAS experiments (Figure 3.4-3). Autocatalytic amplification by released ADP at such
dilute concentrations of PRP will be minimal (See Section 3.4.2).
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These datasets were used to train donor specific neural network models of regular
platelet phenotypes as well as models of patient specific therapy in response to these drug
treatments. The structure of the neural network used for training was identical to the one
previously described (2 processing layers with 8 and 4 neurons respectively and an output
layer) (Figure 3.3-2). Training was continued until the performance of the trained models
(mean squared error between experimental and simulated transients) was ~ 1×10-5. (Also
see Section 3.3.6 for details about model construction and training)
Maloney et al have developed an 8-channel microfluidic flow assay where blood
drawn into PPACK (to inhibit thrombin), and labeled with AlexaFluor 647 conjugated
anti-CD41 (αIIb) antibody to identify platelets, is perfused over focal zones of collagen at
an average wall shear of 210 s-1 [223]. For comparison between experiment and LKMC
simulation, this assay was used by Tom Colace to simultaneously measure platelet
deposition on collagen coated surfaces using the same samples of blood that were used
for calcium phenotyping in Figure 3.7-2 and Figure 3.7-3. Either untreated blood; blood
treated with indomethacin; MRS2395 (Figure 3.7-2) or Illoprost (Figure 3.7-3); or
combinations of Indomethacin and the respective inhibitor were used in each channel of
the device and every condition was tested in replicates of two on the same device. Each
condition was tested in replicates of 6 (on 3 separate devices). The total fluorecense after
5 minutes of perfusion was used as a measure of platelet accumulation. All values were
normalized to the mean value of the control (untreated blood sample) (Figure 3.7-4). The
LKMC simulations of thrombosis will attempt to simulate such flow experiments using
predictions of each platelet’s activation state (integral calcium levels) from corresponding
PAS trained neural network models.
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Although P2Y12 inhibition using MRS2395 has a pronounced effect in decreasing
platelet deposition on collagen surfaces (Figure 3.7-4), we note that there was no
appreciable effect of P2Y12 inhibition on calcium mobilization (Figure 3.7-2). The fact
that calcium transients were unaffected by P2Y12 inhibition can be explained by the fact
that the P2Y12 receptor is not Gq coupled (See Section 1.2), and contributes to
aggregation independently of calcium pathways. Thus, neural network model predictions
of calcium alone will be inadequate to simulate the effect of this inhibitor. Further
experiments using readouts other than calcium mobilization (like flow cytometry), to
quantify the diminution of integrin activation by ADP signaling in the presence of this
inhibitor are underway. Corrections to activation levels predicted by integral calcium
need to be incorporated into the LKMC model to predict the effect of this inhibitor.
In contrast, Illoprost has a pronounced effect in decreasing both calcium
mobilization (Figure 3.7-3) as well as platelet deposition onto an exposed collagen
surface (Figure 3.7-4). Thus LKMC simulations of platelet deposition without or with
Illoprost treatment can be generated using activation state predictions solely obtained
from the PAS trained neural network values of integral calcium. We also note a more
pronounced effect of thromboxane synthesis inhibition (Indomethacin treatment) for
donor W in comparison to donor D for platelet deposition on collagen (Figure 3.7-4).
This correlated with heightened levels of calcium synergy between the thromboxane
analogue U46619 and ADP for donor W (compare ADP-U46619 pairs between Figure
3.7-2 and Figure 3.7-3). We are currently confirming this correlation for a larger donor

sampling. Use of either MRS2395 or Illoprost in conjunction with Indomethacin does not
provide any statistically significant improvement in inhibitory capacity (Figure 3.7-4).
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Figure 3.7-2 Pairwise scan of Donor W for ADP, U46619 and CVX for platelets
treated without or with the P2Y12 inhibitor MRS2395

Calcium mobilization for all pairwise combinations of ADP, U46619 and CVX were
measured for donor W under regular conditions (red) and with the P2Y12 inhibitor
MRS2395 (blue). All conditions were tested in replicates of 4.
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Figure 3.7-3 Pairwise scan of Donor D for ADP, U46619 and CVX for platelets
treated without or with the prostacyclin mimic Illoprost

Calcium mobilization for all pairwise combinations of ADP, U46619 and CVX were
measured for donor D under regular conditions (red) and with the IP receptor stimulant
Illoprost (blue). All conditions were tested in replicates of 4.
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Figure 3.7-4 Concurrent experiments studying platelet deposition phenotypes on
collagen coated surfaces in microfluidic flow devices

Blood was drawn into the thrombin inhibitor PPACK, and platelets were labeled with
AlexaFluor 647 conjugated anti-CD41 (αIIb) antibody. These samples were perfused over
a strip of patterned collagen in an 8 channel microfluidic device [223]. Each channel
contained either regular blood; blood treated with Indomethacin to limit synthesized
thromboxane; blood treated with MRS2395 to inhibit ADP signaling via P2Y12 (panel A
for donor W) or treated with the antiplatelet drug Illoprost to raise intracellular cAMP
levels via IP signaling (panel B for donor D); or with mixtures of Indomethacin and the
respective inhibitor. These samples of blood were perfused for 5 minutes over collagen
coated surfaces at an average wall shear of 210 s-1 and the level of platelet accumulation
was quantified by measuring the final levels of fluorescence. Shown above are the
fluorescence intensities scaled to the mean value of the control (untreated blood sample).
All conditions were tested in replicates of 6 and blood from the same phlebotomy
samples that were used for calcium phenotyping (Figure 3.7-2 for donor W and Figure
3.7-3 for donor D) were used in these flow experiments (panel A and panel B
respectively). (Experiments and analyses courtesy Tom Colace)
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Chapter 4
Future Work
4.1 Studying the contribution of store operated calcium entry
Calcium exists at concentrations of ~100 nM in the platelet cytoplasm, at
concentrations of ~10 µM in the platelet stores (Dense Tubular System (DTS)), and at
levels of ~1.5mM outside the cell. Following agonist stimulation, there are 4 fluxes of
calcium that regulate net cytoplasmic levels. 1) PLC activation leads to the generation of
IP3 downstream of receptor activation (see Section 1.2). This leads to the opening of IP3
gated calcium channels within the platelet DTS, and a sharp increase in cytoplasmic
calcium levels. 2) The emptying of the intracellular stores is conveyed to the cytoplasmic
membrane by the calcium sensor STIM-1 [224] and opens up Orai-1 [225] channels on
the plasma membrane causing a dramatic influx of calcium with the steep concentration
gradient that exists across the cytoplasm. This component of the signal is called “Store
Operated Calcium Entry” (SOCE). There are also pumps that actively transport calcium
against concentration gradients back to regions of higher concentration. 3) Sacro
Endoplasmic Reticulum Calcium ATPase (SERCA) pumps transport calcium back from
the cytosol into the DTS and 4) Plasma Membrane Calcium ATPases transport calcium
back from the cytosol to the extracellular milieu. Most of the PAS experiments reported
thus far were conducted in the presence of EDTA (except those in Section 3.7). Chelation
of extracellular calcium allows us to study the component of the net calcium signal
resulting directly from intracellular release from the DTS, but ignores the contribution of
SOCE.
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4.1.1 Dissecting the calcium signal resulting from agonist stimulation
Separating these components of the net calcium signal (in particular to study the
contribution of store operated calcium entry) requires selective recalcification protocols
into a medium where activation proceeds initially in the absence of external calcium
(using EDTA), as well as judicious use of inhibitors of platelet pumps (Thapsigargin to
inhibit SERCA, and Carboxyeosin to inhibit PMCA) (Figure 4.1-1). Some initial
experiments utilizing these approaches to isolate individual components of the calcium
signal are presented below. These approaches could be explored further.

Figure 4.1-1 The platelet machinery regulating calcium mobilization

Intracellular calcium concentrations downstream of receptor activation are regulated by
1) Release of calcium from IP3 gated channels on the DTS, 2) SOCE across the Orai-1
channels on the plasma membrane after store emptying has been communicated to the
membrane by the intracellular calcium sensor STM-1, 3) Pumping of calcium back into
the DTS using SERCA (inhibited by Thapsigargin) pumps and 4) pumping of calcium
out of the cell using PMCA pumps (inhibited by Carboxyeosin).
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4.1.2 Recalcification protocols to study biphasic calcium signaling
Simultaneous study of the net calcium signal in the absence (using EDTA) or
presence of external calcium allows us to determine the contribution of store operated
calcium entry. Inclusion of exogenous calcium beyond a certain instant during the time
course of calcium mobilization, to a medium that previously contained no external
calcium allows us to study the extent of the SOCE component of the signal for a
particular duration of the total response. This approach is demonstrated in Figure 4.1-2
Platelet Rich Plasma was treated with EDTA (first addition). CVX (left) or TRAP
(right) were then added (second addition) either in the absence of calcium (red) or

presence of calcium (blue). The difference in integrated area between the blue and red
curves (before the third addition of calcium in the red transient) represents the total
difference resulting from the contribution of SOCE in either case. We also note an
increase in intracellular calcium levels by mere recalcification of agonist untreated
platelets at t=7 min (green). Calcium can also be added at an intermediate point along the
complete transient to gauge the level of SOCE resulting for a given state of “emptiness”
of the DTS. This is shown in the recalcification step at t=7 min for the red transients. In
contrast to the CVX signal at t=7 min, where a large amount of calcium has been
released from the store (large integrated area below the transient before recalcification),
the TRAP stimulus empties a much smaller proportion of the store. This accounts for the
relatively minor amount of SOCE observed for TRAP in comparison to CVX.
This experiment can be extended such that recalcification is carried out not just at
t=7 min, but at several points along the transient. Also, the dependence of SOCE on the

concentration of agonist used can be established by carrying out such experiments across
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a wide range of agonist concentrations. Moreover, the driving force for SOCE can be
controlled by merely adjusting the final level of calcium after recalcification. Finally
phenotyping of mice with deletions in either STIM1 or Orai-1 [226] would allow one to
quantify the contributions of these molecules to the overall signal. The ODE based model
of the platelet developed by Purvis et al [168] does not include the contribution of SOCE
to the overall calcium signal resulting from ADP stimulation. Experiments such as these
will be useful to calibrate sub-models of SOCE for inclusion in the existing model.
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Figure 4.1-2 Recalcification protocols to isolate Store Operated Calcium Entry

Calcium mobilization in response to CVX (left) and SFLLRN (right) were studied in the
absence (red) or presence (blue) of external calcium. For experiments carried out in the
absence of external calcium, recalcification at a certain instant during the time course of
calcium mobilization allows us to determine the contribution of SOCE beyond that
instant. Even addition of external calcium without any prior agonist addition (green)
causes some increase in cytoplasmic due to basal activity of calcium channels on the
plasma membrane.
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4.1.3 Use of pharmacological agents to study components of the
calcium flux that attenuate the overall signal
The use of the inhibitors for the PMCA and SERCA pumps (Carboxyeosin and
Thapsigargin), in various sequential cominations allows us to explore the ability of these
two pumps to attenuate the calcium signal. This approach was utilized to identify
differnces between TRAP (Figure 4.1-3) and CVX (Figure 4.1-4) signaling. These
experiments were carried out in EDTA to exclude the possibility of SOCE (and thus
simplify the analysis of these transients).
We note that addition of Thapsigargin (Figure 4.1-3) causes calcium levels to
increase as the SERCA pumps are gradually inhibited (green transient after the first
addition). This is because the ability of SERCA to compensate for constitutively open IP3
channels on the DTS is lost. However the platelet’s PMCA pumps are able to compensate
and the platelet readjusts to a higher steady state of basal calcium. In contrast, inhibition
of the PMCA pumps (red transient after the first addition) causes an uncontrolled
increase in cytosolic calcium. Thus the PMCA is the most important controller of the
constitutive leak out of the DTS, and possible upregulation of SERCA after PMCA
inhibition cannot compensate. The effect of constitutively open channels on the plasma
membrane could not be explored in this experiment, because there is no calcium outside
the cells. Store refilling must constantly occur from extra-cellular calcium to keep the
platelet at a steady state of 100 nM calcium.
TRAP treatment after either of these inhibitions causes a spike in calcium. This
spike is brought down to basal levels by the unaltered PMCA (green transient after the
second addition) or the uninhibited SERCA (red transient after the second addition). We
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note however, that the rate of reduction in signal is faster for the red transient in
comparison to the green transient after the second addition. This suggests faster kinetics
for the SERCA pumps (which remain operational in the red transient after the second
addition) in comparison to the PMCA pumps (which remain operational in the green
transient after the second addition). The ability of the SERCA pumps is however
overwhelmed by the continual leak out of the stores in the absence of PMCA activity and
calcium levels continue to steeply rise (red transient after the second addition). When
both PMCA and SERCA are inhibited (dark blue transient after the second addition), the
subsequent addition of TRAP (third addition), causes a brief spike (barely noticeable at
the high concentations that already exist at the time of TRAP addition because of the
continuous leak that has occurred previously). This spike is not diminished at all with
both pumps inhibited, thus confirming that PMCA and SERCA mediated pumping are
the only mechanisms that attenuate the calcium spike following TRAP stimulation.
SERCA or PMCA inhibition after prior TRAP stimulation (pink and light blue transients
respectively after the second addition) cause either the platelet to adjust to a higher steady
state or an uncontrolled leak out of the DTS as was noted before. Very similar results
were also obtained for ADP stimulation (results not shown).
In comparison to the results obtained with TRAP, a CVX signal is regulated
differently by the PMCA and SERCA pumps (Figure 4.1-4). The CVX signal is not
diminished as the PMCA is inhibited (red transient after the second addition). This is in
contrast to the TRAP stimulus where the SERCA is able to compensate atleast to some
degree for the loss of PMCA (red transient after the second addition in Figure 4.1-3). In
a separate experiment (results not shown) inhibition of SERCA by thapsigargin causes no
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change in the rate at which the CVX stimulus is downregulated (Compare this to the
green transient after the second addition in Figure 4.1-3, where inhibition of SERCA

causes a slower decay of the calcium spike in comparison to uninhibited platelets
following TRAP stimulation). These results suggest that the CVX signal is
downregulated predominantly by the slower PMCA pumps (and not the faster SERCA
pumps). This is in contast to the Gq coupled ADP or SFLLRN responses which appear to
be downregulated by both PMCA and SERCA pumps. This could account for the fact
that a Gq coupled response is quickly brought down to baseline levels, whereas a CVX
response is long lived.

Figure 4.1-3 Studying the components of the SFLLRN induced calcium signal

Buffer, the SERCA inhibitor Thapsigargin, the PMCA inhibitor Carboxyeosin and the
PAR1 activating peptide SFLLRN (TRAP) were added in various sequential
combinations as indicated in the legend to study the components of the calcium flux
resulting from TRAP stimulation. All of these experiments were carried out in EDTA (0
SOCE) and dispenses were made at the instants indicated (20s, 15 min and 30min). These
experiments demonstrated that the TRAP mediated signal is attenuated by both the
PMCA and SERCA pumps, and that the PMCA pumps are the predominant controller of
a steady leak of calcium out of the stores in the absence of refilling via external calcium.
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Figure 4.1-4 Studying the components of the CVX induced calcium signal

Buffer, CVX, Thapsigargin and Carboxyeosin were added in varying sequences as
indicated in the legend to study the components of the calcium flux resulting from CVX
stimulation. These experiments demonstrated that the CVX mediated signal is attenuated
predominantly by the slower PMCA pump (in contrast to the TRAP signal which utilizes
both PMCA and SERCA pumps).
These experiments can be extended further to aid in the calibration of mechanistic
models of platelet metabolism. The experiments reported have utilized only single doses
of agonists / pump inhibitors. Studying the effects of different extents of pump inhibition
or the responses to different doses of agonists will provide a rich dataset for model
calibration as well as mechanistic insight into the process of calcium metabolism. There
are reports in literature that suggest the existence of agonist sensitive calcium pools
within platelets [227]. Using experiments similar to the ones outlined in this section, it
should be possible to distinguish between these different stores. Finally combinations of
the selective recalcification protocols (Section 4.1.2) and the use of pump inhibitors
would allow one to study how SOCE is regulated by the SERCA and PMCA pumps.
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4.2 Downregulation of collagen signaling by prior thrombin
stimulation: Differences between thrombin and PAR1+
PAR4 peptides
ADP, thrombin and CVX were added in various sequential combinations where
the agonists were either added individually, 2 agonists were added followed by a third or
all three agonists were added together (Figure 4.2-1). Many of the conclusions obtained
were similar to those in Section 3.4.5 for ADP, the PAR1 peptide (SFLLRN), and CVX.
However, differences were noted particularly with regard to inhibition of a CVX signal.
Prior stimulation with ADP, does not affect the ability of thrombin (Figure 4.2-1,
panel 1) or CVX (Figure 4.2-1, panel 2) to signal (Similar to the effect of prior ADP

stimulation on the SFLLRN or CVX signals in Figure 3.4-7). Both thrombin (Figure
4.2-1, panel 3) and CVX (Figure 4.2-1, panel 5) however cross down regulate the ADP

signal (Similar to the effect of prior SFLLRN or CVX signals on subsequent ADP
response in Figure 3.4-7). Also prior stimulation with CVX cross-downregulates
thrombin response in Figure 4.2-1, panel 6 (Again similar to the ability of CVX to
downregulate the SFLLRN response in Figure 3.4-7). One of the most intersing
observations in this experiment however, was the fact that prior stimulation with
thrombin cross down regulates the CVX response (Figure 4.2-1, panel 4) (In contrast
SFLLRN does not inhibit the CVX signal in Figure 3.4-7). These observations were also
observed when a third agonist is added to a well that had received two previous agonists
in Figure 4.2-1 panels 1-6, or when two agonists are added together followed by a third
in Figure 4.2-1 panels 7-9, or when all three agonists are added simultaneously
producing a single burst in calcium in Figure 4.2-1 panels 10.
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Figure 4.2-1 Sequential additions of ADP, thrombin and CVX

The agonists ADP, thrombin and CVX were added in various sequential combinations to
platelet suspensions. In addition to the trends noted in (Figure 3.4-7), we also noticed
inhibition of the CVX signal by prior thrombin stimulation. Also the thrombin response
was inhibited by prior CVX stimulation.
We expected initially the responses of thrombin to be identical to those of
mixtures of the two PAR peptides (SFLLRN and AYPGKF). Indeed several of the
conditions involving thrombin which are likely to occur in a realistic thrombotic
environment are very well approximated by mixtures of the PAR peptides (Figure 3.4-8).
However, to test the distinction between thrombin and mixtures of the PAR peptides over
a broad range of conditions we tested the effects of additions of sequential mixtures of
ADP, (SFLLRN+AYPGKF) and CVX (Figure 4.2-2); and compared these to the results
obtained by adding sequences of ADP, thrombin and CVX (Figure 4.2-2).
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Figure 4.2-2 Sequential additions of ADP, PAR1+PAR4 peptide mixtures, and CVX

To distinguish between the responses to thrombin and mixtures of the thrombin receptor
peptides (SFLLRN and AYPGKF), we added various sequential combinations of ADP,
(SFLLRN + AYPGKF) and CVX. Trends noted in Figure 3.4-7 remained unchanged, as
was the ability of CVX to downregulate the (SFLLRN + AYPGKF) response. In contrast
to thrombin however, mixtures of the PAR peptides do not inhibit CVX signaling.
The results obtained with sequential additions of ADP, PAR1+PAR4 peptides and
CVX (Figure 4.2-2) were identical to those noted in Figure 3.4-7. However quite
unexpectedly, an important difference was noted between thrombin and mixtures of the
PAR peptides. The cross down regulation of the CVX stimulus that was obtained by prior
thrombin stimulation (Figure 4.2-1, panel 1) was not obtained with mixtures of the PAR
peptides (Figure 4.2-2, panel 1). This conclusion was consistently observed throughout
all of the conditons tested across Figure 4.2-1 and Figure 4.2-2 (panels 1, 3, 4 and 7).
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Thus there is some property of the intact enzyme thrombin that is not reflected by
synthetic mimics of PAR ligands (cleaved sections of thrombin receptors). One
possibility is that the enzyme thrombin is able to cleave off GPVI from the platelet
surface and thus downregulate signaling via this receptor. In contrast synthetic mixtures
of PAR peptides that do not contain thrombin’s proteoytic activity will not downregulate
the CVX signal.

This hypothesis is being explored further by looking for cleaved

fragments of the GPVI receptor using flow cytometric detection of this receptor’s levels.
Another possibility is that prior thrombin treatment causes the GPVI receptor to be
internalized or downregulated via receptor pathways not yet identified. Confirmation of
this hypothesis too requires further experimentation.

4.3 Incorporating

donor

specific

descriptions

of

platelet

function into models of coagulation
The Platelet-Plasma model developed in Chapter 2, includes a coarse grained
description of platelet function where unbinding rates of platelet dependent reactions are
decreased by two orders of magnitude via the ε function as the platelet’s activate with
thrombin. As a next step ε can be obtained from PAS trained donor specific Neural
Networks (Chapter 3). In addition to donor specificity, this will allow us to account for
the combinatorial effects of the autocatalytically released agonists ADP and
thromboxane. Eventually, a heterogenous model of platelet activation dependent
enzymatic conversion will be developed; incorporating mass transfer of zymogens from
the bulk onto the active platelet surface, coagulation factor assembly on discrete binding
sites provided by the platelet, catalytic conversion of zymogens to active enzymes at
these sites, and finally the release and diffusion away of these enzymes.
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Appendix A: Phenotyping of murine platelets
The high throughput calcium phenotyping protocol that we have developed is
useful not just to study human platelets but can also be used to study murine platelets.
This is especially useful for murine platelets, because very low volumes of blood can be
obtained from mice (about 1 ml from a cardiac puncture for each mouse). Our assay
allows the simultaneous testing of phenotypes across multiple conditions with several
replicates in the same plate, using very small volumes of blood. Moreover experiments
can be designed to compare both wildtype and genetically modified murine platelet
phenotypes side by side on the same plate, and this allows for the rapid identification of
genotype-phenotype linkages.

A.1 Experimental protocol for murine platelet phenotyping
Blood was drawn from the inferior vena cava of anasthetized mice (100 mg/kg
Nembutal) using a heparinized syringe (1000 U/ml, 1:100 dilution with blood), diluted
1:1 with HEPES-Tyrodes buffer, and spun at 800 rpm for 6 min to isolate platelet rich
plasma (PRP). PRP was diluted with HEN buffer (10 mM HEPES pH 6.5, 1 mM EDTA,
150 mM NaCl). The HEN buffer was supplemented with 1 µM PGE1 during the wash
steps to prevent unwarranted platelet activation during rapid sedimentation. Platelets
were sedimented at 1300 rpm for 15 min and then resuspended in HEPES-Tyrode’s
buffer to the desired platelet counts.
Washed platelets pooled from two mice of each genotype (either regular or
genetically modified) were resuspended in 1.5 ml of HEPES-Tyrode’s buffer containing
1 U/ml apyrase and 1 µM PGE1 and incubated with 25 µl of Fura-2AM in DMSO (1
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mg/ml) for 45 min in the dark. Afterwards the platelets were washed with HEN buffer
and resuspended in HEPES-Tyrode’s buffer at 2×108 platelets/ml. A 384 well microtiter
plate containing platelet agonists was prepared on a Perkin Elmer Janus. A separate
microtiter plate containing diluted platelet suspension (1×106 platelets/well) was prepared
on a Perkin Elmer Evolution. Agonists were dispensed on a Molecular Devices
FlexStation. Fura 2 fluorescence was measured at excitation 340/380 nm and emission
510 nm for 4 minutes in every column of the plate. The 340/380 fluorescence ratio R(t)
was scaled to the mean baseline values for each well R0(t) and relative calcium
concentrations were quantified as R(t)/ R0(t). All conditions were tested in replicates of 8.

A.2 Mice with substitution in Gi2α rendering resistance to RGS
signaling
This study explored one of the intrinsic mechanisms that prevent overly robust
platelet activation following vascular injury (in contrast to extrinsic regulators of platelet
function such as NO and PGI2). To study the role of RGS (Regulators of G Protein
Signaling) proteins in platelets, mice with a G184S substitution in Gi2α that blocks
RGS/Gi2 interactions were phenoyped. This allows us to examine the consequences of
lifting constraints on Gi2 dependent signaling without altering receptor effector coupling.
The results showed that the Gi2α (G184S) allele enhances platelet aggregation in vitro and
increases platelet accumulation following vascular injury. These changes occur in concert
with an attenuated rise in cAMP levels in response to PGI2 and a substantial increase in
basal Akt activation.
Because of suggestions in literature that Gi derived Gβγ can activate phospholipase
Cβ, we explored the effect of the Gi2α (G184S) substitution on changes in cytosolic Ca++
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concentration when Gi2α (+/G184S) and matched control platelets were incubated with
ADP, AYPGKF, U46619 or convulxin. Each agonist tested caused an increase in
cytosolic Ca++, but the extent of the increase was unaffected by the presence of the Gi2α
(G184S) substitution (Figure A.2-1). This finding was consistent with the unperturbed
timing and extent of Rap1b activation in response to ADP (one of the critical steps
leading to αIIbβ3 activation in platelets downstream of Gq mediated increases in cytosolic
calcium). It suggests that in this context, there is no crosstalk between Gi2 and Gq
mediated pathways in the presence of the G184S mutation. (The calcium phenoyping
experiments in this section were done in collaboration with Rachel Signarvic).
These experiments collectively 1) demonstrated an active role for RGS proteins in
regulating platelet responsiveness, and 2) suggested that RGS proteins help to prevent
unwarranted platelet activation and limit the magnitude of haemostasis [228].

Figure A.2-1 Comparison between platelet calcium mobilization phenotypes of
wildtype and Gi2α knockin mice

Gi2α (+/G184S) and matched control platelets were loaded with Fura-2 and stimulated
with several concentrations of each of the indicated agonists. Ca++ dependent Fura-2
fluorescence over time for each agonist was measured for wild type and Gi2α (+/G184S)
platelets. A comparison of average maximal fluorescence over the range of agonist
concentrations studied for each genotype is shown above. Each curve represents the
average of 8 replicates. The experiment was performed twice with similar results
obtained. Blood obtained from 2 mice of each genotype was used for each experiment.
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A.3 ESAM-/- mice
Endothelial cell Specific Adhesion Molecule (ESAM), normally found in the
alpha granules of quiescent platelets, is expressed in abundance on the cell surface
following activation. ESAM localizes to the junctions between adjacent platelets
following platelet activation, suggesting a role for this protein in contact dependent
events that regulate thrombus formation. This study explored the role of ESAM by
phenotyping ESAM deleted platelets.
In vivo, ESAM-/- mice achieved more stable hemostasis than wild-type mice

following laser injury of cremaster muscle arterioles. In vitro, ESAM-/- platelets
aggregated at lower concentrations of G protein-dependent agonists than wild type
platelets, and were more resistant to disaggregation.
To examine whether ESAM regulates early platelet signaling events downstream
of agonist stimulation, calcium mobilization was measured in ESAM null platelets and
this phenotype was compared to that of wildtype platelets. Calcium mobilization in
response to either a PAR-4 agonist peptide or ADP was the same in ESAM-/- platelets as
in wild type controls (Figure A.3-1). (The calcium phenoyping experiments in this
section were done in collaboration with Tim Stalker).
Similarly integrin activation measured by flow cytometry using an antibody
selective for the active conformation of αIIbβ3 (or by measuring FITC-labeled fibrinogen
binding) did not differ between ESAM-/- and wild type platelets. Neither was there any
appreciable difference in platelet spreading or alpha granule secretion phenotypes
between wildtype and ESAM-/- platelets. These observations suggest that the gain of
function observed in the absence of ESAM for aggregation or in vivo thrombosis were
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not because of inside out signaling events but were rather dependent on post- aggregation
signaling.
To understand the molecular mechanism by which ESAM regulates platelet
activity, a PDZ domain array was used to identify the scaffold protein NHERF-1 as an
ESAM binding protein, and further experiments were carried out to demonstrate that this
protein associates with ESAM in both resting and activated platelets.
Taken together, these findings support a model in which ESAM localizes to
platelet contacts following platelet activation in order to limit thrombus growth and
stability so that the optimal hemostatic response occurs following vascular injury [33].

Figure A.3-1 Comparison between platelet calcium mobilization phenotypes of
wildtype and ESAM knockout mice

Calcium mobilization in response to ADP (left panel) and the PAR4 agonist AYPGKF
(right panel) were measured using the fluorescent calcium indicator Fura-2. Values are
mean ± SD and are representative of two independent experiments. ESAM did not have
any effect in regulating calcium mobilization in isolated mouse platelets.
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